Document:

Compensation Information for Non-Employee Directors

 EXHIBIT 10.19 
 COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS 
 The tables below provide information regarding the current
annual cash compensation amount and equity compensation for Non-Employee Directors of Exelixis, Inc. Directors who are employees of Exelixis do not receive additional compensation for director services. 
 2007 Cash Compensation for Non-Employee Directors 
  

						
	 Board of Directors
	  	Retainer Fee	  	$	20,000
		  	Additional Chair Retainer Fee	  	$	20,000
		  	Regular Meeting Fee	  	$	2,500
		  	Special Meeting Fee1	  	$	500
	 Audit Committee 
	  	Retainer Fee	  	$	6,000
		  	Additional Chair Retainer Fee	  	$	6,000
		  	Meeting Fee2	  	$	1,000
	 Compensation Committee 
	  	Retainer Fee	  	$	5,000
		  	Additional Chair Retainer Fee	  	$	2,500
		  	Meeting Fee2	  	$	1,000
	 Nominating & Corporate Governance Committee
	  	Retainer Fee	  	$	5,000
		  	Additional Chair Retainer Fee	  	$	2,500
		  	Meeting Fee2	  	$	1,000
	 Research & Development Committee 
	  	Retainer Fee	  	$	10,000
		  	Additional Chair Retainer Fee	  	$	10,000
		  	Meeting Fee2 	  	$	5,000

	 1
	 Meeting at which minutes are
generated. 

	 2
	 In-person meeting or teleconference at which minutes are generated. 

 2007 Equity Compensation for Non-Employee Directors 
  

							
	Board of Directors	 	Initial Option Grant3	 	Number of Options	 	25,000
		 	Annual Option Grant	 	Number of Options	 	10,000

	 3
	 For new directors only. 

 Except as provided above, all other terms and conditions regarding compensation for Non-Employee Directors remain as outlined in the Company’s Proxy Statement for the 2006 Annual Meeting of Stockholders, filed
with the Securities and Exchange Commission on March 29, 2006. Information regarding compensation for Non-Employee Directors will also be provided in the Company’s Proxy Statement for the 2007 Annual Meeting of Stockholders which will be
filed with the Securities and Exchange Commission in March 2007.Collaboration Agreement, between Exelixis, Inc. and Bristol-Myers Squibb Company

 Exhibit 10.38 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 COLLABORATION AGREEMENT 
 THIS COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of
December 15, 2006 (the “Execution Date”) by and between EXELIXIS, INC., a Delaware corporation having its principal place of business at 170 Harbor Way, P.O. Box 511, South San Francisco,
California 94083-0511 (“Exelixis”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, 10154
(“BMS”). Exelixis and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 
 RECITALS 
 A. BMS is a multinational health care company that has expertise and capability in
researching, developing and marketing human pharmaceuticals. 
 B. Exelixis is a drug discovery company that has expertise and proprietary technology
relating to therapeutics that modulate signal transduction pathways involved in oncology and other disease areas. 
 C. BMS and Exelixis desire to
establish a collaboration to apply such Exelixis technology and expertise to the discovery, lead optimization and characterization of small molecule compounds that directly bind and modulate certain targets, with a goal of filing an Investigational
New Drug applications for small molecule compounds in [ * ], and to provide for the development and commercialization of novel therapeutic and prophylactic products based on such compounds. 
 NOW, THEREFORE, the Parties agree as follows: 
  

	1.	DEFINITIONS 

 Capitalized terms used in this Agreement (other than
the headings of the Sections or Articles) have the following meanings set forth in this Article 1, or, if not listed in this Article 1, the meanings as designated in the text of this Agreement. 
 1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership, or other entity that controls, is
controlled by or is under common control with such Party. For the purposes of the definition in this Section 1.1, the word “control” (including, with correlative meaning, the terms “controlled by” or
“under the common control with”) means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the
ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 
 1.2 “Allowable
Expenses” means those expenses that are specifically attributable to a Co-Promotion Product in the U.S. and that consist of: [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

  

 1.3 “ANDA” means an Abbreviated New Drug Application submitted to the FDA in conformance
with applicable laws and regulations, or the foreign equivalent of any such application in any other country. 
 1.4 “Appealable
Matter” means any dispute between the Parties (or their respective designees or Committees) concerning: (a) whether the [ * ] have or may [ * ] have [ * ] the [ * ] of any [ * ]; (b) [ * ]
have or may [ * ] have a [ * ] the [ * ] of any [ * ]. For clarity, any dispute regarding whether [ * ] shall be an Appealable Matter. 
 1.5 “Approved Plan” means, with respect to a Product, any one or more of the Global Development Plans, each Annual Development Plan, the Global Commercialization Strategy, and the U.S.
Commercialization Plan, in each case as adopted or approved under the terms of this Agreement. 
 1.6 “BMS [ * ]” or “[ *
]” means [ * ] which the [ * ] (or a successor thereto) (“[ * ]”) [ * ], including [ * ] (typically, [ * ]) and [ * ] to that effort. At [ * ], the following have been
established: (a) one or more [ * ] (through BMS [ * ]); (b) [ * ] to BMS; (c) [ * ] at [ * ]; (d) [ * ]; (e) assay [ * ] for the [ * ] assays; (f) assays for [
* ]; and (g) [ * ] assays. 
 1.7 “BMS [ * ]” or “[ * ]” means [ * ] which [ * ] for
a compound that has [ * ] and a [ * ] made to [ * ]. For clarity, [ * ]. 
 1.8 “BMS [ * ]” or
“[ * ]” means [ * ] which [ * ] one or more compounds [ * ] to [ * ]. [ * ], the [ * ] for [ * ] information needed [ * ]. [ * ] is [ * ]. This [ * ] is
typically made about [ * ] prior to [ * ]. At [ * ] there will be evidence of [ * ], [ * ], which will include [ * ]. There will be [ * ], and [ * ]. Not all [ * ] testing ([ * ])
will be [ * ] at [ * ], but [ * ] be [ * ] reached. The [ * ] will be [ * ]. 
 1.9 “BMS [
* ]” or “[ * ]” means [ * ] which the BMS [ * ] based [ * ]. An [ * ] follows [ * ]. BMS [ * ] once it contains [ * ]. 
 1.10 “BMS Licensed Know-How” means all Information (other than Patents) Controlled by BMS and its Affiliates, including Information
Controlled jointly with Exelixis, as of the Effective Date and during the term of the Agreement that: (a) covers a Collaboration Compound, a composition containing a Collaboration Compound (e.g., a formulation containing a Collaboration
Compound), or the manufacture or use of a Collaboration Compound; and (b) is [ * ] for Exelixis to exercise the rights licensed to it under the Agreement or to perform its obligations to the Collaboration under the Agreement. 

1.11 “BMS Licensed Patents” means all Patents Controlled by BMS and its Affiliates, including Patents Controlled jointly with
Exelixis, as of the Effective Date and during the term of this Agreement that: (a) cover a Collaboration Compound, a composition containing a Collaboration Compound (e.g., a formulation containing a Collaboration Compound), or the manufacture
or use of a Collaboration Compound; and (b) are [ * ] for Exelixis to exercise the rights licensed to it under the Agreement or to perform its obligations to the Collaboration under the Agreement. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 2 

 1.12 “Change of Control” means any transaction in which a Party: (a) sells, conveys
or otherwise disposes of all or substantially all of its property or business; or (b)(i) merges, consolidates with, or is acquired by any other Person (other than a wholly-owned subsidiary of such Party); or (ii) effects any other transaction
or series of transactions; in each case of clause (i) or (ii), such that the stockholders of such Party immediately prior thereto, in the aggregate, no longer own, directly or indirectly, beneficially or legally, at least fifty percent
(50%) of the outstanding voting securities or capital stock of the surviving Person following the closing of such merger, consolidation, other transaction or series of transactions. As used in this Section 1.12,
“Person” means any corporation, firm, partnership or other legal entity. 
 1.13 “Clinical Costs” means the
costs incurred by a Party or for its account, during the term and pursuant to this Agreement, in connection with clinical studies of a Co-Developed Product in the Co-Development Territory, including the following: (a) the preparation for and
conduct of clinical trials (except for related Manufacturing Costs otherwise included in Development Costs); (b) data collection and analysis, and report writing; and (c) clinical laboratory work. The Clinical Costs shall exclude costs
incurred in connection with [ * ]. 
 1.14 “Co-Developed Product” shall mean a Product for which: (a) Exelixis
has exercised an Exelixis Co-Development Option; and (b) Exelixis has not opted-out pursuant to Section 4.7(a). 
 1.15
“Co-Development Territory” shall mean [ * ]. 
 1.16 “Collaboration” means the collaborative research,
development, and commercialization program between the Parties that is contemplated by this Agreement. 
 1.17 “Collaboration
Compounds” means the Lead Compound and Program Backups in each Lead Op Program, Provisional Collaboration Program or Collaboration Program. 
 1.18 “Commercialize” means to promote, market, distribute, sell (and offer for sale or contract to sell) or provide product support for a Product, including by way of example: (a) detailing and
other promotional activities in support of a Product; (b) advertising and public relations in support of a Product, including market research, development and distribution of selling, advertising and promotional materials, field literature,
direct-to-consumer advertising campaigns, media/journal advertising, and exhibiting at seminars and conventions; (c) developing reimbursement programs and information and data specifically intended for national accounts, managed care
organizations, governmental agencies (e.g., federal, state and local), and other group purchasing organizations, including pull-through activities; (d) co-promotion activities not included in the above; (e) conducting medical education
activities and journal advertising; and (f) [ * ]. For clarity, “Commercializing” and “Commercialization” have a correlative meaning. 
 1.19 “Committee” means the JEC, JRC, JDC, JCC, or JFC, as the case may be. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 3 

 1.20 “Committee-Governed Product” means: (a) any Co-Promotion Product; (b) any
Co-Developed Product; and (c) any Product with respect to which Exelixis exercised its Product-Opt-Out option pursuant to Section 4.7(a) [ * ]. 
 1.21 “Completed Screening Program” means a Screening Program for which there exists a lead molecule that has completed the following activities (as applicable to such lead molecule):
(a) [ * ]; (b) [ * ]; (c) [ * ]; (d) completion of [ * ]; (e) completion of [ * ]; (f) [ * ]. 
 1.22 “Controlled” means, with respect to any compound, material, Information or intellectual property right, that the Party owns or has a license to such compound, material, Information or
intellectual property right and has the ability to grant to the other Party access, a license or a sublicense (as applicable) to such compound, material, Information or intellectual property right as provided for herein without violating the terms
of any agreement or other arrangements with any Third Party existing at the time such Party would be first required hereunder to grant the other Party such access, license or sublicense. 
 1.23 “Co-Promotion Product” means a Product for which Exelixis has exercised its option to Co-Promote in the U.S. as set forth in
Section 6.4. 
 1.24 “Core Program” shall mean, with respect to a Product, [ * ] for which any [ *
] or any [ * ] first [ * ] with respect to such Product. 
 1.25 “Development” means, with respect to a
Product, those activities, including research, pre-clinical development activities, clinical trials, supporting manufacturing activities and related regulatory activities, that are [ * ] to: (a) obtain the approval by the applicable
Regulatory Authorities of the Drug Approval Application with respect to such Product in the applicable regulatory jurisdiction, whether alone or for use together, or in combination, with another active agent or pharmaceutical product;
(b) maintain such approvals; or (c) obtain or maintain compendia listings with respect to such Product. For clarity, “Co-Develop”, “Develop” and “Developing” have a correlative meaning.

 1.26 “Development Candidate” means a [ * ] that has met Exelixis’ internal developability criteria, which
criteria are consistent with Exelixis’ internal developability criteria for all Exelixis programs (including programs outside of the Collaboration), and that has been approved by Exelixis to transition from [ * ] to [ * ].

 1.27 “Development Costs” means the costs incurred by a Party or for its account, during the term and pursuant to this
Agreement, that are specifically identifiable (or reasonably allocable) to the Development of a Co-Developed Product in the Co-Development Territory and that are directed to achieving or maintaining Regulatory Approval of such Co-Developed Product
in the Co-Development Territory. The Development Costs shall include amounts that a Party pays to Third Parties involved in the Development of a Co-Developed Product ([ * ]), and all internal costs incurred by a Party in connection with the
Development of such Co-Developed Product. Development Costs include the following: (a) preclinical costs such as toxicology and formulation development, test method development, delivery system development, stability testing and statistical
analysis; (b) Clinical Costs; (c) expenses related to adverse event reporting; 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 4 

 
(d) Manufacturing Costs for a Co-Developed Product for use in preclinical and clinical activities including the manufacture, purchase or packaging of
comparators or placebo for use in Clinical Trials (with the manufacturing costs for comparators or placebo to be determined in the same manner as Manufacturing Costs are determined for any Product), as well as the direct costs and expenses of
disposal of drugs and other supplies used in such Clinical Trials and any associated release testing and QA/QC development costs; (e) [ * ] incurred in connection with [ * ], to the extent provided therein; and
(f) development of the Manufacturing process for a Co-Developed Product (including with respect to any excipients or any active pharmaceutical ingredient included in such Co-Developed Products) and related scale-up, manufacturing process
validation, manufacturing process improvements, and qualification and validation of Third Party contract manufacturers; (g) regulatory expenses relating to Development activities for the purpose of obtaining Regulatory Approval for an
indication for a Co-Developed Product; (h) costs of real property rented specifically for Development activities (to the extent actually used); and (i) other out-of pocket development expenses including, without limitation institutional
and advisory review boards, investigator meetings, quality of life studies, epidemiology and outcomes research. 
 1.28 “Diligent
Efforts” means the carrying out of obligations or tasks in a sustained manner consistent with the efforts a Party devotes to a product or a research, development or marketing project of similar market potential, profit potential or
strategic value resulting from its own research efforts, based on conditions then prevailing. Diligent Efforts requires that the Party: (a) [ * ], (b) [ * ], and (c) [ * ] with respect to such [ * ].

 1.29 “Distribution Costs” means the costs, [ * ], incurred by a Party or for its account, during the term and
pursuant to the Agreement that are reasonably allocable (as determined by the JFC) to the distribution of a Co-Promotion Product in the U.S., including: (a) handling and transportation to fulfill orders (excluding such costs to the extent they
are treated as a deduction in the definition of Net Sales); (b) customer services, including order entry, billing and adjustments, inquiry and credit and collection; and (c) direct costs of storage and distribution of Co-Promotion
Products. 
 1.30 “Dollars” or “$” means the legal tender of the United States. 
 1.31 “Drug Approval Application” or “DAA” means: (a) in the United States, an NDA (or a supplemental NDA for
following indications), and (b) in any other country or regulatory jurisdiction, an equivalent application for regulatory approval required before commercial sale or use of a Product (or with respect to a subsequent indication) in such country
or regulatory jurisdiction. 
 1.32 “ECN” or “Early Candidate Nomination” means a compound or other
substance that has been approved [ * ] to transition from [ * ] in a [ * ] to [ * ]. 
 1.33
“EMEA” means [ * ] commercial territory, consisting of the following countries and regions: [ * ]. The EMEA also includes: (a) [ * ]; and (b) exports from [ * ] not separately identified in
the list. For clarity, the specific list of countries and regions may change to align with any corresponding [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 5 

 1.34 “EU” means the European Union, as its membership may be altered from time to time,
and any successor thereto. The member countries of the European Union as of the Execution Date are Belgium, Denmark, Germany, Greece, Spain, France, Ireland, Italy, Luxembourg, The Netherlands, Austria, Portugal, Finland, Sweden, the United Kingdom,
Estonia, Latvia, Lithuania, Poland, Czech Republic, Slovakia, Hungary, Slovenia, Malta, and Cyprus. 
 1.35 “Executive Officers”
means: (a) in the case of Exelixis, the President and Chief Executive Officer of Exelixis; and (b) in the case of BMS, either (i) a direct report of the BMS CSO (for disputes involving development matters) or (ii) the Head of
U.S. Operations (for disputes involving commercial matters). 
 1.36 “Exelixis Licensed Know-How” means all
Information (other than Patents) Controlled by Exelixis and its Affiliates, including Information Controlled jointly with BMS, as of the Effective Date and during the term of this Agreement that: (a) covers a Collaboration Compound, a
composition containing a Collaboration Compound (e.g., a formulation containing a Collaboration Compound), or the manufacture or use of a Collaboration Compound; and (b) is [ * ] for BMS to exercise the rights licensed to it under the
Agreement or to perform its obligations to the Collaboration under the Agreement. 
 1.37 “Exelixis Licensed Patents” means
all Patents controlled by Exelixis and its Affiliates, including patents controlled jointly with BMS, as of the Effective Date and during the term of this Agreement that: (a) cover a Collaboration Compound, a composition containing a
Collaboration Compound (e.g., a formulation containing a Collaboration Compound), or the manufacture or use of a Collaboration Compound; and (b) are [ * ] for BMS to exercise the rights licensed to it under the Agreement or to perform
its obligations to the Collaboration under the Agreement. 
 1.38 “FDA” means the U.S. Food and Drug Administration, and any
successor thereto. 
 1.39 “FTE” means the equivalent of the work of one (1) employee full time for one (1) year
consisting of a total of [ * ] hours per year (or such other number as may be agreed to by the JFC) directly related to the Development or Commercialization of any Co-Developed Product or Co-Promotion Product, as the case may be, or any other
activities contemplated under this Agreement. Any individual who devotes less than [ * ] hours per year (or such other number as may be agreed by the JFC) shall be treated as an FTE on a pro-rata basis upon the actual number of hours
worked divided by [ * ] (or such other number as may be agreed by the JFC). Unless modified by the JFC, the [ * ] figure shall be used without regard to the Parties’ own internal definition of the number of hours that
comprises an FTE. 
 1.40 “GAAP” means U.S. generally accepted accounting principles, consistently applied. 
 1.41 “[ * ]” means, with respect to a particular Product in a country, [ * ] such Product ([ * ]); and (b) is [ *
] or otherwise), whether [ * ] or [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 6 

 1.42 “HSR Act” means the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended from time to time, and the rules, regulations, guidance and requirements promulgated thereunder as may be in effect from time to time. 
 1.43 “Identified Target(s)” means the set of one or more Lead Op Targets or Collaboration Targets (as applicable) that the JRC, the JDC or the Parties (as the case may be) reasonably believes [ * ] in such Lead Op
Program, Provisional Collaboration Program or Collaboration Program. 
 1.44 “IND” means an Investigational New Drug
Application submitted to the FDA in conformance with applicable laws and regulations, or the foreign equivalent of any such application in any other country. 
 1.45 “Information” means information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including, databases, practices, methods, techniques, specifications,
formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and
procedures. For clarity, Information does not include any Patents. 
 1.46 “Initial Lead Op Programs” means the [ * ]
programs conducted by Exelixis on the initial Lead Op Targets selected by the Parties pursuant to Section 3.3(a). 
 1.47
“Invention” means any and all inventions and improvements thereto, invented or discovered by or on behalf of a Party (and/or its Affiliates) in the performance of its obligations under this Agreement. 
 1.48 “Joint Invention” means any Invention invented or discovered jointly by or on behalf of the employee(s), contractor(s) or agent(s)
of both Parties (and/or their Affiliates). 
 1.49 “Joint Commercialization Committee” or “JCC” means the
committee described in Section 2.4. 
 1.50 “Joint Development and Regulatory Committee” or
“JDC” means the committee described in Section 2.3. 
 1.51 “Joint Executive Committee” or
“JEC” means the committee described in Section 2.2. 
 1.52 “Joint Finance Committee” or
“JFC” means the committee described in Section 2.6. 
 1.53 “Joint Research Committee” or
“JRC” means the committee described in Section 2.5. 
 1.54 “Knowledge” means, with respect of
a Party, the good faith [ * ] facts and information in the possession of an [ * ] of such Party, or any [ * ] of, or [ * ], such Party or its Affiliates, [ * ] execution of this Agreement. For purposes of this
definition, an “[ * ]” means any person in the [ * ] of a Party. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 7 

 1.55 “Launch” means, for each Product in each country, the first arm’s-length sale
to a Third Party for use or consumption by the public of such Product in such country after Regulatory Approval of such Product in such country. A Launch shall not include any Product sold for use in clinical trials, for research or for other
non-commercial uses, or that is supplied as part of a compassionate use or similar program. 
 1.56 “Lead Compound”
means, with respect to a Provisional Collaboration Program or Collaboration Program: (a) the Program Lead for such Provisional Collaboration Program or Collaboration Program; and (b) any [ * ] compound described in subsection (a).

 1.57 “Lead Op Program” has the meaning described in Section 3.3. The Lead Op Programs include:
(a) Initial Lead Op Programs; and (b) any [ * ] programs that were [ * ] and that were [ * ] programs pursuant to Section 3.3(c). 
 1.58 “Lead Op Target(s)” means: (a) the initial list of targets identified by the Parties pursuant to Section 3.3(a);
and (b) any additional target(s) identified by the Parties pursuant to Sections 3.2(b) or 3.3(a). The Lead Op Targets shall be listed in Exhibit 3.3, which shall be updated periodically by the Parties. 
 1.59 “Major European Countries” means France, Germany, Spain, Italy, and the United Kingdom. 
 1.60 “Major Territory” means each of the following territories: (a) [ * ]. 
 1.61 “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling,
inspection, receiving, holding and shipping of Lead Compounds, Program Backups, Collaboration Compounds, Products, or any raw materials or packaging materials with respect thereto, or any intermediate of any of the foregoing, including process and
cost optimization, process qualification and validation, commercial manufacture, stability and release testing, quality assurance and quality control. For clarity, “Manufacture” has a correlative meaning. 
 1.62 “Manufacturing Costs” means costs that relate to a Co-Developed Product or a Co-Promotion Product which is: (a) supplied by a
Third Party; or (b) manufactured directly by a Party or its Affiliate, in each case to the extent such costs relate to the development of a Co-Developed Product or the Commercialization of a Co-Promotion Product in the U.S., as further
described below and as allocated in accordance with GAAP. 
 For costs in subsection (a), Manufacturing Costs means: (i) the
amount paid to such a Third Party [ * ]; plus (ii) the relevant manufacturing Party’s reasonable direct and identifiable internal costs and out-of-pocket costs, incurred or accrued (including any prepayments) by the manufacturing
Party in connection with manufacturing process improvements, storage, manufacturing scale-up, manufacturing site qualification, quality assurance and quality control (including testing), supply chain management, capital equipment, similar activities
comprising the manufacturing Party’s oversight of the manufacturing process of the non-Affiliate Third Party, and any value-added tax or similar tax due for amounts paid to such Third Party. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 8 

 For costs in subsection (b), Manufacturing Costs means the “standard cost” per unit,
including variances to standard costs and inventory write-offs. This standard cost shall include the cost of raw materials, labor, and other direct and identifiable variable costs incurred or accrued by the manufacturing Party in connection with the
manufacture of a Co-Promotion Product, manufacturing process improvements, storage, manufacturing scale-up, manufacturing site qualification, quality assurance and quality control (including testing), supply chain management, and costs of equipment,
plant operations and plant support services necessary to produce a Co-Promotion Product. These costs of plant operations and support services shall include [ * ] and other similar activities, including [ * ] charges. Costs that cannot
be identified to a specific activity supporting manufacturing of a Co-Promotion Product, such as charges for corporate overhead that are not controllable by the manufacturing plant, shall be [ * ] from the determination of Manufacturing Cost.

 Subject to the preceding paragraph, “standard cost” per unit for purposes of ongoing cost accounting purposes shall be
calculated in accordance with [ * ]. The Parties shall reconcile the standard cost charges and appropriate credit or payment shall be made to effect such reconciliation as directed by the JFC not less than annually against the above
Manufacturing Cost definition. 
 Manufacturing Costs shall include costs of such activities that are undertaken at any time during the term
of this Agreement (including [ * ]). 
 1.63 “Medical Education Activities” means activities designed to ensure or
improve appropriate medical use of, conduct medical education of, or further research regarding, a Co-Promotion Product sold in the U.S., including by way of example: (a) activities of medical sales liaisons; (b) grants to support
continuing medical education, symposia, or research related to a Co-Promotion Product in the U.S. (excluding Phase IV Clinical Trials and Development activities conducted for purposes of obtaining an initial Regulatory Approval for an indication for
a Co-Promotion Product in the U.S.); (c) development, publication and dissemination of publications relating to Co-Promotion Product in the U.S., as well as medical information services provided in response to inquiries communicated via sales
representatives or received by letter, phone call or email; and (d) conducting advisory board meetings or other consultant programs, the purpose of which is to obtain advice and feedback related to the Development or Commercialization of a
Co-Promotion Product in the U.S. 
 1.64 “NDA” means a New Drug Application submitted to the FDA in conformance with
applicable laws and regulations. 
 1.65 “Net Sales” means the amount invoiced or otherwise billed by BMS or its Affiliate
or sublicensee for sales or other commercial disposition of a Product to a Third Party purchaser, less the following to the extent included in such billing or otherwise actually allowed or incurred with respect to such sales: (a) discounts,
including cash, trade and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a product, charge-back payments and rebates granted to managed health care organizations or to federal, 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 9 

 
state and local governments (or their respective agencies, purchasers and reimbursers) or to trade customers, including but not limited to, wholesalers and
chain and pharmacy buying groups; (b) credits or allowances actually granted upon rejections or returns of Products, including for recalls or damaged goods; (c) freight, postage, shipping and insurance charges actually allowed or paid for
delivery of Products, to the extent billed; (d) customs duties, surcharges and other governmental charges incurred in connection with the exportation or importation of a Product; (e) bad debts relating to sales of Products that are
actually written off by BMS in accordance with GAAP during the applicable calculation period; (f) costs due to the factoring of receivables; and (g) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on
sale of Products, including value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based on net income of the seller;
provided that all of the foregoing deductions are calculated in accordance with generally accepted accounting principles consistently applied throughout the Party’s organization. 
 Notwithstanding the foregoing, if any Product is sold under a bundled or capitated arrangement with other BMS products, then, solely for the purpose of calculating Net Sales under this Agreement, any discount on such
Products sold under such an arrangement shall be [ * ] for the applicable accounting period. In case of any dispute as to the applicable [ * ] under the preceding sentence, the determination of same shall be calculated and certified by
[ * ], whose decision shall be binding. 
 A sale of a Product is deemed to occur upon invoicing. [ * ]. 
 For sake of clarity and avoidance of doubt, sales by BMS, its Affiliates or sublicensees of a Product to [ * ]. Any Products [ * ] considered in
determining Net Sales hereunder. 
 In the event a Product is sold as an end-user product consisting of a combination of active functional elements or as a
combined product and/or service, Net Sales, for purposes of determining royalty payments on such Product, shall be calculated by multiplying the Net Sales of the end-user product and/or service by the fraction A over A+B, in which A is the gross
selling price of the Product portion of the end-user product and/or service when such Product is sold separately during the applicable accounting period in which the sales of the end-user product were made, and B is the gross selling price of the
other active elements and/or service, as the case may be, of the end-user product and/or service sold separately during the accounting period in question. All gross selling prices of the elements of such end-user product and/or service shall be
calculated as the average gross selling price of the said elements during the applicable accounting period for which the Net Sales are being calculated. In the event that, in any country or countries, no separate sale of either such above-designated
Product or such above designated elements of the end-user product and/or service are made during the accounting period in which the sale was made or if gross retail selling price for an active functional element, component or service, as the case
may be, cannot be determined for an accounting period, Net Sales allocable to the Product in each such country shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question based
on an equitable method of determining same that takes into account, on a country-by-country basis, variations in potency, the relative contribution of each active agent, component or service, as the 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 10 

 
case may be, in the combination, and relative value to the end user of each active agent, component or service, as the case may be. Notwithstanding the
foregoing, the Parties agree that, for purposes of this paragraph, drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients” or “active functional elements”. 
 1.66 “Operating Profit (or Loss)” means Net Sales of Co-Promotion Products in the U.S. less Allowable Expenses in the U.S. For sake of
clarity, Operating Profit (or Loss) shall be determined [ * ], and if such terms are used individually, “Operating Profit” shall mean a positive Operating Profit (or Loss), and “Operating Loss” shall mean a
negative Operating Profit (or Loss). 
 1.67 “Patent” means all: (a) unexpired letters patent (including
inventor’s certificates and utility models) which have not been held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time period (and which have not been
admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement), including any substitution, extension,
registration, confirmation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions, renewal or any like filing thereof; (b) pending applications for letters patent which have not been canceled,
withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever reason (and from which no appeal is or can be taken), and/or abandoned in accordance with or as permitted by the terms
of this Agreement or by mutual written consent, including any continuation, division or continuation-in-part thereof and any provisional or other priority applications; and (c) any international counterparts, and counterparts in any country, to
clauses (a) and (b) above. 
 1.68 “Phase I Clinical Trial” means a clinical trial of a Product on sufficient
numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use, can be delivered in a dose(s) that is therapeutically useful, and to support its continued testing in Phase II Clinical
Trials. 
 1.69 “Phase II Clinical Trial” means a Phase IIa Clinical Trial or a Phase IIb Clinical Trial. 
 1.70 “Phase IIa Clinical Trial” means a controlled clinical trial of a Product that utilizes the pharmacokinetic and pharmacodynamic
information obtained from one (1) or more previously conducted Phase I Clinical Trial(s) and/or other Phase IIa Clinical Trial(s) in order to confirm the optimal manner of use of such Product (dose and dose regimens) and to better determine
safety and efficacy. 
 1.71 “Phase IIb Clinical Trial” means a clinical trial of a Product on sufficient numbers of
patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens. 
 1.72 “Phase III Clinical Trial” means a clinical trial of a Product on sufficient numbers of patients that is designed to establish that
such Product is safe and efficacious for its 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 11 

 
intended use, and to define warnings, precautions and adverse reactions that are associated with such Product in the dosage range to be prescribed, and to
support Regulatory Approval of such Product or label expansion of such Product. 
 1.73 “Phase IIIb Clinical Trial” means a
clinical trial of a Product, initiated before regulatory approval and is not required for same, but which may provide data that further defines how and where the drug should be used. A Phase IIIb Clinical Trial may include epidemiological studies,
modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials that are approved by the JDC and that otherwise fit the foregoing definition. 
 1.74 “Phase IV Clinical Trial” means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical
Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by the JDC and that otherwise fit the foregoing definition. 
 1.75 “Product” means any therapeutic or prophylactic product (for use in animals or humans) that contains or comprises a Collaboration
Compound for which BMS has exercised its Co-Development Option in accordance with the terms of this Agreement. 
 1.76 “Program
Backups” means, with respect to a Lead Op Program, Provisional Collaboration Program or Collaboration Program any compounds, other than the Program Lead, that: (a) were created by BMS or Exelixis as part of such Lead Op Program,
Provisional Collaboration Program or Collaboration Program (or Backup Program pursuant to Section 3.5); (b) [ * ] the applicable Lead Op Target(s) or Collaboration Target(s) [ * ]; and (c) [ * ] Lead Op
Target(s) or Collaboration Target(s), based on the [ * ], and any [ * ] of any such compounds described in ((a), (b) and (c)) above. 
 1.77 “Program Lead” means, for any Lead Op Program, Provisional Collaboration Program or Collaboration Program, a small molecule compound that: (a) was created by Exelixis as part of the relevant
Lead Op Program, Provisional Collaboration or Collaboration Program; (b) [ * ] the applicable Lead Op Target(s) or Collaboration Target(s) [ * ]; (c) [ * ] Lead Op Target(s) or Collaboration Target(s), based on the
[ * ]; (d) meets Exelixis’ internal standards applicable to a Development Candidate; and (e) is [ * ] that would otherwise result in [ * ]. 
 1.78 “Registrational Trial” means, with respect to a given Product, either (i) a Phase III Clinical Trial with such Product or
(ii) a Phase IIb Clinical Trial that, at the time of commencement, is expected to be the basis for initial Regulatory Approval of such Product. 
 1.79 “Regulatory Approval” means any and all approvals (including Drug Approval Applications, supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses,
registrations or authorizations of any Regulatory Authority, national, supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental
entity, that are necessary for the manufacture, distribution, use or sale of a Product in a regulatory jurisdiction. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 12 

 1.80 “Regulatory Authority” means the applicable national (e.g., the FDA),
supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity that, in each case, governs the approval of a Product in such
applicable regulatory jurisdiction. 
 1.81 “Regulatory Expenses” means costs incurred to prepare product regulatory
submissions and to obtain and maintain Regulatory Approval in the U.S. and to comply with Regulatory Approvals and requirements of Regulatory Authorities, including FDA user and other fees, reporting and regulatory affairs activities, and recalls
and withdrawals for Co-Promotion Product (other than costs for Co-Promotion Product that are deductible from Net Sales or that are included as Development Costs). 
 1.82 “Reporting-Only Product” means any Product with respect to which Exelixis exercised a Product Opt-Out pursuant to Section 4.7(a) prior to [ * ] such Product. 
 1.83 “Royalty-Bearing Product” means a Product: (a) with respect to which Exelixis failed to make the co-development election
contemplated by Section 3.7(c); or (b) with respect to which: (i) Exelixis has notified BMS of a Product Opt-Out; or (ii) with respect to which Exelixis elected not to exercise its Co-Promotion Option or where such
Co-Promotion Option expired unexercised. 
 1.84 “Royalty Territory” means the world, excluding the U.S. 
 1.85 “Sales and Marketing Costs” means the [ * ] costs that are [ * ] the sales and marketing of a Co-Promotion Product in
the U.S., including: (a) activities directed to the advertising and marketing of a Co-Promotion Product; (b) professional education (to the extent not performed by sales representatives), including launch meetings; (c) costs of
advertising, public relations and medical education agencies; (d) peer-to-peer activities, such as continuing medical education, grand rounds, and lunch and dinner meetings; (e) speaker programs, including the training of such speakers;
(f) grants to support continuing medical education or research (excluding Clinical Costs); (g) development, publication and dissemination of publications relating to a Co-Promotion Product; (h) developing, obtaining and providing
training packages of a Co-Promotion Product, promotional literature, promotional materials and other selling materials; (i) developing and performing market research; (j) conducting symposia and opinion leader development activities;
(k) development reimbursement programs; (l) developing information and data specifically intended for national accounts, managed care organizations and group purchasing organizations; (m) [ * ] incurred in connection with [
* ], to the extent provided therein; (n) direct expenses relating to selling by non-Affiliate Third Parties; (o) costs of transporting, housing and maintaining sales representatives for training; (p) conducting Phase IIIb Clinical
Trials and Phase IV Clinical Trials, and clinical trials performed for marketing purposes and post-marketing surveillance activities; (q) administration, operation and maintenance of the sales force that promotes a Co-Promotion Product in the
U.S., sales bulletins and other communications, sales meetings, specialty sales forces, consultants, call reporting and other monitoring/tracking costs, district and regional sales management, home office personnel who support the sales force; and
(r) costs associated with Medical Education Activities, and other ancillary services to the foregoing (to the extent not otherwise falling within 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 13 

 
subsections (a) through (r). Sales and Marketing Costs shall include costs of such activities that are undertaken at any time during the term of
this Agreement (including prior to the initial Regulatory Approval of a Co-Promotion Product in the U.S.). 
 1.86 “Screening
Target(s)” means any one or more targets that: (a) the Parties mutually agree becomes part of the Collaboration pursuant to Section 3.2(a); and (b) are not the subject of: (i) a collaboration between Exelixis and
a Third Party; or (ii) discussions between Exelixis and a Third Party concerning a bona fide collaboration. The Screening Targets shall be listed in Exhibit 3.2, which shall be updated periodically by the Parties. 
 1.87 “Sole Invention” means any Invention invented or discovered solely by or on behalf of a Party (or its Affiliate) and its employees,
contractors and/or agents. 
 1.88 “Specificity Criteria” means, for each Collaboration Compound, that such Collaboration
Compound: (a) demonstrates [ * ] as determined [ * ]; and (b) has a [ * ] in such [ * ]. 
 1.89 “Target Potency
Threshold” means, for each Collaboration Compound, that such Collaboration Compound [ * ]. 
 1.90 “Territory”
means the world. 
 1.91 “Third Party” means any entity other than: (a) Exelixis; (b) BMS; or (c) an
Affiliate of either Party. 
 1.92 “Third Party Royalties” means royalties and other payments payable to a Third Party in
consideration for rights [ * ] for the [ * ] of Co-Promotion Product. 
 1.93 “Trademark Costs” mean the fees
and expenses paid to outside counsel and other Third Parties, direct costs of in-house counsel and filing and maintenance expenses, incurred in connection with the establishment and maintenance of rights under trademarks applicable to Co-Promotion
Product in the U.S., including costs of filing and registration fees, actions to enforce or maintain a trademark and other proceedings. 
 1.94 “United States” or “U.S.” means the United States of America, and its territories, districts and possessions. 
 1.95 “Unrelated Compound” means, with respect to a Lead Op Program, Provisional Collaboration Program or Collaboration Program, any Program Backups that: (a) were created by BMS or Exelixis as
part of such Lead Op Program, Provisional Collaboration Program or Collaboration Program (or Backup Program pursuant to Section 3.5); and (b) either: (i) [ * ] applicable Lead Op Target(s) or Collaboration Target(s) [
* ]; or (ii) are [ * ] Lead Op Target(s) or Collaboration Target(s), based on the [ * ]. 
 1.96 “Valid
Claim” means (a) a claim in an issued Patent that has not: (i) expired or been canceled; (ii) been declared invalid by an unreversed and unappealable or unappealed decision of a court or other appropriate body of competent
jurisdiction; (iii) been admitted to be 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 14 

 
invalid or unenforceable through reissue, disclaimer or otherwise; or (iv) been abandoned in accordance with or as permitted by the terms of this
Agreement or by mutual written agreement of the Parties; or (b) a claim under an application for a Patent that has been pending for [ * ] for [ * ], and, in any case, which has not been canceled, withdrawn from consideration, finally determined
to be unallowable by the applicable governmental authority or court for whatever reason (and from which no appeal is or can be taken), or abandoned. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 15 

 Additional Definitions 
 The following table identifies the location of definitions set forth in various Sections of the Agreement. 
  

			
	 Definition
	 	 Location (Section)

	Alliance Manager	 	2.8(a)
	Annual Development Plan	 	4.2(a)
	Backup Program	 	3.5(b)(i)
	[ * ]	 	[ * ]
	BMS Rejected Lead Op Target	 	3.3(d)
	Co-Development Option	 	3.1(b)
	Collaboration Program	 	3.4(b)(i)
	Collaboration Target	 	3.3(b)
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	Co-Promotion Agreement	 	6.4(a)
	Co-Promotion Notice	 	6.4(b)
	Co-Promotion Option	 	6.4(a)
	DCP	 	3.3(b)
	[ * ]	 	[ * ]
	Effective Date	 	13.6
	Exelixis Co-Development Option	 	3.7(c)
	[ * ]	 	[ * ]
	Global Commercialization Strategy	 	6.2(a)
	Global Development Plan	 	4.1(a)
	Indication Opt-Out	 	4.7(b)
	JAMS	 	3.6(b)(iii)
	Lead Op Candidate	 	3.2(b)
	[ * ]	 	[ * ]
	Party Implementation Matter	 	2.7(c)(ii)
	Party Vote	 	2.7(c)(i)
	Pharmacovigilance Agreement	 	5.7
	Product Opt-Out	 	4.7(a)
	Provisional Collaboration Program	 	3.4(a)
	Rejected Lead Op Target	 	3.3(c)
	[ * ]	 	[ * ]
	Rejected Screening Target	 	3.2(b)
	Research Term	 	3.10
	ROC	 	1.6
	Royalty Term	 	9.11
	Screening Program	 	3.2
	[ * ]	 	[ * ]
	[ * ]	 	[ * ]
	Term	 	12.1
	U.S. Commercialization Plan	 	6.2(a)
	Working Group	 	2.7(f)

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 16 

	2.	MANAGEMENT OF COLLABORATION 

 2.1 General.

 (a) Role of Committees. Subject to Section 2.1(b) and the other terms and conditions of this Agreement, the Parties
shall establish: (i) a joint executive committee (the “Joint Executive Committee” or “JEC”) that will oversee the Collaboration and facilitate communications between the Parties with respect to the Development,
Regulatory Approval, and Commercialization of Committee-Governed Products hereunder; and (ii) four (4) specialized joint committees consisting of one to focus on each of the following areas arising out of the Collaboration:
(A) discovery efforts in connection with Screening Programs, Lead Op Programs, Provisional Collaboration Programs and Collaboration Programs, as described in Article 3 (such committee, the “Joint Research Committee” or
“JRC”); (B) Development and Regulatory Approval and other regulatory matters (such committee, the “Joint Development and Regulatory Committee” or “JDC”); (C) Commercialization (such
committee, the “Joint Commercialization Committee” or “JCC”); and (D) financial issues (such committee, the “Joint Finance Committee” or “JFC”). Each Committee shall have
the responsibilities and authority allocated to it in this Article 2 and elsewhere in this Agreement. It is contemplated that: (X) all significant matters (other than Party Implementation Matters, as defined in
Section 2.7(c)(ii)) relating to: (I) the discovery and pre-clinical Development of Collaboration Compounds; and (II) the clinical Development of Committee-Governed Products and the Commercialization of Co-Promotion Products, in each
case under this Agreement will be addressed by the applicable first-tier Committees (i.e., the JRC, the JDC, the JCC, or the JFC) and, if appropriate, by the JEC, as contemplated by Section 2.7(c); and (Y) the Parties’
respective activities under this Agreement (including Party Implementation Matters) will be reported to the relevant Committees in a reasonable and appropriate level of detail. Each of the JRC (to the extent applicable), JDC, JCC, and the JFC shall
provide, on a [ * ] basis (unless otherwise requested by the JEC), updates on its activities and achievements to the JEC for review and comment. The Parties intend that their respective organizations will work together to assure the success
of the Collaboration. 
 (b) Limitations on the Authority of Committees. Notwithstanding the Committee structure established
pursuant to Section 2.1(a) to oversee the Collaboration, each Party shall retain the rights, powers and discretion granted to it under this Agreement, and no such rights, powers, or discretion shall be delegated to or vested in a
Committee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. Without limiting the generality of the foregoing, no Committee shall have any authority or
jurisdiction to: (i) amend, modify, or waive compliance with this Agreement, any of which shall require mutual written agreement of the Parties; (ii) interpret this Agreement, or determine whether or not a Party has met its diligence
or other obligations under the Agreement or whether or not a breach of this Agreement has occurred; (iii) require Exelixis to [ * ] (other than [ * ], [ * ] that are carried out in accordance with the [ * ], and any
[ * ] obligations with respect to [ * ] that are set forth in the applicable [ * ]) without Exelixis’ express written consent ([ * ]); (iv) require Exelixis to [ * ] (other than [ * ], [ * ]
that are carried out in accordance with [ * ], and any [ * ] with respect to [ * ] that are set forth in the applicable [ * ]) 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 17 

 
without Exelixis’ express written consent (which [ * ]); (v) require BMS to [ * ] (other than [ * ]) without BMS’ express
written consent (which [ * ]); (vi) make any decision on any matter that this Agreement expressly states is an option or election to be made by a Party; (vii) make any retroactive updates, amendments and modifications to, or waivers
of provisions of, an Approved Plan, any which shall require the mutual agreement of the Parties; and (viii) such other matters as are reserved to the consent, approval, agreement or other decision-making authority of one or both Parties in this
Agreement and that are not required by this Agreement to be considered by one or more Committees prior to the exercise of such consent, approval or other decision-making authority. For clarity, a Party’s right to cast a deciding vote on a
matter in a Committee pursuant to Article 2 shall not, in and of itself, subject such matter to the preceding sentence. Notwithstanding the foregoing, neither Party shall be restricted from bringing before any appropriate Committee for
discussion any matter relating to the Collaboration that it believes warrants discussion between the Parties through the Committees, provided that the consideration of any such matter by any Committee shall not infringe or limit the exercise
of a Party’s right of consent or approval or other decision-making authority granted to it by this Agreement nor shall any such consideration, as contemplated by this sentence, subject any such right of consent or approval or other
decision-making authority to any dispute resolution mechanism provided for in Section 2.7(c) or Article 15 or elsewhere in this Agreement. 
 2.2 Joint Executive Committee. 
 (a) Formation and Purpose. Exelixis and BMS shall
establish the JEC within [ * ] after the first exercise by BMS of its Co-Development Option pursuant to Section 3.4(b). Subject to Sections 2.1(b) and 2.7(c), the JEC shall have overall responsibility for the
success of the Collaboration, and its general areas of responsibility shall be: (a) to determine the global Development, regulatory, Commercialization, and manufacturing strategy for the Collaboration; (b) to coordinate the
Parties’ activities hereunder; and (c) as applicable, to review, comment on, approve, and resolve disputes with respect to, plans and budgets for, and the implementation of, the Collaboration, including the specific responsibilities of the
JEC outlined below, in each case (clauses (a), (b) and (c) above) solely with respect to Committee-Governed Products. The JEC shall have the membership and shall operate by the procedures set forth in Section 2.7.

 (b) Specific Responsibilities of the JEC. In addition to its overall responsibility for the Collaboration, but subject to
Sections 2.1(b) and 2.7(c), the JEC shall, in particular, have the following specific responsibilities with respect to Committee-Governed Products: 
 (i) approve the global development, regulatory and commercialization strategies for the Collaboration; 
 (ii) coordinate the Parties’ activities hereunder; 
 (iii) approve plans and budgets for the Collaboration
proposed by the JDC or JCC; 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 18 

 (iv) review all significant and strategic issues within the purview of the various Committees;

 (v) manage and oversee the development and commercialization of each Product pursuant to the terms of the Agreement; 

(vi) review and approve any material amendments to the Approved Plans and any other items submitted to the JEC by the JDC or JCC; 

(vii) oversee life cycle management of, and intellectual property protection for, a Product; 
 (viii) provide a forum for dispute resolution; and 
 (ix) such other responsibilities as may be assigned to the JEC pursuant to the Agreement or as may be agreed between the Parties from time to time. 
 2.3 Joint Development and Regulatory Committee. 
 (a) Formation and Purpose. Exelixis and BMS shall establish the JDC within [ * ] after the earlier of: (i) [ * ]; or (ii) [ * ]. Subject to Sections 2.1(b) and 2.7(c),
the JDC shall oversee, coordinate and expedite the Development of, and the making of regulatory filings for, each Committee-Governed Product worldwide in order to obtain Regulatory Approvals (or compendia listings, as applicable). The JDC will
also facilitate the flow of information with respect to Development activities being conducted for each Product and oversee Development activities required to support Regulatory Approvals (or compendia listings, as applicable). The JDC shall
have the membership and shall operate by the procedures set forth in Section 2.7. 
 (b) Specific Responsibilities of the
JDC. In support of its responsibility for overseeing, coordinating and expediting the Development of, and regulatory filings for, each Committee-Governed Product, but subject to Sections 2.1(b) and 2.7(c), the JDC shall, in
particular, and solely with respect to Committee Governed Products: 
 (i) monitor Development activities; 
 (ii) prepare the Global Development Plan and each Annual Development Plan; 
 (iii) review all material information generated in the course of implementing the Global Development Plan and the Annual Development Plans;

 (iv) assist in coordinating scientific interactions and division of responsibilities with respect to Development Activities, and
resolving disagreements during the course of implementing the Global Development Plan and the Annual Development Plans; 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 19 

 (v) design, in collaboration with the JCC, pharmacoeconomic studies or Phase IV Clinical Trials;

 (vi) monitor and coordinate all regulatory actions, communications and submissions for Products, including establishing the
schedule and implementation strategy for all regulatory filings for Products; 
 (vii) provide on a quarterly basis updates on its
activities and achievements to the JEC for review and comment; 
 (viii) pursuant to Section 3.6(b), review and determine
whether the definition of Identified Target(s) for each applicable Lead Op Program, Provisional Collaboration Program and Collaboration Program need to be modified; and 
 (ix) such other responsibilities as may be assigned to the JDC pursuant to the Agreement or as may be agreed between the Parties from time to time. 
 2.4 Joint Commercialization Committee. 
 (a) Formation and Purpose. Exelixis and BMS shall establish the JCC within [ * ] after [ * ], which Committee shall, subject to Sections 2.1(b) and 2.7(c), oversee: (i) the Commercialization strategy of
each Co-Promotion Product in the Co-Development Territory; and (ii) the Commercialization of Co-Promotion Products in the U.S. including the marketing, sales and distribution of each Co-Promotion Product in the U.S. The JCC shall have the
membership and shall operate by the procedures set forth in Section 2.7. 
 (b) Specific Responsibilities of the
JCC. In support of its responsibilities as described in clause (a) above, the JCC shall, subject to Sections 2.1(b) and 2.7(c), perform the following activities solely with respect to Co-Promotion Products: 
 (i) prepare the Global Commercialization Strategy and the U.S. Commercialization Plan, and any updates thereto; 
 (ii) review the allocation of Commercialization responsibilities between the Parties to ensure consistency with the terms of this Agreement, the
Global Commercialization Strategy, and the U.S. Commercialization Plan; 
 (iii) coordinate and oversee the Parties’ plans for
labeling, branding and selecting trademarks for each Product; 
 (iv) review life cycle management opportunities; 
 (v) review pricing and reimbursement strategies with respect to Products in the Royalty Territory and 
 (vi) With respect to Co-Promotion Products in the U.S. only: 
 (1) review and approve advertising materials and strategies and promotional materials developed by a Party for the Parties’ Sales Representatives; 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 20 

 (2) approve the selection of major or key marketing vendors (e.g., public relations and
advertising agencies and medical education agencies) ; 
 (3) approve pricing and reimbursement, patient assistance, vendor return
and co-pay strategies; 
 (4) design, in collaboration with the JDC, pharmacoeconomic studies or Phase IV Clinical Trials;

 (5) approve market research plans; 
 (6) approve and coordinate all sales force activities, including training, number, proportion of time to be devoted to promotion, and territory alignment; 
 (7) approve packaging designs, and oversee educational and professional symposia, and speaker and peer-to-peer activity programs; 
 (8) discuss a range of suggested prices at which a Co-Promotion Product will be sold to unaffiliated Third Parties and any discount strategies
for such Co-Promotion Product (it being understood that BMS will determine all pricing and reimbursement terms for Co-Promotion Products sold to customers); 
 (9) review of each Party’s reports pertaining to its Sales and Marketing Costs; and 
 (10)
review early access and compassionate use programs. 
 (c) Available Resources. Except as otherwise provided in Article 6
or any applicable Co-Promotion Agreement, the JCC shall, in allocating responsibilities between the Parties with respect to Commercialization activities for Co-Promotion Products under this Agreement in the United States: (i) endeavor to take
advantage of the respective resources, capabilities and expertise of Exelixis and BMS; and (ii) endeavor to: (A) maintain, to the extent reasonably practical and commercially appropriate, continuity in functions and commitments of
personnel and physical resources of the Parties; (B) avoid duplication of efforts by the Parties; and (C) foster efficient use by the Parties of resources and personnel, consistent with this Agreement and the applicable Global
Commercialization Strategy and the applicable U.S. Commercialization Plan. For clarity, BMS shall be solely responsible for the Commercialization of each Product in the Royalty Territory and for each Royalty-Bearing Product in the United States.

 2.5 Joint Research Committee. Exelixis and BMS shall establish the JRC within [ * ] after the Effective Date, which
Committee shall, subject to Sections 2.1(b) and 2.7(c), oversee the discovery efforts with respect to Screening Programs, Lead Op Programs, Provisional Collaboration Programs and Collaboration Programs, as described in Article 3,
including work 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 21 

 
performed by BMS on Provisional Collaboration Programs in accordance with Section 3.4(a). The JRC shall have the membership and shall operate by
the procedures set forth in Section 2.7, and shall disband subsequent to the Research Term or otherwise at the direction of the JEC. Without limiting the generality of the foregoing, the JRC shall have the specific responsibilities set
forth below: 
 (a) provide a forum to allow BMS to review and comment with respect to discovery and pre-clinical Development
activities and for Exelixis to report progress with respect to discovery and pre-clinical Development activities; 
 (b) make decisions
with respect to: (i) which targets will become Screening Targets, Lead Op Candidates and Lead-Op Programs; (ii) which Screening Targets, Lead Op Candidates, Lead-Op Targets and Collaboration Candidates will be terminated; and
(iii) which compounds will become Program Leads; 
 (c) review [ * ] proposed by BMS, and discuss the progress of Lead-Op
Candidates, Development Candidates and Collaboration Candidates in relation to those [ * ]; and 
 (d) pursuant to
Section 3.6(b), review and determine whether the definition of Identified Target(s) for each applicable Lead Op Program, Provisional Collaboration Program and Collaboration Program need to be modified. 
 2.6 Joint Finance Committee. Exelixis and BMS shall establish a JFC within forty-[ * ] subsequent to the [ * ]. The JFC shall provide support to
all other Committees with respect to accounting and financial matters relating to Committee-Governed Products. The JFC shall have the membership and shall operate by the procedures set forth in Section 2.7. 
 2.7 General Committee Membership and Procedures. 
 (a) Membership. Each Committee shall be composed of such number of representatives as may be agreed by the Parties. Each of BMS and Exelixis shall designate representatives with appropriate expertise to serve
as members of each Committee, and each representative may serve on more than one Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time upon written notice to the
other Party. Each Committee shall have co-chairpersons. BMS and Exelixis shall each select from their representatives a co-chairperson for each of the Committees, and each Party may change its designated co-chairpersons from time to time
upon written notice to the other Party. The Alliance Managers shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within
[ * ] thereafter; provided that a Committee co-chairperson shall call a meeting of the applicable Committee promptly upon the written request of the other co-chairperson to convene such a meeting. The minutes of each meeting shall, among
other things, record all matters acted upon and approved or disapproved by the Committee, actions to be taken, and any matters the Committee failed to resolve. Such minutes will not be finalized until both Alliance Managers review and confirm
in writing the accuracy of such minutes. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 22 

 (b) Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no
event shall such meetings be held less frequently than once every [ * ] for the JRC and once every [ * ] for the JDC, the JCC, and the JFC, and once every [ * ] for the JEC. Each Committee shall meet alternately at
Exelixis’ facilities in South San Francisco, California, and BMS’ facilities in Princeton, New Jersey, or at such other locations as the Parties may agree. The Alliance Managers shall, and other employees of each Party involved in the
Development, Manufacture or Commercialization of any Product may as needed, attend meetings of each Committee (as nonvoting participants unless they are members of such Committee), and consultants, representatives or advisors involved in the
Development, Manufacture or Commercialization of any Product may attend meetings of each Committee as nonvoting observers; provided that such Third Party representatives are under obligations of confidentiality and non-use applicable to the
Confidential Information of each Party that are at least as stringent as those set forth in Article 11, and in the case of non-employees of a Party, subject to the consent of the other Party, which shall not be unreasonably withheld or
delayed. Each Party shall be responsible for all of its own expenses of participating in any Committee (including in any Working Group). Meetings of any Committee may be held by audio or video teleconference with the consent of each Party, which
shall not be unreasonably withheld or delayed; provided that at least [ * ] per year of such Committee shall be held in person. No action taken at any meeting of a Committee shall be effective unless a representative of each Party is
participating. 
 (c) Decision-Making. 
 (i) Voting on Committee Decisions. Subject to Section 2.1(b), each Party’s designees on a Committee shall, collectively, have one (1) vote (the “Party Vote”) on all
matters brought before the Committee, which Party Vote shall be determined by [ * ] of such Party’s designees present (in person or otherwise) at the meeting. Except as expressly provided in this Section 2.7(c) and
subject to Section 2.1(b), each Committee shall operate as to matters within its jurisdiction by unanimous Party Vote. All decisions of a Committee shall be documented in writing in the minutes of the applicable Committee meeting by the
Alliance Managers, and, to the extent applicable, included on the target status list described in Section 3.9. 
 (ii)
Operational Decisions. Before selection by BMS of a Collaboration Program pursuant to exercise of BMS’ Co-Development Option, day-to-day operational level decisions concerning the identification, optimization, non-clinical development and
clinical development (up through IND submission) of Collaboration Compound shall be made by Exelixis, except as expressly stated in this Agreement. Following selection by BMS of a Collaboration Program pursuant to exercise of BMS’
Co-Development Option, day-to-day operational level decisions concerning the Development and Commercialization of Products in such Collaboration Program shall be made by the Party to which responsibility for such decisions has been allocated under
the Agreement (each such decision, a “Party Implementation Matter”). Unless otherwise directed by the appropriate Committee(s), [ * ] shall be the lead Party, and shall be primarily responsible for, all Development,
regulatory activities and Manufacturing and, subject to [ * ], Commercialization activities with respect to a Product. Any disputes with respect to a Party Implementation Matter shall first be referred to the Alliance Managers, and, if the
dispute is not resolved within [ * ] after such referral to the Alliance 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 23 

 
Managers, then it shall, upon written notice by a Party to the other, be referred for resolution as follows: (A) disputes between designees of BMS and
Exelixis with respect to Development and Regulatory Approval matters shall be referred to the JDC for resolution; and (B) disputes between designees of BMS and Exelixis with respect to Commercialization shall be referred to the JCC for
resolution. In each case, except for Appealable Matters, the Committee to which such matter is referred shall have final decision-making authority with respect to such matter, and [ * ] shall [ * ] with respect to such matter, [ *
]. 
 (iii) Disagreements on Committees. Except for: (A) matters outside the jurisdiction and authority of the
Committees as provided in Section 2.1(b); and (B) any Party Implementation Matter (other than Appealable Matters), and in any event without limiting the other rights and obligations of the Parties under this Agreement, any
disagreement between the designees of BMS and Exelixis on the JDC, JCC, JRC or JFC as to matters within such Committee’s jurisdiction shall, at the election of either Party, be addressed, first, with the Alliance Managers, and, if the dispute
is not resolved within [ * ] after such referral to the Alliance Managers, then it shall, upon written notice by a Party to the other, be submitted to the JEC for resolution (except that (1) any disputes arising from the JFC shall be
submitted to the Committee to which such dispute relates (i.e., the JRC, JDC, or the JCC), and (2) prior to the creation of the JEC, disputes at the JRC shall be referred to management of the Parties as set forth in the following sentence). If
the JEC (or JRC, prior to the creation of the JEC) does not resolve any such matter submitted to it for resolution within [ * ] after such submission, or in the event of any disagreement between the designees of BMS and Exelixis on the JEC
(or JRC, prior to the creation of the JEC) with respect to any other matter within its jurisdiction, then, subject to Section 2.1(b), the JEC (or JRC, prior to the creation of the JEC) shall submit the respective positions of the Parties
with respect to such matter for discussion in good faith by the Chief Executive Officer of Exelixis and either the Head of R&D or Head of U.S. Operations of BMS (depending on the nature of the dispute). If such individuals are not able to
mutually agree upon the resolution to such matter within [ * ] after submission of the matter to them, then: (X) [ * ], the [ * ], subject to Section [ * ]; [ * ] (Y) [ * ], the [ * ],
subject to Section [ * ]. 
 (iv) [ * ] Decisions. [ * ] right to [ * ] pursuant to Section [ * ]
(“[ * ] Decisions”) shall be subject to the following limitations: 
 (1) All [ * ] Decisions shall be made in
good faith, with due regard for the impact of such decisions on Collaboration Compounds. No such decision by [ * ] shall violate or breach any term or condition of this Agreement. [ * ] shall make all [ * ] Decisions only after
[ * ] (through its JEC or JRC members, as applicable) on such matters and the proposed [ * ] Decision. 
 (2) [ * ]
shall [ * ]: (A) on matters that would [ * ]; (B) on any decision that would [ * ]; (C) any decision that would [ * ]; (D) on [ * ]; (E) on which [ * ] (F) on [ * ];
(G) on [ * ] for Collaboration Compounds within the associated [ * ]; (H) on [ * ]; (I) to [ * ]; (J) on [ * ] in [ * ]; (K) whether to [ * ]; or (J) decisions described
in Section [ * ]. Resolution of disputes relating to the foregoing matters shall [ * ] (except as otherwise expressly set forth in this Agreement). 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 24 

 (v) [ * ] Decisions. [ * ] right to [ * ] (“[ * ] Decisions”)
shall be subject to the following limitations: 
 (1) All [ * ] Decisions shall be made in good faith, with due regard for the
impact of such decisions on Products [ * ], and, consistent in all material respects with the applicable Approved Plan and the terms of this Agreement. No such decision [ * ] shall violate or breach any term or condition of this
Agreement. [ * ] shall make all [ * ] Decisions only after [ * ] (through its JEC or JRC members, as applicable) on such matters and [ * ], and in the case of [ * ] Decision made pursuant to Section [ * ],
only after [ * ] and the [ * ] on such matters. 
 (2) [ * ] shall [ * ]: (A) on any decision that would
[ * ]; (B) any decision that would amend, violate or breach any provision of this Agreement; (C) on which [ * ] within the associated [ * ]; (D) on the decision to [ * ] (except to the extent provided for
in Section [ * ]); (E) to adjust the [ * ]; (F) on the [ * ]; (G) on matters related to the determination of [ * ]; or (H) whether [ * ]. Resolution of disputes relating to the foregoing matters
shall [ * ] (except as otherwise expressly set forth in this Agreement). 
 (d) Meeting Agendas and Minutes. Each Party shall
disclose to the other proposed agenda items along with appropriate information at least [ * ] in advance of each meeting of the applicable Committee; provided that under exigent circumstances requiring Committee input, a Party may
provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such
agenda items or the absence of a specific agenda for such Committee meeting. 
 (e) Multiple JDCs and JCCs at the Discretion of the
JEC. The JEC may determine that a separate JDC and/or JCC be formed for each Provisional Collaboration Program or Collaboration Program. In such event, the Parties will appoint representatives to such additional committees and such committees
will be subject to the all of the applicable terms and conditions of this Agreement with respect to the JDC and the JCC, in each case, solely with respect to the Provisional Collaboration Program or Collaboration Program to which such Committees
relate. 
 (f) Working Groups. From time to time, the JEC, JDC, JCC, JRC or JFC may establish and delegate duties to other
committees, sub-committees or directed teams (each, a “Working Group”) on an “as-needed” basis to oversee particular projects or activities, which delegation shall be reflected in the minutes of the meetings of the
applicable Committee. Each such Working Group shall be constituted and shall operate as the JEC, JDC, JCC, JRC or JFC, as the case may be, determines. The Working Groups may be established on an ad hoc basis for purposes of a specific project, for
the life of a Product, or on such other basis as the applicable Committee may determine. Each Working Group and its activities shall be subject to the oversight, review and approval of, and shall report to, the Committee that established such
Working Group. In no event shall the authority of the Working Group exceed that specified for the relevant Committee in this Article 2. Any disagreement between the designees of BMS and Exelixis on a Working Group shall be referred to the
applicable Committee for resolution. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 25 

 (g) Interactions Between Committees and Internal Teams. The Parties recognize that each Party
possesses an internal structure (including various committees, teams and review boards) that will be involved in administering such Party’s activities under this Agreement. Each Committee shall establish procedures to facilitate communications
between such Committee or Working Group and the relevant internal committee, team or board of each of the Parties in order to maximize the efficiency of the Collaboration, including by requiring appropriate members of such Committee to be available
at reasonable times and places and upon reasonable prior notice for making appropriate oral reports to, and responding to reasonable inquiries from, the relevant internal committee, team or board. 
 2.8 Alliance Managers. 
 (a)
Appointment. Each of the Parties shall appoint a single individual to act as a single point of contact between the Parties to assure a successful Collaboration (each, an “Alliance Manager”). Each Party may change its designated
Alliance Manager from time to time upon written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other Party. 
 (b) Responsibilities. The Alliance Managers shall use good faith efforts to attend all Committee meetings and support the co-chairpersons of each
Committee in the discharge of their responsibilities. Alliance Managers shall be nonvoting participants in such Committee meetings, unless they are also appointed members of such Committee pursuant to Section 2.7(a). An Alliance Manager
may bring any matter to the attention of any Committee if such Alliance Manager reasonably believes that such matter warrants such attention. Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment
within and among the Committees. In addition, each Alliance Manager: (i) will be the point of first referral in all matters of conflict resolution; (ii) will coordinate the relevant functional representatives of the Parties in developing
and executing strategies and plans for the Products in an effort to ensure consistency and efficiency throughout the world; (iii) will provide a single point of communication for seeking consensus both internally within the respective
Parties’ organizations and between the Parties regarding key strategy and plan issues; (iv) will identify and bring disputes to the attention of the appropriate Committee in a timely manner; (v) will plan and coordinate cooperative
efforts and internal and external communications (including the preparation of the target status list described in Section 3.9); and (vi) will take responsibility for ensuring that governance activities, such as the conduct of
required Committee meetings and production of meeting minutes, occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. 
 2.9 Collaboration Guidelines. 
 (a)
General. Each Party, in working with the other to Develop and Commercialize each Product and otherwise as set forth herein, shall assign responsibilities for the various operational aspects of the Collaboration to those portions of its
organization that have the appropriate resources, expertise and responsibility for such functions and, consistent with this Agreement, treat each Product as if it were a proprietary product solely of its own organization. In all matters related to
the Collaboration, the Parties shall strive to balance as best they can the legitimate interests and concerns of the Parties and to realize the full economic potential of each Product (taking into account the risks and costs of further Development
and Commercialization). 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 26 

 (b) Independence. Subject to the terms of this Agreement, the activities and resources of each
Party shall be managed by such Party, acting independently and in its individual capacity. The relationship between Exelixis and BMS is that of independent contractors and neither Party shall have the power to bind or obligate the other Party in any
manner. 
 2.10 Reports Relating to Reporting-Only Products. Beginning [ * ] after the first existence of a Reporting-Only
Product or a Royalty-Bearing Product, and every [ * ] thereafter during the term of the Agreement, BMS shall submit to Exelixis a written progress report [ * ] the research and development performed by BMS on Reporting-Only Products.
If reasonably [ * ] for Exelixis to exercise its rights under this Agreement, Exelixis may request that BMS provide more detailed information and data regarding such reports by BMS, and BMS shall promptly provide Exelixis with information and
data as is reasonably related to such request, at Exelixis’ expense. All such reports shall be considered Confidential Information of BMS. 
 2.11 Overview of Accounting. 
 (a) Development Costs and Allowable Expenses. For purposes of determining Development
Costs and Allowable Expenses, any expense allocated by either Party to a particular category under Development Costs or Allowable Expenses for a particular Co-Promotion Product shall not be allocated to another category under Development Costs or
Allowable Expenses for such Co-Promotion Product. Each Party agrees to determine Development Costs and Allowable Expenses for Co-Promotion Products using its standard accounting procedures, consistently applied, to the maximum extent practical as if
such Co-Promotion Product were a solely owned Product of such Party, except as specifically provided in this Agreement. The Parties also recognize that such procedures may change from time to time and that any such changes may affect the definition
of Development Costs or Allowable Expenses. The Parties agree that, where such changes are economically material to either Party, and consistent with GAAP, adjustments shall be made to compensate the affected Party to preserve the same economics as
reflected under this Agreement under such Party’s accounting procedures in effect as of the date on which the activity in question (e.g., Development, Commercialization or Manufacturing) first commences under this Agreement. Where the change is
or would be material to the other Party, the Party proposing to make the change shall provide the other Party with an explanation for the proposed change and an accounting of the effect of the change on the relevant expense category. Should the
Parties disagree on the adjustment, the matter shall be placed before the JFC to resolve. Transfers between a Party and its Affiliates (or between its Affiliates) shall not have effect for purposes of calculating revenues, costs, profits, royalties
or other payments or expenses under this Agreement. 
 (b) Affiliates. If either Party enters into any agreement with any of its
Affiliates for the provision of materials or services pursuant to this Agreement, all costs incurred for the provision of such materials or services that are shared by the Parties under this Agreement shall be accounted for on the basis of the cost
thereof to such Affiliate and not on the basis of any higher transfer price in effect between such Party and such Affiliate. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 27 

 2.12 Compliance with Law. Each Party hereby covenants and agrees to comply with applicable law in
performing its activities connected with the Development, manufacture and Commercialization (as applicable) of each Product. 
 2.13
Records. Each Party shall maintain complete and accurate records of all work conducted under the Collaboration and all results, data and developments made pursuant to its efforts under the Collaboration. Such records shall be complete and
accurate and shall fully and properly reflect all work done and results achieved in the performance of the Collaboration in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Each Party shall maintain
such records for a period of [ * ] after such records are created; provided that the following records may be maintained for a longer period, in accordance with each Party’s internal policies on record retention, provided that in no case
shall such period be shorter than [ * ] from the date of creation of such records: (a) scientific notebooks; and (b) any other records that the other Party reasonably requests be retained in order to ensure the preservation,
prosecution, maintenance or enforcement of intellectual property rights. Either Party shall have the right to review and copy such records of the other Party at reasonable times to the extent [ * ] for it to conduct its obligations or enforce
its rights under this Agreement 
  

	3.	DISCOVERY PROGRAM 

 3.1 Overview. 

(a) Programs. During the Research Term, Exelixis shall be responsible for conducting the [ * ]. Exelixis will devote to each program
similar resources (including comparably qualified and experienced personnel) and funding as it does to internal programs at a similar stage of discovery or pre-clinical development, with the goal of delivering not less than six (6) Provisional
Collaboration Programs for possible exercise by BMS of up to three (3) of its Co-Development Options. 
 (b) BMS Co-Development
Option. BMS shall have the [ * ] option to select each Provisional Collaboration Program as a Collaboration Program for collaborative Development and Commercialization under this Agreement (the “Co-Development Option”);
provided, however, that in no event would BMS be permitted to select more than three (3) Collaboration Programs pursuant to this Co-Development Option. The Co-Development Option shall be exercisable solely in accordance with the
remainder of this Article 3. 
 3.2 Screening Programs. 
 (a) In General. During each year of the Research Term, as described in more detail below, Exelixis shall conduct programs as part of the
Collaboration (“Screening Programs”) in which Exelixis will [ * ]. As of the Execution Date, the Parties shall mutually agree to the initial prioritized list of up to [ * ] Screening Targets for the [ * ]
Research Term, which shall be listed in Exhibit 3.2. No later than at the last JRC meeting prior to the [ * ], 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 28 

 
Exelixis will share its list of planned screening targets for the [ * ] Research Term and, within [ * ] subsequent to the date upon which such
planned screening targets are shared, BMS shall select up to [ * ] such prioritized targets as Screening Targets for the [ * ] Research Term, which shall be added to the table described in Section 3.9; provided that BMS may
[ * ] Screening Targets and up to [ * ] such targets [ * ] Screening Targets by mutual agreement of the Parties. If at the start of the [ * ] Research Term, or during any quarter thereafter, and subject to
Section 3.2(c), the number of Lead Op Candidates has dropped below [ * ], then Exelixis shall conduct at least [ * ] Screening Programs in each subsequent calendar quarter, with the Screening Targets for such new Screening
Programs [ * ] or, [ * ] added to the table described in Section 3.9. Such [ * ] shall continue until such time as either: (A) [ * ]; or (B) there [ * ]. Each quarter during the [ * ]
Research Term, the JRC (by mutual agreement) may [ * ], in which case the Alliance Managers shall reflect such [ * ] pursuant to Section 3.9. 
 (b) Completion of Screening; Lead Op Candidates. After a given Screening Program has become a Completed Screening Program, [ * ] (such Completed Screening Program, if [ * ], becomes a
“Lead Op Candidate”). If the [ * ], then the target(s) associated with such Lead Op Program shall become a “Lead Op Target(s).” If the [ * ], not to maintain such Lead Op Candidate(s) within the
Collaboration, then the Screening Target(s) associated with such advanced Screening Program shall no longer be Screening Target(s) but shall instead be “Rejected Screening Target(s)”, subject to Section 8.6(b).
Otherwise, such Lead Op Candidate(s) shall remain Lead Op Candidate(s) (pending a future decision by: (i) [ * ]. For clarity, Exelixis may, [ * ], [ * ](s) into a [ * ], provided that: (I) Exelixis will maintain
an [ * ] (by mutual agreement) [ * ]; and (II) [ * ] will remain subject to the terms and conditions of this Agreement, including without limitation Section [ * ]; provided that BMS may [ * ] at any time prior to
the [ * ], and (for clarity) [ * ] be deemed to be either (1) [ * ] a Lead Op Program pursuant to Section [ * ], or (2) [ * ] with respect to such Lead Op Program for purposes of Section [ * ] and
or Section [ * ]. 
 (c) Removal of Lead Op Candidates. Notwithstanding the Parties designation of a Screening Program as a
Lead Op Candidate, [ * ] may, at any time after the number of Lead Op Candidates becomes greater than [ * ], designate a Lead Op Candidate as Rejected Screening Target, except if such designation would reduce the number of Lead Op
Candidates below [ * ]. 
 3.3 Lead Op Programs. 
 (a) In General. During each [ * ] Research Term, as described in more detail below, Exelixis shall conduct programs as part of the Collaboration (“Lead Op Programs”) in which Exelixis
will optimize lead compounds that were identified in Screening Programs for the purpose of advancing a lead compound to Development Candidate status. As of the Execution Date, the initial list of the [ * ] Lead Op Targets for the first year
of the Research Term is set forth in Exhibit 3.3. These initial Lead Op Targets shall serve as the targets for the Initial Lead Op Programs. Additional Lead Op Targets shall be added to the table described in Section 3.9, which
shall be updated by the Alliance Managers pursuant to Section 3.9. Exelixis shall use Diligent Efforts to maintain and advance, [ * ] Lead Op Programs on behalf of the Collaboration during the Research Term [ * ] Lead Op
Programs [ * ] Exelixis shall use Diligent Efforts to 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 29 

 
maintain and advance [ * ] during the [ * ] Research Term (such minimum Lead Op Programs, “[ * ]”). For clarity, Exelixis may,
[ * ], advance [ * ] Lead Op Candidate(s) into lead optimization programs other than [ * ], provided that such lead optimization programs will remain subject to the terms and conditions of this Agreement (as described in the
last sentence of Section 3.2(b)). 
 (b) Completion of Lead Op Programs. Once Exelixis determines that a compound in any
Lead Op Program has completed lead optimization and has met the criteria of a Program Lead, Exelixis will so notify BMS in writing and provide BMS with the Development Candidate proposal including such information as included in [ * ] and
documenting the properties of such Program Lead as per [ * ] (the “DCP”). Within [ * ] of receiving the DCP, BMS shall notify Exelixis in writing if BMS will [ * ] with respect to the Lead Op Program that
generated such Program Lead. If Exelixis receives BMS’ notice stating that [ * ], then the provisions of Section [ * ] shall apply. Otherwise, Exelixis will advance such Lead Op Program into preclinical development as a
Provisional Collaboration Program, and [ * ] on [ * ]. The target(s) associated with each such Provisional Collaboration Program shall no longer be Lead Op Target(s) but shall instead automatically be a “Collaboration
Target(s).” 
 (c) Termination of Lead Op Programs. If the JRC (by mutual agreement) elects to terminate a Lead Op Program
before the lead compound in such Lead Op Program has completed lead optimization, then, [ * ]. If no such [ * ], or if [ * ], then Exelixis will [ * ] (subject to Exelixis’ obligations to a Third Party that would
[ * ]), which program shall be [ * ]; or (ii) in the event that [ * ]. In any case, any such Lead Op Target(s) associated with such a terminated Lead Op Program shall no longer be Lead Op Target(s) but shall instead
automatically be a “Rejected Lead Op Target(s)”, subject to Section 8.6(e). 
 (d) Limited Replacement of
Lead Op Programs. At any time prior to the date which is [ * ] subsequent to the delivery by Exelixis of the DCP with respect to a given Lead Op Program in accordance with Section 3.3(b), [ * ] replace such Lead Op
Program, [ * ], with any of the following: (i) [ * ] for which Exelixis [ * ]; (ii) [ * ]; or (iii) a [ * ]. [ * ] shall cease after [ * ]. The target(s) associated with each such
former Lead Op Program shall no longer be Lead Op Target(s) but shall instead automatically be “Rejected Lead Op Target(s)”, subject to Section 8.6(e). 
 3.4 Provisional Collaboration Programs; Exercise of BMS’ Co-Development Option. 
 (a) In General. Exelixis shall conduct programs as part of the Collaboration in which Exelixis pre-clinically develops compounds (that were
identified as Program Leads in Lead Op Programs) with the goal of submitting an IND on such compound where such IND meets the criteria for clinical development that is consistent with Exelixis’ internal criteria for all Exelixis programs
(including programs outside of the Collaboration) and, where reasonably possible, takes into account the [ * ] (such programs, “Provisional Collaboration Programs”). BMS [ * ] activities (for purposes of [ * ])
that were [ * ], including one or more of the following: [ * ] as needed to help [ * ] for Provisional Collaboration Programs [ * ]. [ * ] solely for use [ * ] described in this Section 3.4(a).

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 30 

 (b) Exercise of BMS’ Co-Development Option. Once Exelixis determines that [ * ],
Exelixis will provide to BMS written notice and a data package (containing data not already in BMS’ possession) with sufficient detail regarding such Collaboration Compound (and any Program Backups) as per Exelixis’ internal standards and
incorporating data applicable to the [ * ]. Upon receipt of each such data package, BMS will have [ * ] to notify Exelixis in writing whether BMS exercised its Co-Development Option with respect to the Provisional Collaboration Program
to which such Collaboration Compound relates; provided that such [ * ]. For clarity, BMS may exercise its Co-Development Option at any time prior to such date, including [ * ]. 
 (i) Acceptance. If Exelixis receives BMS’ notice (within the applicable [ * ] period) stating that BMS exercised its Co-Development
Option for a given Provisional Collaboration Program, then such Provisional Collaboration Program shall become a “Collaboration Program”, and the provisions of Section 3.7 shall apply, and BMS shall be responsible for
submitting the IND for such Collaboration Program’s Lead Compound (and other applicable regulatory and clinical documents). 
 (ii)
Rejection. If Exelixis receives BMS’ notice (within the applicable [ * ] period) stating that BMS did not exercise its Co-Development Option for a given Provisional Collaboration Program, or if Exelixis did not receive BMS’
notice within the applicable [ * ] period, then in either case, the provisions of Section 3.8 shall apply, and BMS shall not be responsible for submitting the IND for such Provisional Collaboration Program’s Lead Compound
(and other applicable regulatory and clinical documents). 
 (iii) [ * ]. If Exelixis receives BMS’ notice (within the
applicable [ * ] period) stating that [ * ] its Co-Development Option for a given Provisional Collaboration Program, [ * ] set forth in such notice, then Exelixis may [ * ]. Alternatively, Exelixis may [ * ]. If
the [ * ] for such Lead Compound, then Exelixis may elect to either (i) [ * ] or (ii) [ * ]. If the [ * ] for such Provisional Collaboration Program’s Lead Compound, then Exelixis will so notify BMS in
writing. BMS will [ * ]. Upon receipt of such notice from BMS, the provisions of Section [ * ] shall apply if Exelixis received BMS’ notice (within the applicable [ * ] period) stating that [ * ], or Section [ *
] shall apply if either (A) [ * ], or (B) [ * ]. 
 3.5 Backup Compounds. 
 (a) Provisions Relating to BMS’ Exercise of its Co-Development Option. If BMS does not exercise its Co-Development Option with respect to a
Provisional Collaboration Program by the applicable deadline, then Exelixis shall retain all right, title and interest in all compounds generated for such Provisional Collaboration Program, subject to [ * ]. If BMS does exercise its
Co-Development Option with respect to a Provisional Collaboration Program, then any compounds generated for such Provisional Collaboration Program (or Lead Op Program that became such Provisional Collaboration Program) that satisfy the definition of
a Program Backup shall become part of the Collaboration Program, and, subject to Section 8.1(d), neither Party shall use any such compounds for any purpose outside of the Collaboration without the prior written consent of the other
Party. The compounds generated for such Provisional Collaboration Program (or Lead Op Program that became such Provisional Collaboration Program) that do not 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 31 

 
satisfy the definition of Program Backups shall become Unrelated Compounds, and Exelixis shall be free to use such Unrelated Compounds outside of the
Collaboration, subject to Section 8.6. For clarity, BMS shall pay Exelixis the milestone payments described in Section 9.5 for Program Backups that are Royalty-Bearing Products and that meet the applicable milestone events.

 (b) Provisions Relating to Exercise of the Exelixis Co-Development Option. In the event that Exelixis has exercised the Exelixis
Co-Development Option with respect to a Collaboration Program, then the following terms shall apply with respect to Backup Programs: 
 (i) Commencement of a Backup Program. The Parties shall determine, via the JDC, whether or not to commence a backup program (a “Backup Program”) with respect to some or all of the Collaboration Programs, as well as
the appropriate timing for such Backup Program(s). The Backup Program(s) shall be subject JDC oversight and decision making and to a Backup Research Plan to be established by the JDC prior to the start of backup work. 
 (ii) Exelixis Conduct of Backup Programs. Exelixis shall have the first right to conduct such backup work up until designation of a backup
compound as a Development Candidate and shall promptly notify the JDC in writing whether Exelixis will conduct such Backup Program. Upon designation of a backup compound as a Development Candidate, the JDC shall determine [ * ] (with [ *
], in any case, having the right to perform [ * ]. In the event that [ * ] work on Backup Programs for Collaboration Programs shall be [ * ], to the extent such work is incurred and with reimbursement on a quarterly basis,
up to [ * ] Dollars ($[ * ]) per Backup Program (such amount, the “[ * ] Backup Funding”); provided, however, that: (A) such [ * ] Backup Funding shall not be deemed to be [ * ] (except as set
forth below); and (B) any costs associated with such Backup Program that are in excess of [ * ] shall be [ * ]. Notwithstanding clause (A) above, [ * ], then the [ * ] Backup Funding [ * ]. 
 (iii) BMS Conduct of Backup Programs. If Exelixis notifies BMS that Exelixis will not conduct such Backup Program, or in the event that Exelixis
opts-out of co-Development with respect to such Collaboration Program, then BMS may conduct such Backup Program and such any costs associated with such Backup Program shall be [ * ] and shall be [ * ]. Exelixis will transition to BMS
any necessary [ * ] and other know-how necessary or reasonably useful for BMS to conduct such Backup Program. 
 (iv) Reporting and Accounting. Except as set forth in paragraph (ii) above, reporting and accounting of shared costs for the Backup Programs shall be as set forth in Section 4.6 for Development Costs. 
 3.6 Information Exchange; [ * ]; and Identified Targets. 
 (a) Information Exchange and [ * ]. BMS, through the JRC, shall be allowed to review data from Screening Programs, Lead Op Programs and Provisional Collaboration Programs on a [ * ] basis, excluding any
[ * ] relating to any compounds in any 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 32 

 
such Screening Programs, Lead Op Programs or Provisional Collaboration Programs (unless the Parties expressly agree in writing to disclosure of such [ *
]; [ * ]). Once a Lead Op Program or Provisional Collaboration Program contains a Program Lead, BMS shall be notified and may at any time (or from time to time) thereafter (with reasonable prior written notice) request that Exelixis
provide[ * ] with the following information solely for the purpose of [ * ]: (i) a summary describing the [ * ] such Program Lead; (ii) the [ * ]; (iii) a list of [ * ]; and (iv) any other
information reasonably requested by BMS and in the possession of Exelixis. In the event that BMS has not provided written request for disclosure, or has only made written request for disclosure [ * ], then Exelixis shall at all times [ *
]. BMS may make suggestions with respect to the direction or conduct of a Screening Program, Lead Op Program or Provisional Collaboration Program, but Exelixis shall retain all authority over the conduct of such program (subject to Sections
3.2(b), 3.3(c), 3.3(d), 3.4(a) and 3.5). To maximize the probability that a Provisional Collaboration Program will be ultimately accepted by BMS, Exelixis shall give good faith consideration to the [ * ] (the “[ * ]”) and
shall endeavor through the JRC to work with BMS to [ * ]; provided, however, that Exelixis shall not be required to [ * ]. It is expected that both Parties will work closely together through the JRC to discuss and to endeavor to
jointly establish the [ * ]. 
 (b) Identified Targets, Potency Threshold and Specificity Criteria. 
 (i) Determination. For each Lead Op Program, Provisional Collaboration Program and Collaboration Program (as applicable), the JRC or the JDC (or
the Parties in the case of a Collaboration Program with respect to which Exelixis has exercised a Product Opt-Out) shall determine: (A) whether the definition of Identified Target(s) for each applicable Lead Op Program, Provisional
Collaboration Program and Collaboration Program need to be [ * ]; and/or (B) whether the definition of the Target Potency Threshold and/or Specificity Criteria need to be [ * ]. If so, the Parties shall do so by mutual agreement
and in writing through a separate side letter. The JRC, JDC or the Parties (as the case may be) shall also specify [ * ] If the Parties mutually agree that the definitions of Identified Target(s), Target Potency Threshold or Specificity
Criteria (as applicable) [ * ]. If the Parties mutually agree that the definitions of Identified Target(s), Target Potency Threshold or Specificity Criteria (as applicable) [ * ], then Exelixis may [ * ] the Collaboration as
[ * ] to the extent such [ * ] (as applicable), and subject to [ * ]. 
 (ii) Party Resolution of Disputes. If
the JRC or JDC (or the Parties, as the case may be) is unable to agree on the definition of Identified Target(s), Target Potency Threshold or Specificity Criteria (as applicable) at the applicable JRC or JDC meeting (or other meetings and
correspondence between the Parties), including as to whether such definition(s) need revision, then the Parties shall try to settle their differences amicably between themselves first, by referring the disputed matter to the Party’s respective
Executive Officers. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and, within [ * ] after such notice, such Executive Officers shall meet for attempted resolution by good
faith negotiations. If such Executive Officers are unable to resolve such dispute within [ * ] of their first meeting for such negotiations, then the Parties shall proceed to dispute resolution pursuant to Section 3.6(c)(iii). 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 33 

 (iii) Arbitration of Disputes. Any dispute not resolved internally by the Parties pursuant to
Section 3.6(b)(ii) must be finally resolved through binding arbitration by JAMS (formerly, the Judicial Arbitration and Mediation Service) (“JAMS”) in accordance with its Streamlined Arbitration Rules and Procedures in effect at the
time the dispute arises, except as modified in this Agreement and applying the substantive law specified in Section 15.2. Either Party may initiate arbitration under this Section 3.6(b)(iii) by written notice to the other Party of its
intention to arbitrate, and such notice shall specify in reasonable detail the nature of the dispute. For each arbitration: (A) each Party shall submit to the arbitrator its proposal for resolving such dispute, such proposal based on the
applicable scientific factors, and shall provide a copy of such proposal to the other Party; (B) each Party may, within [ * ] of receipt of the other Party’s proposal, provide a rebuttal to such other Party’s proposal to the
arbitrator (which rebuttal shall be limited to responding to arguments or scientific evidence presented in such other Party’s proposal), and shall provide a copy of such rebuttal to the other Party; (C) the arbitrator shall select the
proposal that is the most scientifically reasonable; and (D) such proposal shall become the new definition of Identified Target(s), Target Potency Threshold or Specificity Criteria (as applicable). Notwithstanding anything to the contrary, the
arbitrators will not have the ability to change the terms of either Party’s proposal. The determination of the arbitrator shall be final. The arbitration proceedings shall be conducted in such location as determined by the arbitrator. The
Parties agree that they shall share equally the cost of the arbitration filing and hearing fees, and the cost of the arbitrator. Each Party shall bear its own attorneys’ fees and associated costs and expenses. 
 3.7 Acceptance of Collaboration Programs. In the event that BMS timely exercises its Co-Development Option with respect to a Provisional
Collaboration Program, then such Provisional Collaboration Program shall become a Collaboration Program, and each of the following shall apply: 
 (a) Payment. BMS shall pay the fee set forth in Section 9.2. 
 (b) [ * ] CMC Responsibilities. If not
already completed (i.e., [ * ]), [ * ] shall: (i) complete the Chemistry, Manufacturing and Control (“CMC”) portion of an IND submission package for each Collaboration Compound approved for IND submission (as well
as such other sections of the IND submission package as may be reasonably required of it); and (ii) complete any pre-IND toxicity testing and other testing reasonably required to file an IND for the applicable Collaboration Compound.

 (c) Exelixis Co-Development Option. Exelixis shall provide written notice to BMS, within [ * ] after the acceptance of such
Collaboration Program by BMS, as to whether or not Exelixis will exercise its option to Co-Develop with BMS the Lead Compound arising from such Collaboration Program (the “Exelixis Co-Development Option”). In the event Exelixis
declines to exercise its right to Co-Develop such Lead Compound, Exelixis shall lose any right to Co-Develop and Co-Promote any Product containing such Lead Compound and any subsequent Products or Related Products generated from such Collaboration
Program. 
 (d) Transfer. Exelixis shall use Diligent Efforts to transfer to BMS within [ * ] of BMS’ exercise of its
Co-Development Option: (i) reasonable quantities of the relevant Lead 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 34 

 
Compound; (ii) all Information reasonably necessary for the further development and commercialization of such Collaboration Program’s Lead
Compound; (iii) all regulatory filings (including any INDs, drug dossiers, and drug master files) in Exelixis’ name for such Lead Compound; (iv) any agreements with Third Parties necessary for the further development and
commercialization of such Collaboration Program’s Lead Compound (including any agreements relating to the conduct of the Phase I Clinical Studies of such Lead Compound); and (v) any trademark rights Controlled by Exelixis covering such
Collaboration Program’s Lead Compound, that in each case ((i) through (v)) are existing, in Exelixis’ Control, and specifically relate to such Lead Compound. The costs and expenses incurred by Exelixis in carrying out such transfer shall
be either: (A) treated as Development Expenses in the event that such expenses relate to a Co-Developed Product, or (B) reimbursed one hundred percent (100%) by BMS in the in the event that such expenses relate to a Royalty-Bearing
Product. For clarity, Exelixis’ transfer of Manufacturing-related rights and materials shall be governed by Section 7.3. 
 3.8 Rejection of Provisional Collaboration Programs. In the event that BMS declines to exercise its Co-Development Option with respect to a Provisional Collaboration Program, or if Exelixis does not receive BMS’ notice of
exercising its Co-Development Option with respect to a Provisional Collaboration Program, then each of the following shall apply: 
 (a)
Reversion of Rights. All rights with respect to such Provisional Collaboration Program shall automatically revert to Exelixis, and BMS shall have no further rights with respect to the Development or Commercialization of any compounds (including
Program Backups) by Exelixis under such Provisional Collaboration Program ([ * ]. 
 (b) Expiration of Rights. Without limiting
the generality of Section 3.8(a), Exelixis’ obligations, and BMS rights, under Sections 3.1, 3.4(a) (to the extent applicable), and 3.6 shall expire with respect to such Provisional Collaboration Program. 

(c) Phase I Clinical Trial Requirement. [ * ] shall be required to use Diligent Efforts to commence a Phase I Clinical Trial with
respect to such Provisional Collaboration Program within [ * ] subsequent to acceptance of an IND with respect to such Provisional Collaboration Program. For purposes of this Section 3.8(c), “commence a Phase I Clinical
Trial” means that the first site at which such clinical trial will be conducted has received approval from the appropriate investigational review board (“IRB”) and is ready to enroll patients. 
 (d) Transfer & Transition. If BMS conducted any work on such Provisional Collaboration Program pursuant to Section 3.4(a),
then BMS shall: (i) provide to Exelixis all data generated by BMS with respect to the studies undertaken by it; (ii) grant to Exelixis the license set forth in Section 8.2(c); and (iii) transition over to Exelixis any
ongoing studies then being conducted by BMS (with Exelixis to assume the cost therefore from and after the date that BMS transfers such studies). With the prior written agreement of the Parties, BMS may complete any of the ongoing studies described
in the foregoing clause (iii) at Exelixis’ expense. 
 (e) [ * ]. For any compound arising out of a Provisional
Collaboration Program that [ * ] (a “[ * ]”), if Exelixis decides to [ * ] prior to [ * ] (whichever occurs first) for such [ * ], then [ * ]. During the [ * ], [ * ]. If [ * ]
at or before the end of such [ * ] (or at such earlier time that [ * ]), then [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 35 

 Nothing herein shall preclude [ * ], including with the goal of [ * ], and any such work shall not [ *
], unless otherwise agreed by the Parties in writing. Additionally, if BMS declines to exercise its Co-Development Option with respect to a Provisional Collaboration Program, then any [ * ] as the Provisional Collaboration Program [ *
] shall not [ * ]. 
 3.9 Target Status List. Based on the applicable minutes from each JRC and JDC meeting, the respective
Alliance Managers shall prepare a list that is substantially in the form of Exhibit 3.9 and that shall reflect the status of each target that is active (or was at one time) within the Collaboration. Each target shall be labeled with one of
the following: Screening Target (chosen-awaiting-screening); Screening Target (screen-in-progress); Rejected Screening Target; Lead Op Candidate; Lead Op Target; Rejected Lead Op Target; or Collaboration Target. The updated target list shall be
attached to all JRC and JDC minutes with written confirmation provided in a timely manner by the Alliance Managers. 
 3.10 Research Term.
The “Research Term” shall commence on the Effective Date and continue until the earliest to occur of the following: (a) [ * ]; or (b) delivery to BMS of the [ * ] for possible exercise of its
Co-Development Option. The Parties may extend the Research Term upon their mutual written agreement. Following the end of the Research Term, Exelixis shall have no obligation to conduct any work under any Screening Programs, Lead Op Programs,
Provisional Collaboration Programs and Collaboration Programs (other than Exelixis’ responsibilities, as set forth in the remainder of this Agreement, with respect to Co-Developed Products and Backup Programs for Collaboration Targets), and all
rights with respect to Lead Op Candidates, Lead Op Targets and Collaboration Compounds, other than Collaboration Compounds included in a Collaboration Program for which BMS has exercised its Co-Development Option under Section 3.4, and
in any case subject to Section 3.8(e), shall revert to Exelixis. 
 3.11 Record of Discovery Efforts; Inspection. Exelixis
shall keep complete, true and accurate books of accounts and records for the purpose of determining the resources and funding that Exelixis provides pursuant to Section 3.1. All such books, records and accounts shall be retained by
Exelixis for a period of [ * ] after the end of the period to which such books, records and accounts pertain or such longer period as may be required by applicable law. BMS shall have the right to have an independent certified public
accountant, reasonably acceptable to Exelixis, have access during normal business hours, and upon reasonable prior written notice, to examine only those records of Exelixis as may be reasonably necessary to determine, with respect to any calendar
year ending not more than [ * ] prior to such Party’s request, Exelixis’ compliance with the requirements of Section 3.1. The foregoing right of review may be exercised only once per year and only once with respect to
any given period. Results of any such examination shall be: (i) limited to information relating to the applicable Screening Program, Lead Op Program, Provisional Collaboration Program or Collaboration Program; (ii) made available to both
Parties; and (iii) subject to Article 11. In general, BMS shall bear the full cost of the performance of any such audit. However, if such audit discloses a [ * ] to the applicable Screening Program, Lead Op Program, Provisional
Collaboration Program or Collaboration Program, [ * ] (as determined by the auditor(s)), then Exelixis shall bear the full cost of the performance of such audit. The results of such audit shall be final, absent manifest error. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 36 

	4.	DEVELOPMENT OF PRODUCTS 

 4.1 Global Development
Plans. 
 (a) Scope. The Development of each Co-Developed Product shall be governed by a comprehensive, multi-year, worldwide plan
(each, a “Global Development Plan”) covering the Development of such Product for use in the U.S., Canada, each of the Major European Countries and Europe as a whole, and, broken out on a region-by-region or country-by-country basis
only to the extent BMS does so for its own internal oncology products, the remaining countries in the Co-Development Territory. Each Global Development Plan shall: (i) provide a planned Development program that is designed to generate the
non-clinical, clinical and regulatory information required for submitting Drug Approval Applications and to obtain Regulatory Approvals for the relevant indications in the U.S.; (ii) provide a planned Development program that is designed to
generate the non-clinical, clinical and regulatory information required for submitting Drug Approval Applications and to achieve Regulatory Approvals for the relevant indications in the Royalty Territory, (iii) indicate the Core Program [ *
], (iv) set forth those obligations assigned to each Party with respect to the performance of the Development activities contemplated by such Global Development Plan; and (v) provide an expected forecast, based on the information
available at the time, including patient estimates and cost forecasts (and methodology, if available). 
 (b) Initial Global Development
Plan. As soon as practicable following designation of a Collaboration Program in accordance with Article 3 (and consistent with BMS’ internal [ * ] process), the JDC shall prepare, and submit to the JEC for its approval, a
Global Development Plan, or an amendment to an existing Global Development Plan, that meets the requirements set forth in Section 4.1(a). 
 (c) Updates to the Global Development Plan. Following approval by the JEC of an initial Global Development Plan pursuant to Section 4.1(b), any material update, amendment or modification to, or
waiver of, any provisions of such Global Development Plan shall require the approval of the JEC. 
 4.2 Annual Development Plans.

 (a) Scope. The Development of each Co-Developed Product in the Co-Development Territory for a given calendar year shall be
governed by a detailed and specific worldwide Development plan (each, an “Annual Development Plan”) covering all material Development activities to be performed for such Co-Developed Product for such year, and budgets covering all
Development Costs for those Development activities for such Co-Developed Product conducted in support of Regulatory Approvals in the Co-Development Territory. Each Annual Development Plan and Budget shall be proposed by the JDC for approval by the
JEC. Each Annual Development Plan for a Co-Developed Product, and any modifications thereto, shall cover, and be consistent in all material respects with, all the Development activities and budgets in the then-current Global Development Plan for
such Co-Developed Product that are to be performed in that particular calendar year. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 37 

 (b) Procedure. Within [ * ] after the date on which a Global Development Plan (or an
amendment to an existing Global Development Plan, as the case may be) is first approved with respect to a particular Co-Developed Product, the JDC shall submit for approval by the JEC an Annual Development Plan for such Co-Developed Product,
covering the activities contemplated by the Global Development Plan with respect thereto for the remainder of such calendar year and the next subsequent calendar year. Thereafter, the JDC shall submit on an annual basis an Annual Development Plan
for such Co-Developed Product to the JEC for its review, comment, and approval. Each such submission shall be no later than [ * ] calendar year immediately preceding the year covered by such Annual Development Plan, with a goal of having the
Annual Development Plan approved, and any disputes resolved, by [ * ] of such immediately preceding calendar year. 
 4.3 Lead
Development Party. It is expected that BMS would act as the lead development Party for each Product, although the Annual Development Plan may specify that outside contractors (and/or, in the case of Co-Promotion Products, Exelixis) will have
responsibility to direct and conduct any additional pre-clinical activities and applicable clinical trials in any country. The JDC shall make such determinations in the best interests of the Collaboration. In the event Exelixis files an IND on a
Provisional Collaboration Program’s Lead Compound, and BMS exercises its Co-Development Option for such Provisional Collaboration Program pursuant to Section 3.4(b)(iii), then any Phase I Clinical Study agreements that were entered
into between Exelixis and a clinical site before the effective date of BMS’ exercise of its Co-Development Option and that specifically relate to such Lead Compound, shall become part of the initial Global Development Plan and initial Annual
Development Plan. 
 4.4 Diligence. Each Party shall use Diligent Efforts to carry out its responsibilities under the Global
Development Plan and the then-applicable Annual Development Plan. 
 4.5 Limitations on Development. After the Effective Date and
during the term of this Agreement, neither Party nor any of its Affiliates shall, directly or through any Third Party, sponsor, conduct or cause to be conducted, otherwise assist in, supply any Product for use in connection with, or otherwise fund,
any clinical trial or clinical study of any Product outside of the Global Development Plan or any Annual Development Plan, without the prior written consent of the other Party. 
 4.6 Development Costs. 
 (a) In
general. Subject to Section 4.6(e), any Development Costs incurred by either Party shall be borne by the Parties as follows: 
 (i) BMS shall bear [ * ] percent ([ * ]%) of all Development Costs, and Exelixis shall bear [ * ] ([ * ]%) of all Development Costs; and, 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 38 

 (ii) for clarity, all costs relating to Development activities undertaken solely for the purposes
of seeking Regulatory Approval(s) in [ * ], BMS shall bear one hundred percent (100%) of such costs. 
 (b) FTE Records and
Calculations; Adjustments to FTE Rate. Each Party shall record and account for its FTE effort for the Development of each Product to the extent that such FTE efforts are included in Development Costs or Allowable Expenses that are, or may in the
future be, shared under this Agreement, and shall report such FTE effort to the JDC on a quarterly basis, in each case in a manner that allocates such FTE effort to the extent practicable to each applicable indication. Except to the extent provided
herein, each Party shall calculate and maintain records of FTE effort incurred by it in the same manner as used for other products developed by such Party. The JFC shall facilitate any reporting hereunder. The FTE rate shall initially be [ *
] for FTEs associated with activities prior to IND submission with respect to a Collaboration Program and [ * ] for all other FTEs and shall be adjusted annually, with each annual adjustment effective as of January 1 of each Year,
with the first such annual adjustment to be made as of January 1, 2008, by mutual agreement of the JRC or the JFC. 
 (c) Other
Expenses. Any expenses incurred by a Party for Development activities that do not fall within the definitions of Development Costs shall be borne solely by such Party unless the JDC determines otherwise. 
 (d) Reports. Each Party shall report to the other Party within [ * ] after the end of each quarter with regard to the Development Costs
incurred by it during such quarter. Such report shall specify in reasonable detail (as agreed by the JFC) all expenses included in such Development Costs during such quarter and shall be accompanied by invoices, and/or such other appropriate
supporting documentation as may be required by the JFC. Within [ * ] after the end of each of the first three quarters and, for the last quarter in a year, within [ * ] after the end of such quarter, the Party that has incurred
less than its share of such Development Costs shall make a reconciling payment to the other Party to achieve the appropriate allocation of Development Costs provided for in Section 4.6(a). Each Party shall report to the other
Development Costs incurred by it for comparison against the Annual Development Plan, on a line item basis (e.g., budgeted FTE costs and actual out-of-pocket cost). The Parties shall seek to resolve any questions related to such accounting
statements within [ * ] following receipt by each Party of the other Party’s report hereunder. The JFC shall facilitate the reporting of Development Costs hereunder and the resolution of any questions concerning such
reports. Each Party shall have the right at reasonable times and upon reasonable prior notice to audit the other Party’s records as provided in Section 9.19 to confirm the accuracy of the other Party’s costs and reports
with respect to Development Costs that are shared under this Agreement. 
 (e) Exelixis’ Development Cost Obligations. If the
Development Costs in a particular calendar quarter cause Exelixis’ aggregate share of the Development Costs with respect to a particular Collaboration Program to exceed [ * ]), then Exelixis may elect to defer payment of its share of
such Development Costs that are in excess of [ * ] with respect to such Collaboration Program in accordance with the remainder of this Section 4.6(e). Such election may be made in writing anytime during the [ * ] following
the end of such calendar quarter. If Exelixis does not make such election, then Exelixis would continue to pay its share of the 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 39 

 
Development Costs with respect to such Collaboration Program in accordance with Section 4.6(a). If Exelixis does make such election, then
Exelixis’ shall have no obligation to pay its share of such Development Costs, to the extent such share exceeds [ * ] (such excess amount, the “Deferred Development Costs”) until [ * ] first Product arising from
such Collaboration Program. Until such [ * ], BMS shall bear [ * ] Development Costs with respect to such Collaboration Program, and after such Regulatory Approval, Exelixis shall make a payment to BMS in an amount equal to [ *
] Deferred Development Costs (the “Development Cost Mechanism Amount”), which payment shall be paid by Exelixis as an offset: (i) against Exelixis’ share of the [ * ] from such Product, up to a maximum of [ *
] of such [ * ] in any given quarter (in the case where Exelixis has not exercised its Product Opt-Out for such Product); or (ii) [ * ] with respect to such Product, up to a maximum of [ * ] in any given quarter. Once
the Development Cost Mechanism Amount is fully paid to BMS, Exelixis shall receive [ * ] consistent with Article 9. For clarity, Exelixis will continue to fund its share of Development Costs for indications outside of the Core Program
with respect to a Collaboration Program for which Exelixis has not opted out pursuant to Section 4.7. 
 (f) Records. Each
Party shall keep detailed records of the Development Costs it incurs, including all supporting documentation for such expenses. Each Party shall keep such records for at least [ * ] after the date that such expense was incurred. 

4.7 Exelixis’ Opt-Out Rights. 
 (a) Entire Product. Within [ * ] after the completion of any Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial for a particular Co-Promotion Product, the Party primarily responsible for the conduct of
such clinical trial shall prepare and deliver to the other Party a data package detailing the clinical outcome of such trial. Exelixis shall have the right to cease its involvement in the Development and Commercialization of such Product (a
“Product Opt-Out”), upon written notice to BMS within [ * ] after the delivery of such data package. Commencing on the date that Exelixis provides BMS with written notice of a Product Opt-Out, Exelixis shall have no further
responsibility for conducting new activities or funding new Development or Commercialization activities with respect to the applicable Product, and shall complete any ongoing activities with respect to such Product subject to reimbursement by BMS of
one hundred percent (100%) of any costs associated with such continuing activities unless such work is transferred to BMS at the discretion of the JDC. 
 (b) [ * ]. Before [ * ], Exelixis [ * ] the right to [ * ] the Development and Commercialization of such Product [ * ]. After [ * ], Exelixis shall have the right to [ *
] as follows. Within [ * ] after [ * ], for a Product [ * ] for such Product (as specified in the Global Development Plan for such Product), BMS shall prepare and deliver to Exelixis: (i) [ * ]; or (ii) [
* ]. Exelixis shall [ * ] BMS within [ * ] after [ * ] (as appropriate). For purposes of this Section 4.7(b), [ * ] shall not include [ * ]. Notwithstanding the foregoing, if Exelixis exercises its
Co-Promotion Option with respect to a Product, it will be required to [ * ]. Commencing the date that Exelixis [ * ], Exelixis shall [ * ], and shall [ * ] thereto. For clarity, Exelixis may [ * ], and in the event
that Exelixis decides to [ * ], it [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 40 

	5.	REGULATORY 

 5.1 Regulatory Lead Party. BMS
shall be the lead Party for all regulatory activities regarding a Product. However, Exelixis shall have a participatory role in all [ * ] that [ * ] All [ * ] would be made and implemented after conferring with the JDC. [ *
] Regulatory Authorities as well as [ * ] will be [ * ] through the JDC. BMS shall be the lead Party for worldwide pharmacovigilance. Notwithstanding any other provision of this Agreement, in the event any dispute with respect to
the content of any regulatory filing or dossier, pharmacovigilance reports, patient risk management strategies and plans, Core Data Sheet, Product labeling, safety, and the decision to file any DAA is not resolved by the JEC, [ * ] with
respect to such matters at the JEC [ * ] referring such dispute to the Designated Officers or submitting such dispute to any other dispute resolution procedures provided for in Section 15.1. 
 5.2 Ownership of Regulatory Dossier. BMS will own all regulatory filings for Products in order to facilitate BMS’ interactions with
Regulatory Authorities. For any Collaboration Program for which Exelixis filed the IND for such Collaboration Program’s Lead Compound and for which BMS exercised its Co-Development Option pursuant to Section 3.4(b)(iii), Exelixis
hereby agrees to transfer and assign to BMS, and BMS hereby agrees to receive from Exelixis, all of Exelixis’ right, title and interest to such IND. Additionally, Exelixis shall notify the applicable Regulatory Authorities in writing that it is
transferring such IND for the applicable Lead Compound to BMS, and BMS shall notify the applicable Regulatory Authorities in writing that it is accepting such IND and all responsibilities associated therewith, including without limitation, the
responsibility for reporting adverse events. 
 5.3 Regulatory Matters Relating to Co-Promotion Products in the United
States. With respect to Co-Promotion Products in the United States: 
 (a) Regulatory Filings. Through their members on
the JDC, Exelixis and BMS shall cooperate in the drafting and review of all submissions (including any supplements or modifications thereto, but excluding routine adverse event filings (i.e., not relating to serious adverse events as defined
by applicable law) to the FDA (including the preparation of an electronic submission of a Drug Approval Application to the FDA, with BMS having primary responsibility for preparing the electronic dossier for each indication). Each Party shall have a
right to review and approve (through its members of the appropriate Committee), the content and subject matter of, and strategy for, each Drug Approval Application to be filed in the United States, all correspondence submitted to the FDA related to
clinical trial design, all proposed Product labeling (including the final FDA-approved labeling) and post-Regulatory Approval labeling changes. Each Party shall promptly provide the other with copies of all written or electronic communications
received by it from, or sent by it to, the FDA with respect to obtaining and maintaining, Regulatory Approvals for a Product in the United States (it being understood that routine adverse event filings (i.e., not relating to serious adverse
events as defined by applicable law) shall not fall within the meaning of maintenance) and copies of all contact reports produced by such Party. BMS shall be the [ * ] point of contact with any Regulatory Authorities (except as provided in
Section [ * ]). 
 (b) Notice of Regulatory Filing Requirements. BMS shall provide to Exelixis, within [ * ] of
discovery by BMS, notice of any event with respect to any Co- 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 41 

 
Promotion Product that triggers any FDA filing requirement that is subject to a deadline imposed by applicable law of less than twenty-one (21) days
after the discovery of such an event. The co-chairpersons of the JDC shall discuss in good faith and on a timely basis determine the most effective and expeditious means of responding to such FDA filing requirement. 
 (c) Notice of Changed Regulatory Requirements. BMS shall provide notice to Exelixis of any additional requirements which the FDA may impose
with respect to obtaining or maintaining Regulatory Approval for a Co-Promotion Product (including additional clinical trials), and of all FDA inquiries with respect to a Co-Promotion Product requiring a response within [ * ] of receipt
thereof by BMS. 
 (d) Regulatory Meetings. BMS shall provide Exelixis with notice of all meetings, conferences, and discussions
(including FDA advisory committee meetings and any other meeting of experts convened by the FDA concerning any topic relevant to a Co-Promotion Product, as well as Product labeling and post-Regulatory Approval Product labeling discussions with the
FDA) scheduled with the FDA concerning any pending Drug Approval Application or any material regulatory matters relating to a Co-Promotion Product within [ * ] after BMS receives notice of the scheduling of such meeting, conference, or
discussion (or within such shorter period as may be necessary in order to give Exelixis a reasonable opportunity to participate in such meetings, conferences and discussions). Exelixis shall be entitled to be present at, and to participate in, all
such meetings, conferences or discussions. Exelixis’ and BMS’ respective members of the JDC shall use reasonable efforts to agree in advance on the scheduling of such meetings and on the objectives to be accomplished at such meetings,
conferences, and discussions and the agenda for the meetings, conferences, and discussions with the FDA. BMS shall also include Exelixis in any unscheduled, ad-hoc meetings, conferences and discussions with the FDA concerning any pending IND,
Drug Approval Application or any material regulatory matters relating to a Product. 
 (e) Regulatory Data. Each Party shall
provide to the other Party on a timely basis copies of all material pre-clinical and clinical data compiled in support of a Drug Approval Application or other regulatory filings in the United States with respect to each Product (via electronic
copies of such data in a form that may be analyzed and manipulated by the other Party). 
 (f) Common Database. If deemed
appropriate by the JDC, the Parties will establish a common database to be controlled, maintained and administered by BMS for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of data arising from clinical
trials for Products. The Parties shall agree upon guidelines and procedures for such common database that shall be in accordance with, and enable the Parties and their Affiliates to fulfill their reporting obligations under applicable
law. Furthermore, such guidelines and procedures shall be consistent with relevant International Council for Harmonisation (“ICH”) guidelines. The Parties’ costs incurred in connection with receiving, investigating,
recording, reviewing, communicating, and exchanging such efficacy data shall be included as an element of Development Costs or as Allowable Expenses (to the extent specifically identifiable to or reasonably allocable to the Development or
Commercialization of Products for the United States), calculated on a FTE cost and direct out-of-pocket cost basis. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 42 

 (g) Rights of Reference. Each Party shall have the right to cross reference, file or
incorporate by reference any regulatory filing or drug master file (as defined in the Code of Federal Regulations) (and any data contained therein) for any Product, or any component thereof, made in any country in the Territory (including all
Approvals) in order to support regulatory filings that such Party is permitted to make under this Agreement for any Product in the United States and to enable either Party to fulfill its obligations under this Agreement to Develop or manufacture
(anywhere in the world) any such Product for use in the United States or Commercialize any such Product in the United States. Each Party shall support the other, as may be reasonably necessary, in obtaining Regulatory Approvals for each Product
in the United States, including providing necessary documents, or other materials required by applicable law to obtain Regulatory Approvals, in each case in accordance with the terms and conditions of this Agreement. 
 5.4 Recalls in the United States. Any decision to initiate a recall or withdrawal of a Co-Developed or Co-Promotion Product in the United
States shall be [ * ], [ * ]; provided, however, that if, as a result of patient safety concerns, there is not [ * ], and in any event before [ * ], the Parties shall promptly and in good faith discuss the reasons
therefor and the strategy for implementing any such recall or withdrawal. The costs of any such recall or withdrawal relating to: (i) the Development of a Co-Developed Product for an indication prior to the approval of the Drug Approval
Application (or compendia listing, as the case may be) for such indication (other than with respect to a recall related to a [ * ]); or (ii) the Commercialization of a Co-Promotion Product shall each be included in Regulatory Expenses.
The costs of any such recall or withdrawal relating to the Development of a Co-Developed Product for a [ * ] or the Commercialization of a Royalty-Bearing Product, each shall be borne solely by BMS and shall be excluded from Development Costs
and Allowable Expenses. Notwithstanding the preceding two (2) sentences, to the extent that any such recall or withdrawal is attributable to the negligence of a Party, such Party shall bear such costs, and such costs shall be excluded from
Development Costs and Allowable Expenses. Under no circumstances shall either Party unreasonably object to a recall or withdrawal requested by the other Party, and with respect to Co-Developed and Co-Promotion Products, neither Party shall have
any right to object to a recall or withdrawal requested by the other Party for failure of a Product to meet the Specifications, for material safety concerns, for the manufacture of such Product in a manner that does not comply with applicable law or
as requested by Regulatory Authorities. In the event of any recall or withdrawal, BMS shall take any and all necessary action to implement such recall or withdrawal in accordance with applicable law, with assistance from Exelixis as reasonably
requested. 
 5.5 Regulatory Matters Relating to Royalty-Bearing Products in the United States and Products in the Royalty
Territory. With respect to Royalty-Bearing Products in the United States and Products in the Royalty Territory: 
 (a) Preparation
of Regulatory Filings. BMS shall prepare and draft all filings (including any supplements or modifications thereto and including the preparation of any electronic submission of a Drug Approval Application) to Regulatory Authorities in each
such 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 43 

 
country. BMS shall keep Exelixis informed with respect to, and shall promptly provide to Exelixis copies of, all material written or electronic
communications received by it from, or sent by it to: (a) a Regulatory Authority in the U.S., Japan, a Major European Country or for the EU; and (b) a Regulatory Authority outside the Major European Countries to the extent that the
substance of such communications: (i) vary materially from what BMS has already disclosed to Exelixis with respect to the U.S., Japan, a Major European Country or for the EU under this Section 5.4(a); and (ii) [ * ].

 (b) Pricing and Reimbursement Approvals. [ * ] in all pricing and reimbursement approval proceedings relating to each
Product in the Royalty Territory. 
 (c) Rights of Reference. BMS shall have the right to cross reference, file or incorporate by
reference any regulatory filing or drug master file (as defined in the Code of Federal Regulations) (and any data contained therein) for any Product made in any country in the Territory (including all Approvals) in order to support regulatory
filings that BMS is permitted to make under this Agreement for any such Product in the Royalty Territory and to enable BMS to fulfill its obligations under this Agreement to Develop, Manufacture (anywhere in the world), or Commercialize any such
Product for use in the Royalty Territory.
 5.6 Recalls in the Royalty Territory. Any decision to initiate a recall or withdrawal
of a Product in the Royalty Territory shall be made by BMS. In the event of any recall or withdrawal, BMS shall take any and all necessary action to implement such recall or withdrawal in accordance with applicable law, with assistance from the
non-lead Party as reasonably requested by BMS. The costs of any such recall or withdrawal in the Royalty Territory shall be borne solely by BMS, except to the extent that the recall or withdrawal is attributable to: (a) the negligence of
Exelixis, in which event Exelixis shall bear such costs; or (b) the negligence of both Parties, in which event each Party shall bear such costs to the extent of its respective responsibility, and in either case ((a) or (b)), such costs shall be
excluded from Development Costs and Allowable Expenses.
 5.7 Pharmacovigilance Agreement. Subject to the terms of this Agreement, and
within [ * ] after the [ * ] with respect to a Collaboration Program, BMS and Exelixis (under the guidance of their respective Pharmacovigilance Departments, or equivalent thereof) shall define and finalize the responsibilities the
Parties shall employ to protect patients and promote their well-being in a written Agreement (hereafter referred to as the “Pharmacovigilance Agreement”). These responsibilities shall include mutually acceptable guidelines and
procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, and any other information concerning the safety of any Product. Such guidelines and procedures
shall be in accordance with, and enable the Parties and their Affiliates to fulfill, local and national regulatory reporting obligations to government authorities. Furthermore, such agreed procedures shall be consistent with relevant International
Council for Harmonisation (ICH) guidelines, except where said guidelines may conflict with existing local regulatory safety reporting requirements, in which case local reporting requirements shall prevail. The Pharmacovigilance Agreement will
provide for a worldwide safety database to be maintained by BMS. Each Party hereby agrees to comply with its respective obligations under such Pharmacovigilance Agreement (as the Parties may agree to modify it from time to time) and to cause its
Affiliates and Sublicensees to comply with such obligations. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 44 

	6.	COMMERCIALIZATION 

 6.1 Overview. As between
the Parties, BMS shall be the lead Party for all Commercialization activities throughout the world, and BMS shall book sales of all Products in all countries. 
 6.2 Commercialization Plans. 
 (a) Commercialization Plans. For each Product, the JCC shall be
responsible for creating a global strategy for the Commercialization of each Product pursuant to a comprehensive, rolling, three-year commercialization plan (the “Global Commercialization Strategy”), along with creating a
comprehensive, rolling, three-year commercialization plan setting forth the anticipated Commercialization activities in the U.S. (including without limitation market research, launch plans, product positioning, and detailing activities) and
timelines for such activities (the “U.S. Commercialization Plan”). The U.S. Commercialization Plan shall, in the case of Co-Promotion Products, allocate responsibility for carrying out such activities between BMS and Exelixis, and
shall include a detailed and specific budget for all such activities. Each U.S. Commercialization Plan shall be consistent with the then-current Global Commercialization Strategy and the Co-Promotion Agreement, and the U.S. Commercialization Plan
may be included as a part of the Global Commercialization Strategy. 
 (b) No later than [ * ] after commencement of the [ *
] for a particular Product, and on an annual basis thereafter, the JCC shall prepare, and submit to the JEC for its approval, a U.S. Commercialization Plan that meets the requirements of Section 6.2(a). Each updated U.S.
Commercialization Plan for a particular Product, once approved by the JEC, shall become effective and supersede the previous U.S. Commercialization Plan for such Product as of the date of such approval or at such other time decided by the JEC. The
JEC shall not approve a U.S. Commercialization Plan that is inconsistent with or contradicts the terms of this Agreement or the Co-Promotion Agreement without the written consent of the Parties, and in the event of any inconsistency between the U.S.
Commercialization Plan, on the one hand, and this Agreement or the Co-Promotion Agreement, on the other hand, the terms of this Agreement or the Co-Promotion Agreement, as the case may be, shall prevail. 
 6.3 Diligent Commercialization. BMS (and Exelixis with respect to Co-Promotion Products in the U.S.) shall use Diligent Efforts to Commercialize
each Product in each country in the Major Territory for each indication for which it receives Regulatory Approval. 
 6.4 Option to
Co-Promote. 
 (a) In General. BMS hereby grants to Exelixis the first and exclusive option (a “Co-Promotion
Option”) to co-promote each Co-Developed Product in the U.S. in accordance with a co-promotion agreement (a “Co-Promotion Agreement”) to be negotiated in good faith by the Parties following Exelixis’ exercise of the
Co-Promotion Option with respect to a particular Co-Developed Product. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 45 

 (b) Exercise. BMS shall give Exelixis prompt written notice (the “Co-Promotion
Notice”) of the [ * ] for each Co-Developed Product, and shall provide with such notice: (i) the anticipated date of Launch of the applicable Product in the U.S.; and (ii) any material updates to the budget for the
then-current U.S. Commercialization Plan. Exelixis may exercise its Co-Promotion Option with respect to such Co-Developed Product by written notice to BMS no later than [ * ] after Exelixis receives a Co-Promotion Notice. If Exelixis timely
exercises its Co-Promotion Option with respect to such Co-Developed Product, then such Co-Developed Product shall become a Co-Promotion Product, and the Parties shall share Operating Profits (or Losses) in accordance with Sections 6.5 and
9.3. If Exelixis does not timely exercise its Co-Promotion Option with respect to such Co-Developed Product, then such Co-Developed Product shall become a Royalty-Bearing Product. Exelixis’ exercise or failure to exercise its Co-Promotion
Option with respect to a particular Co-Developed Product shall not have any effect on its Co-Promotion Options for other Co-Developed Products. 
 (c) Co-Promotion Agreement. The Co-Promotion Agreement will include the specific terms set forth in Exhibit 6.4(c), along with additional terms and conditions customary in the industry for an agreement of this type. In the
event of any inconsistency between the terms of this Agreement and the terms of the Co-Promotion Agreement, the terms of this Agreement shall prevail. 
 6.5 Commercialization Costs. All costs and expenses incurred by the Parties in connection with the Commercialization of Co-Promotion Products in the U.S. shall be included in the calculation of Operating Profit
(or Losses), and shall be allocated between the Parties, in accordance with Sections 9.3 and 9.4. BMS shall bear all costs and expenses incurred by the Parties in connection with the Commercialization of: (a) all Products in the Royalty
Territory; and (b) all Royalty-Bearing Products in the U.S. 
 6.6 Commercialization Reports. BMS shall keep the JCC fully
informed regarding the progress and results of its Commercialization activities and those of its Affiliates, sublicensees, and Third Party contractors in the Royalty Territory. On a [ * ] basis, BMS shall provide the JCC with a written report
that summarizes, in reasonable detail, all Commercialization activities performed during the preceding [ * ] period, and compares such performance with the goals and timelines set forth in the Global Commercialization Strategy and (as
appropriate) the U.S. Commercialization Plan. BMS shall also promptly provide any additional Information regarding the Commercialization of Products reasonably requested by the JCC or by Exelixis. For clarity, each Party will provide [ * ]
updates to the JCC with respect to its Commercialization activities relating to Co-Promotion Products in the U.S. 
 6.7 Standards of
Conduct. BMS shall perform, or shall ensure that its Affiliates, sublicensees and Third Party contractors perform, all Commercialization activities in a good scientific and ethical business manner and in compliance with applicable laws, rules
and regulations. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 46 

 6.8 Sales Force Training. BMS shall develop and conduct training programs specifically relating to
the Products for its sales representatives. BMS agrees to utilize such training programs on an ongoing basis to assure a consistent, focused promotional strategy. 
  

	7.	MANUFACTURING 

 7.1 Research Supply. Exelixis
shall Manufacture, or arrange with Third Parties for the Manufacture of, Lead Compounds and Program Backups for the purpose of Exelixis’ research and Development activities to be performed under Article 3 prior to BMS’ exercise of its
Co-Development Option with respect to such compounds and for BMS’ research activities under Section 3.4(a). 
 7.2 Clinical and
Commercial Supply. After BMS’ selection of a Collaboration Program and prior to the completion of Exelixis’ transfer under Section 7.3 of the Manufacturing technology for the Collaboration Compounds in such Collaboration
Program, Exelixis shall Manufacture, or arrange with Third Parties for the Manufacture of, the Lead Compound in such Collaboration Program for the purpose of transitional supply of Lead Compound for the first Phase I Clinical Trial of such Lead
Compound. As part of such Phase I Clinical Trial supply, Exelixis will enable BMS’ regulatory function to test and release all supplies of such Lead Compound for such Phase I Clinical Trial (if applicable). The costs and expenses incurred by
Exelixis in carrying out such Manufacturing shall be either: (a) treated as Development Expenses in the event that such expenses relate to a Co-Developed Product; or (b) reimbursed one hundred percent (100%) by BMS in the in the event
that such expenses relate to a Royalty-Bearing Product. After the completion of Exelixis’ transfer under Section 7.3 of the Manufacturing technology for the Collaboration Compounds in such Collaboration Program, BMS shall
Manufacture, or arrange with Third Parties for the Manufacture of, Collaboration Compounds and Products (in bulk and finished form) for use in Development and for commercial sale. 
 7.3 Transfer of Manufacturing Right. 
 (a) Promptly following [ * ], Exelixis shall transfer the Manufacturing technology for the Collaboration Compounds in such Collaboration Program to either (i) BMS or (ii) a Third Party manufacturer reasonably
acceptable to Exelixis, which election shall be made by BMS. As soon as is practicable after its receipt of such request, Exelixis shall transfer to BMS or such Third Party manufacturer, as the case may be, all Information Controlled by Exelixis
that is related to the Manufacturing of such Collaboration Compounds and is reasonably [ * ] to enable BMS or such Third Party manufacturer (as appropriate) to Manufacture such Collaboration Compounds. The costs and expenses incurred by
Exelixis in carrying out such transfer shall be either: (i) treated as Development Expenses in the event that such expenses relate to a Co-Developed Product; or (ii) reimbursed one hundred percent (100%) by BMS in the in the event
that such expenses relate to a Royalty-Bearing Product. 
 (b) BMS and/or its Third Party manufacturer shall use any Information
transferred pursuant to Section 7.3(a) solely for the purpose of Manufacturing Products containing such Collaboration Compounds for use by Exelixis or BMS under this Agreement, and for no other purpose. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 47 

 (c) BMS acknowledges and agrees that Exelixis may condition its agreement to transfer of any
Manufacturing technology or Information to a Third Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and Exelixis that contains terms substantially equivalent to those of Article 11 of
this Agreement. 
  

	8.	LICENSES; EXCLUSIVITY 

 8.1 Licenses to BMS.
Subject to the terms of this Agreement: 
 (a) Research. Exelixis hereby grants to BMS a non-exclusive, worldwide, royalty-free license
(without the right to sublicense except with prior written consent of Exelixis) under the Exelixis Licensed Patents and the Exelixis Licensed Know-How solely to [ * ] in accordance [ * ]. 
 (b) Clinical Development and Commercialization. 
 (i) Exelixis hereby grants to BMS a co-exclusive, revenue-bearing license under the Exelixis Licensed Patents and the Exelixis Licensed Know-How to clinically develop, make, use, sell, offer for sale and import
Co-Promotion Products in the U.S. 
 (ii) Exelixis hereby grants to BMS an exclusive, royalty-bearing license under the Exelixis
Licensed Patents and the Exelixis Licensed Know-How to clinically develop, make, use, sell, offer for sale and import (A) Royalty-Bearing Products in the U.S. and (B) Products in the Royalty Territory. 
 (c) Sublicensing. The licenses granted to BMS in Sections 8.1(a) and 8.1(b)(i) are, subject to Section 8.5(b),
sublicensable solely with the prior written consent of Exelixis, which consent shall not be unreasonably withheld. The license granted to BMS in Section 8.1(b)(ii) shall be freely sublicensable by BMS. 
 (d) Exelixis Retained Rights. Exelixis retains all rights to use the Exelixis Licensed Know-How and Exelixis Patents except those expressly
granted to BMS on an exclusive basis under the terms of this Agreement. In addition, notwithstanding the exclusive licenses granted to BMS pursuant to Section 8.1(b), Exelixis retains the right under the Exelixis Licensed Patents and the
Exelixis Licensed Know-How to make, have made, use, and test Collaboration Compounds solely for internal research purposes. 
 8.2
Licenses to Exelixis. 
 (a) Research. Subject to the terms of this Agreement, BMS hereby grants to Exelixis a non-exclusive,
worldwide, royalty-free license under the BMS Licensed Know-How and BMS Patents, solely to perform its obligations with respect to Screening Programs, Lead Op Programs and Collaboration Programs, as contemplated by Article 3. 
 (b) Clinical Development and Commercialization. Subject to the terms of this Agreement, BMS hereby grants to Exelixis a co-exclusive,
revenue-bearing license under the BMS Licensed Patents and the BMS Licensed Know-How to clinically develop, make, use, sell, offer for sale and import Co-Promotion Products in the U.S. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 48 

 (c) Other Licenses. In the event that BMS declines to exercise its Co-Development Option with
respect to a Collaboration Program that was a Provisional Collaboration Program, then BMS shall grant to Exelixis: 
 (i) a
non-exclusive, worldwide, fully paid-up, sublicensable license under all Patents and Information that: (A) [ * ], in each case, to use and practice such Patents and Information for any purpose; and 
 (ii) a worldwide, fully paid-up, sublicensable license under all Patents and Information that: (A) [ * ] to continue to develop,
make, use, sell, offer for sale and import Products comprising the applicable Collaboration Compound(s). The license described in this Section 8.2(c)(ii) shall be non-exclusive, except that it shall be exclusive with respect to the
manufacture, use and sale of such Collaboration Compound(s), and shall be limited to the use and practice of such Patents and Information for the development, manufacture, use, sale, offer for sale or import of the applicable Collaboration
Compound(s). 
 (d) Sublicensing. The licenses granted to Exelixis in Sections 8.2(a) and 8.2(b) are, subject to
Section 8.5(b), sublicensable solely with the prior written consent of BMS, which consent shall not be unreasonably withheld. The license granted to Exelixis in Section 8.2(c)(i) shall be freely sublicensable solely in
connection with the development, manufacture, use, sale, offer for sale or import of a pharmaceutical product discovered or created by Exelixis, and the license granted to Exelixis in Section 8.2(c)(ii) shall be freely sublicensable
solely in connection with the development, manufacture, use, sale, offer for sale or import of the applicable Collaboration Compound. 
 (e) BMS Retained Rights. BMS retains all rights to use the BMS Licensed Know-How and BMS Patents except those expressly granted to Exelixis on an exclusive basis under the terms of this Agreement. 
 8.3 Mutual Covenants. 
 (a) BMS
hereby covenants that BMS shall not (and shall ensure that any of its permitted sublicensees shall not) use any Exelixis Licensed Know-How or Exelixis Licensed Patents for a purpose other than that expressly permitted in Section 8.1.

 (b) Exelixis hereby covenants that Exelixis shall not (and shall ensure that any of its permitted sublicensees shall not) use any
BMS Licensed Know-How or BMS Patents for a purpose other than that expressly permitted in Section 8.2. 
 8.4 No Additional
Licenses. Except as expressly provided in Sections 8.1, 8.2, and Article 12, nothing in this Agreement grants either Party any right, title or interest in and to the intellectual property rights of the other Party (either expressly
or by implication or estoppel). 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 49 

 8.5 Sublicensing. 
 (a) In General. Each Party shall provide the other Party with the name of each permitted sublicensee of its rights under this Article 8 and a copy of the applicable sublicense agreement; provided that
each Party may redact confidential or proprietary terms from such copy, including financial terms. The sublicensing Party shall remain responsible for each permitted sublicensee’s compliance with the applicable terms and conditions of this
Agreement. 
 (b) Right of First Refusal for Sublicense of Co-Promotion Rights. During the Term, should Exelixis decide to sublicense
its rights under Section 8.2(b) to any Third Party, or should BMS decide to sublicense its rights under Section 8.1(b) to any Third Party, then the Party desiring to grant such sublicense (the “Sublicensing
Party”) shall promptly notify the other Party (the “Other Party”) in writing. The Other Party shall have a first and exclusive right of negotiation to obtain from the Sublicensing Party such sublicense on commercially
reasonable terms. If the Other Party exercises this right by so notifying the Sublicensing Party in writing within [ * ] receipt of the Sublicensing Party’s notice, the Parties shall negotiate in good faith for [ * ] (the
“Negotiation Period”) from the date the Sublicensing Party receives such notice from the Other Party to arrive at commercially reasonable terms (including any applicable royalty rate or other consideration) of an agreement for such
a sublicense. If mutual agreement is not reached during the Negotiation Period, then the Sublicensing Party shall be free to pursue a Third Party sublicensee, subject to Section 8.2(d); provided, however, that the Sublicensing
Party may not grant a sublicense to such Third Party on terms more favorable to such Third Party (taking into consideration the overall aggregate of economic factors) than those which the Sublicensing Party last offered to the Other Party; and
provided further that in the event that no such sublicense to a Third Party occurs for a period of [ * ] subsequent to the expiration of the Negotiation Period described above, then the terms of this Section 8.5(b) shall once
again apply to any proposed sublicense by the Sublicensing Party (i.e., as if the Negotiation Period had never occurred). 
 8.6
Exclusivity. The Collaboration will be exclusive with respect to the research, development, manufacture, and commercialization of [ * ] that are intended to [ * ] the targets that are part of the Collaboration, as described below.

 (a) Screening Targets. Following the designation of a target as a Screening Target and until such time as such Screening Target
becomes a Rejected Screening Target (in which case the terms of Section 8.6(b) shall apply) or a Lead Op Candidate (in which case the terms of Section 8.6(c) shall apply), [ * ] conduct (directly or indirectly, and
either with or without a bona fide collaborator), [ * ] such Screening Target. 
 (b) Rejected Screening Targets. [ * ]
conduct (directly or indirectly, and either with or without a bona fide collaborator) programs outside the scope of this Collaboration to identify, optimize, develop and commercialize compounds that [ * ] Rejected Screening Target [
* ], except as follows. If: (i) [ * ], then [ * ] the Collaboration, directly or indirectly and either with or without a bona fide collaborator, in programs: (A) that are intended to research, develop and/or
commercialize compounds that [ * ]; or (B) where such program’s compounds [ * ], in either case ((A) or (B)) [ * ] Rejected Screening Target. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 50 

 (c) Lead Op Candidates. Subsequent to the designation of a target as a Lead Op Candidate and until
such time as such Lead Op Candidate becomes a [ * ] (in which case the terms of Section 8.6(d) shall apply) or a Rejected Lead Op Candidate (in which case the terms of Section 8.6(e) shall apply), [ * ]
(directly or indirectly, and either with or without a bona fide collaborator) outside the scope of this Collaboration any programs: (A) that are intended to identify, optimize, develop and commercialize compounds that [ * ] such
Lead Op Candidate; or (B) (i) [ * ] as such Lead Op Candidate [ * ], and (ii) [ * ] such program’s compounds [ * ] the same Identified Target(s) as such Lead Op Candidate [ * ]. 
 (d) Lead Op Targets. Following the designation of a Lead Op Program’s Identified Target(s) and until such time as such Identified Target(s)
become Collaboration Target(s) (in which case the terms of Section 8.6(f) shall apply), [ * ] (directly or indirectly, and either with or without a bona fide collaborator) outside the scope of this Collaboration any
programs: (i) that are intended to identify, optimize, develop and commercialize compounds that [ * ]; or (ii) (I) [ * ] Lead Op Target [ * ], and (II) [ * ] such program’s compounds [ * ] Lead
Op Target [ * ]. 
 (e) Rejected Lead Op Targets. Each Party shall be free to conduct (directly or indirectly, and either with
or without a bona fide collaborator) outside the scope of this Collaboration programs to identify, optimize, develop and commercialize compounds that [ * ] a Rejected Lead Op Target without any further obligation to the other Party,
except as follows. If: (i) [ * ] the Collaboration (directly or indirectly, and either with or without a bona fide collaborator), in any programs: (A) that are intended to research, develop and/or commercialize compounds that
[ * ]; or (B) where [ * ], in either case ((A) or (B)) [ * ] after the designation of such Rejected Lead Op Target. 
 (f) Collaboration Targets. 
 (i) Prior to Commercialization. Subsequent to [ * ] and until the initial
Commercialization of a Product within the Collaboration Program to which such Identified Target(s) relates ([ * ] with respect to such Collaboration Program, in which case this clause (i) [ * ], [ * ] (directly or
indirectly, and either with or without a bona fide collaborator ) outside the scope of this Collaboration any programs: (I) that are intended to identify, optimize, develop and commercialize compounds that [ * ] such Identified
Target(s); or (II) (x) [ * ], and (y) [ * ] such program’s compounds [ * ] Identified Target(s) [ * ] where the [ * ]. 
 (1) [ * ] Termination of a Collaboration Program. Upon either (A) the [ * ] termination of a Provisional Collaboration Program or a Collaboration Program [ * ]; (B) the [ * ]
pursuant to Section [ * ]; or (C) the[ * ] pursuant to Section [ * ]; [ * ] (directly or indirectly, and either with or without a bona fide collaborator) outside the scope of this Collaboration programs to
identify, optimize, develop and commercialize compounds that [ * ] (subject, where applicable, to [ * ]). 
 (2) [ * ]
Termination of a Provisional Collaboration Program. In the event that a [ * ] is discontinued prior to [ * ] and where: (A) [ * ] (directly or indirectly, and either with or without a bona fide collaborator)
outside the scope of this Collaboration any programs to identify, optimize, develop and commercialize compounds that [ * ] Identified Targets [ * ] after the termination of the Provisional Collaboration Program. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 51 

 (ii) Subsequent to Commercialization. Subsequent to the initial Commercialization of a Product
within the Collaboration Program to which Identified Targets relate [ * ]), [ * ] (directly or indirectly, and either with or without a bona fide collaborator ) outside the scope of this Collaboration any programs to identify,
optimize and develop compounds that [ * ] such Identified Targets [ * ], subject to the following terms and conditions: 
 (1) Commercial Launch of [ * ]. [ * ] commercialize [ * ] the Collaboration, [ * ] such Identified Targets; or (B) where [ * ] (any such product, a “[ * ]”), [ * ] within such Collaboration Program; or (Y) [ * ]
within such Collaboration Program. 
 (2) [ * ]. In the event of any [ * ] that is permitted under Section 8.6(f)(ii)(1), the
Party [ * ] the other Party [ * ]: (A) [ * ] subsequent to [ * ] within such Collaboration Program and [ * ]. 
 (iii) Upon
Conclusion of the Research Term. Upon the end of the Research Term as set forth in Section 3.10, either Party shall be free to conduct (directly or indirectly, and either with or without a bona fide collaborator) outside the
scope of this Collaboration any programs to identify, optimize, develop and commercialize compounds that [ * ] that exist as of the end of the Research Term. 
 (g) [ * ]. Notwithstanding anything to the contrary set forth in this Article 8, if a Party is engaged in research of a program [ * ], and compounds in such program [ * ] Collaboration
Program, such Party shall [ * ]. For clarity, the exclusivity associated with a Lead Op Program, Provisional Collaboration Program or a Collaboration Program containing multiple Identified Targets [ * ] Lead Op Program, Provisional
Collaboration Program or Collaboration Program. 
 (h) Not Applicable to [ * ]. The restrictions in this Section 8.6 shall
not apply with respect to either Party for compounds that are [ * ]. 
 (i) [ * ]. In the event that, [ * ], a Party is
either (A) [ * ] (directly or indirectly, and either with or without a bona fide collaborator) outside the scope of this Collaboration any programs [ * ] that: (1) that are intended to identify, optimize, develop and
commercialize compounds that [ * ] Identified Target(s) as a Lead Op Program, a Provisional Collaboration Program or a Collaboration Program; or (2) where the conducting Party [ * ] Identified Target(s) as a Lead Op Program, a
Provisional Collaboration Program or a Collaboration Program [ * ] ([ * ]); or (B) commercializing [ * ], then the following terms and conditions shall apply: 
 (i) In the event that a Party controls [ * ], such Party [ * ] (or Lead Op Programs, Provisional Collaboration Programs or
Collaboration Programs, as applicable) using [ * ]; and (b) [ * ], either: 
 (1)(A) in the case of [ * ],
or (B) in the case of [ * ]; 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 52 

 (2) [ * ]; or 
 (3) [ * ]; 
 and in any case ((1), (2) or (3) above), provide written notice to the other Party of its
decision with respect to subsection (b) above and use Diligent Efforts to effect such decision as soon as practicable but in any case no later than [ * ] subsequent to such written notice. 
 (ii) In the event that a Party [ * ], where the [ * ], solely with respect to [ * ], either: 
 (1)(A) in the case of [ * ], or (B) in the case of [ * ]; or 
 (2) [ * ]; 
 and in either case ((1) or
(2) above), provide written notice to the other Party of its decision with respect to this Section 8.6(i)((ii) and use Diligent Efforts to effect such decision as soon as practicable but in any case no later than [ * ]
subsequent to such written notice. 
 (iii) In the event that a Party [ * ], where the [ * ], the terms of
Section 8.6(f)(ii)(2) shall apply as if [ * ]. 
  

	9.	COMPENSATION 

 9.1 Upfront Payment. BMS shall
pay Exelixis a one-time fee of sixty million dollars ($60,000,000) within [ * ] after the Effective Date. Such fee shall be noncreditable and nonrefundable. 
 9.2 Achievement Payments. For each Collaboration Compound selected by BMS pursuant to Section 3.7 (up to a maximum of three (3) such Collaboration Compounds selected), BMS shall pay Exelixis twenty
million dollars ($20,000,000) million within [ * ] of Exelixis’ receipt of written notice describing such selection. Each such payment shall be noncreditable and nonrefundable. 
 9.3 Profit Sharing the U.S. The terms and conditions of this Section 9.3 shall govern each Party’s rights and obligations with
respect to Operating Profits (or Losses) relating to each Co-Promotion Product in the U.S. For clarity, Exelixis shall have no right to share Operating Profits, and, except as set forth in Section 9.4(a)(iii) below, no obligation to bear
any Operating Losses, in each case pursuant to this Section 9.3, with respect to (x) any Product in the U.S. other than a Co-Promotion Product; or (y) any Product in the Royalty Territory, and in each case Exelixis shall
instead be entitled to receive from BMS royalties pursuant to Section 9.6. 
 (a) Basic Concept. The Parties shall share
equally all Operating Profits and all Operating Losses (as applicable) for each Co-Promotion Product in the U.S. Specifically, the Net Sales of Co-Promotion Product in the U.S. shall be allocated first to reimburse each Party for 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 53 

 
fifty percent (50%) of its Allowable Expenses for Co-Promotion Product in the U.S., and any remaining sums, shall be Operating Profit or Operating Loss
(as applicable), which shall be shared fifty percent (50%) by each Party. The JFC will determine future financial flows regarding the sharing of Operating Profits and Allowable Expenses consistent with the first sentence of this
Section 9.3(a) and with each partner’s then existing tax and transfer pricing policies.  
 (b) [ * ]. If
Exelixis elects [ * ] Co-Promotion Product (a “[ * ]”), then, solely during the period in which BMS is actually promoting the Co-Promotion Product [ * ], BMS shall receive [ * ] (such [ * ], the “[ * ]”) of Operating Profits (or
Losses) for such Co-Promoted Product (resulting in [ * ] for such Co-Promoted Product [ * ] during such period). The Parties agree that the Co-Promotion Agreement shall contain a mechanism by which the Parties shall [ * ]. The Co-Promotion Agreement
shall also contain a mechanism, similar to that described in Section 9.12(b), for arbitrating any disputes if the Parties are unable to mutually agree on [ * ] Co-Promotion Product. 
 (c) Commercialization Overruns. If the Allowable Expenses for Commercialization activities exceed the amounts budgeted for all such activities in
the applicable Annual Commercialization Plan (and taking into account any amendments to such Annual Commercialization Plan and Budget that may be approved during a calendar year) by more than [ * ] (calculated for all costs incurred over such
calendar year for all budgeted activities), such excess Allowable Expenses (each, a “Commercialization Overrun”) shall be borne by [ * ] and such excess Allowable Expenses shall be [ * ]. Notwithstanding the foregoing,
in the event and to the extent that such Commercialization Overrun was [ * ], or did not [ * ], then such Commercialization Overrun shall be [ * ], as the case may be. 
 9.4 Calculation and Payment of Profit or Loss Share. 
 (a) Reports and Payments in General. With respect to a Co-Promotion Product, or a Co-Developed Product for which Exelixis has not yet elected whether to exercise its Co-Promotion Option, each Party shall report
to the other Party, within [ * ] after the end of each quarter, with regard to Net Sales and Allowable Expenses incurred by such Party (including any Allowable Expenses incurred by a Party prior to Regulatory Approval of such Product) for
such Product during such quarter in the U.S. Each such report shall specify in reasonable detail all deductions allowed in the calculation of such Net Sales and all expenses included in Allowable Expenses, and, if requested by a Party,
any invoices or other supporting documentation for any payments to a Third Party that individually exceed [ * ] (or such other amount approved by the JFC) shall be promptly provided. Within [ * ] after the end of each quarter (or for
the last quarter in a year, [ * ] after the end of such quarter), the Parties shall reconcile all Net Sales and Allowable Expenses to ascertain whether there is an Operating Profit or an Operating Loss and payments shall be made as set forth
in paragraphs (i) and (ii) below, as applicable. 
 (i) If there is an Operating Profit for such quarter, then BMS shall
reimburse Exelixis for Allowable Expenses incurred by Exelixis in such quarter and shall pay to Exelixis, subject to Section 4.6(e) and 9.3(b), an amount equal to fifty percent (50%) of the Operating Profit for such quarter; or

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 54 

 (ii) If there is an Operating Loss for such quarter, then the Party that has borne less than its
share of the Operating Loss in such quarter shall make a reconciling payment to the other Party to assure that each Party bears its share of such Operating Loss during such quarter. 
 (iii) In the event that Exelixis has borne Allowable Expenses, or has made reconciling payments to BMS relating to Allowable Expenses pursuant to
clause (ii) above, with respect to a Co-Developed Product for which Exelixis does not elect to Co-Promote, then BMS shall reimburse Exelixis for such Allowable Expenses during the calendar quarter in which Exelixis elects not to Co-Promote such
Product. 
 (b) Last Calendar Quarter. No separate payment shall be made for the last quarter in any year. Instead, at the end of each
such year, a final reconciliation shall be conducted by comparing the share of Operating Profit (or Loss) to which a Party is otherwise entitled for such year pursuant to Section 9.3 against the sum of all amounts (if any) previously
paid or retained by such Party for prior quarters during such year, and the Parties shall make reconciling payments to one another no later than [ * ] after the end of such quarter, if and as necessary to ensure that each Party receives for
such year its share of Operating Profits and bears its share of Operating Losses in accordance with Section 9.3. 
 9.5
Milestone Payments to Exelixis. 
 (a) For each Royalty-Bearing Product, BMS shall make the milestone payments set forth below to
Exelixis within [ * ] after the first achievement of each indicated event by BMS or any of its Affiliates or sublicensees with respect to such Royalty-Bearing Product. All milestone payments made by BMS to Exelixis hereunder shall be
noncreditable and nonrefundable. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 55 

			
	 Event
	  	 Milestone Payment

	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]
		
	 [ * ]
	  	[ * ]

	 *
	 [ * ].

 (b) Milestone Payment Restrictions. Each milestone payment set forth in Section 9.5(a) shall be paid
[ * ]. 
 (c) Milestone Payments with Respect to Program Backups. Milestone payments for a Program Backup within a
Collaboration Program shall [ * ] such Collaboration Program has [ * ] and, in such event, will be payable [ * ]. For clarity, in the event that a [ * ] development milestones set forth above, and [ * ], then:
(i) such [ * ] milestones shall be due and payable with respect to such Program Backup [ * ]; and (ii) in the event that the [ * ] that were paid with respect to the [ * ], such milestones shall be [ * ]
(or [ * ], if applicable) has [ * ] and will be payable [ * ]. 
 (d) Where milestones are payable for the
achievement of [ * ] with respect to a Royalty-Bearing Product, such [ * ] such milestone payment [ * ]. 
 9.6
Royalty Payments to Exelixis. 
 (a) Sales of Products in the Royalty Territory. For each Product, BMS shall pay to Exelixis
royalties on Net Sales of such Product by BMS (or its Affiliates or sublicensees) in the Royalty Territory at a royalty rate determined by aggregate Net Sales in the Royalty Territory of such Product in a calendar year as follows: 
  

			
	 Calendar year Net Sales of Product in Royalty Territory
	  	 Royalty Rate

	 First $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ]
	  	[ * ]%

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 56 

 For clarity, Net Sales shall be [ * ]. All royalty payments made by BMS to Exelixis hereunder shall be
noncreditable and nonrefundable, except in the event that an audit pursuant to Section 9.19 confirms that BMS had overpaid royalties to Exelixis, in which case such overpayment shall be credited against future royalties due to Exelixis (or, in
the event that such audit takes place subsequent to the Royalty Term, such overpayment shall be refunded to BMS). 
 (b) Sales of
Royalty-Bearing Products in the United States. For each Royalty-Bearing Product during the applicable Royalty Term, BMS shall pay to Exelixis royalties on Net Sales in the U.S. of such Royalty-Bearing Product by BMS (or its Affiliates or
sublicensees) at a royalty rate determined by aggregate Net Sales in the U.S. of such Royalty-Bearing Product in a calendar year as follows: 
 (i) If Exelixis elected not to co-Develop such Royalty-Bearing Product by failing to “opt-in” pursuant to Section 3.7(c) or if Exelixis opted-out of the Development of such Royalty-Bearing Product prior to [
* ] with respect to such Royalty-Bearing Product: 
  

			
	 Calendar year, Net Sales of Royalty-Bearing Product in the U.S.
	  	 Royalty Rate

	 First $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ]
	  	[ * ]%

 (ii) If Exelixis opted-out of the Development of such Royalty-Bearing Product after [ *
] but prior to [ * ] with respect to such Royalty-Bearing Product: 
  

			
	 Calendar year, Net Sales of Royalty-Bearing Product in the U.S.
	  	 Royalty Rate

	 First $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ]
	  	[ * ]%

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 57 

 (iii) If Exelixis opted-out of the Development of such Royalty-Bearing Product after [ * ]
but prior to the completion of [ * ] with respect to such Royalty-Bearing Product or prior to [ * ] for such Royalty-Bearing Product: 
  

			
	 Calendar year, Net Sales of Royalty-Bearing Product in the U.S.
	  	 Royalty Rate

	 First $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ]
	  	[ * ]%

 (iv) If Exelixis opted-out of the Development of such Royalty-Bearing Product after [ *
] or [ * ] with respect to such Royalty-Bearing Product: 
  

			
	 Calendar year, Net Sales of Royalty-Bearing Product in the U.S.
	  	 Royalty Rate

	 First $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ] and up to and including $[ * ]
	  	[ * ]%
		
	 Portion above $[ * ]
	  	[ * ]%

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 58 

 9.7 Third Party Royalties for Products in the Royalty Territory and Royalty-Bearing Products in the
U.S. 
 (a) [ * ] Third Party milestones and royalties owed with respect to either a Product in the Royalty Territory or a
Royalty-Bearing Product in the U.S., on intellectual property that: (i) [ * ]; or (ii) is intellectual property that: (A) [ * ] from a Third Party prior to the Effective Date and [ * ]; and (B) [ * ].
Subject to Section 9.7(b) and Section 9.8, [ * ] Third Party milestones and royalties owed on intellectual property in connection with the development and commercialization of a Product [ * ]; provided that each
Party shall bear all Third Party royalties arising from any infringing activities by such Party prior to the Effective Date. 
 (b)
BMS may deduct from the royalties it would otherwise owe to Exelixis pursuant to Section 9.6 for a particular Product, an amount equal to [ * ] of all royalties and other payments payable to a Third Party in consideration for
rights [ * ] for the manufacture, use or sale of such Product, up to a maximum deduction of [ * ] royalties due Exelixis for such Product. 
 9.8 [ * ]. During the applicable Royalty Term for a particular Royalty-Bearing Product, if any Third Parties are: (a) [ * ] in any given country in any year; and (b) such [ * ] in such
country for such year are, [ * ]: 
 (i) [ * ], but [ * ] of the [ * ] in such country, then [ * ]; or

 (ii) [ * ], [ * ]. 
 9.9 Limitation on Deductions. Notwithstanding anything to the contrary in this Agreement, the operation of Section 9.7 and Section 9.8 for a given Product, whether singularly or in combination with each other,
shall not [ * ]. 
 9.10 Quarterly Payments and Reports. All royalties due under Section 9.6 shall be paid
quarterly, on a country-by-country basis, within [ * ] end of the relevant quarter for which royalties are due. BMS shall provide to Exelixis within [ * ] after the end of each quarter a report that summarizes the Net Sales of a
Royalty-Bearing Product during such quarter, provided that to the extent additional information is reasonably required by Exelixis to comply with its obligations to any of its licensors, the Parties shall work together in good faith to timely
compile and produce such additional information. Such reports shall also include detailed information regarding the calculation of royalties due pursuant to Section 9.6, including allowable deductions in the calculation of Net Sales
of each Royalty-Bearing Product on which royalties are paid, and, to the extent Section 9.8 is applicable, the calculation of sales and market share (by volume) of Generic Products. 
 9.11 Term of Royalties. Exelixis’ right to receive royalties under Section 9.6 shall expire on a country-by-country and
Royalty-Bearing Product-by-Royalty-Bearing Product basis upon the later of: (a) [ * ]; or (b) [ * ] (the “Royalty Term”). Upon the expiration of the Royalty Term with respect to a Royalty-Bearing-Product in a
country, BMS shall have a fully-paid-up perpetual license under Section 8.1 for the making, using, selling, offering for sale and importing of such Royalty-Bearing-Product in such country. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 59 

 9.12 Sales of [ * ] Product Against [ * ]. 
 (a) In General. The Parties recognize that the exclusivity provisions set forth in Section 8.6 may allow for situations where a Party
is [ * ] and such product [ * ] (each such product, a “[ * ]”). If a Party asks the JEC to determine whether [ * ], the JEC shall determine whether [ * ] using [ * ] (or any other [ * ]
reasonably acceptable to the Parties). If such [ * ] are [ * ] then the JEC shall determine if the [ * ] of such [ * ] is due to the [ * ] or if such [ * ] is due to the [ * ]. If the [ * ] of
such [ * ], then the JEC shall determine the extent to which sales of such [ * ]. The Party commercializing such [ * ] at: (i) a [ * ] (as determined by the JEC); and (ii) (A) in the case of BMS [ *
], and (B) in the case of Exelixis [ * ]. [ * ] would be [ * ]. 
 (b) Disputes. If the JEC cannot
agree: (i) whether [ * ]; (ii) on the [ * ]; (iii) whether such [ * ]; (iv) if the [ * ] is due to the [ * ] (or a combination thereof); (v) the degree to [ * ]; or (vi) on the
[ * ] as if such Party were [ * ] with respect to any [ * ] Product in the U.S., then, in each case, at the election of either Party, such dispute must be finally resolved through binding arbitration by JAMS in accordance with
its Streamlined Arbitration Rules and Procedures in effect at the time the failure arises, except as modified in this Agreement and applying the substantive law specified in Section 15.2. Either Party may initiate arbitration under this
Section 9.12(b) by written notice to the other Party of its intention to arbitrate, and such notice shall specify in reasonable detail the nature of the dispute. For each arbitration: (A) each Party shall submit to the arbitrator
its proposal for resolving such dispute, with such proposal based on the applicable commercial and scientific factors discussed by the JEC; (B) the arbitrator shall select the proposal that is the most commercially and scientifically
reasonable; and (C) such proposal shall become the applicable JEC determination. Notwithstanding anything to the contrary, the arbitrators will not have the ability to change the terms of either Party’s proposal. The award of the
arbitrator shall be final and judgment upon such an award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order of enforcement. The arbitration proceedings shall be
conducted at such location as shall be determined by the Arbitrator. The Parties agree that they shall share equally the cost of the arbitration filing and hearing fees, and the cost of the arbitrator. Each Party shall bear its own attorneys’
fees and associated costs and expenses. 
 9.13 Payment Method. All payments due under this Agreement to Exelixis shall be made by
bank wire transfer in immediately available funds to an account designated by Exelixis. All payments hereunder shall be made in Dollars. 
 9.14 Taxes. Exelixis shall pay any and all taxes levied on account of all payments it receives under this Agreement. If laws or regulations require that taxes be withheld, BMS shall: (a) deduct those taxes from the remittable
payment; (b) pay the taxes to the proper taxing authority; and (c) send evidence of the obligation together with proof of tax payment to Exelixis within [ * ] following that tax payment. The JFC shall discuss appropriate mechanisms
for minimizing such taxes to the extent possible in compliance with applicable law. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 60 

 9.15 Blocked Currency. In each country where the local currency is blocked and cannot be removed
from the country, royalties accrued in that country shall be paid to Exelixis in Dollars based on the Dollar reported sales for the quarter (translated for such country per Statement of Financial Standards No. 52), unless otherwise mutually
agreed. 
 9.16 Sublicenses. In the event BMS grants any permitted licenses or sublicenses to Third Parties to sell Products that
are subject to royalty payments under Section 9.6, BMS shall have the responsibility to account for and report sales of any Product by a licensee or a sublicensee on the same basis as if such sales were Net Sales by BMS. BMS shall
pay to Exelixis (or cause the licensee or sublicensee to pay to Exelixis, with BMS remaining responsible for any failure of the licensee or sublicensee to pay amounts when due under this Agreement): (a) royalties on such sales as if such sales
of the licensee or sublicensee were Net Sales of BMS or any of its Affiliates; and (b) milestones payments pursuant to Section 9.5 based on the achievement by such licensee or sublicensee of any milestone event contemplated in such
Sections as if such milestone event had been achieved by BMS or any of its Affiliates hereunder. 
 9.17 Foreign Exchange. Conversion
of sales recorded in local currencies to Dollars shall be performed in a manner consistent with BMS’ normal practices used to prepare its audited financial statements for internal and external reporting purposes, which uses a widely accepted
source of published exchange rates. 
 9.18 Records. Each Party shall keep (and shall ensure that its Affiliates and sublicensees
shall keep) such records as are required to determine, in a manner consistent with GAAP and this Agreement, the sums or credits due under this Agreement, including Development Costs, Allowable Expenses and Net Sales. All such books, records and
accounts shall be retained by such Party until the later of (a) [ * ] after the end of the period to which such books, records and accounts pertain and (b) the [ * ] (or any extensions thereof), or for such longer period as
may be required by applicable law. Each Party shall require its sublicensees to provide to it a report detailing the foregoing expenses and calculations incurred or made by such sublicensee, which report shall be made available to the other Party in
connection with any audit conducted by such other Party pursuant to this Section 9.18. 
 9.19 Audits. Each Party shall
have the right to have an independent certified public accountant, reasonably acceptable to the audited Party, to have access during normal business hours, and upon reasonable prior written notice, to examine only those records of the audited Party
(and its Affiliates and sublicensees) as may be reasonably necessary to determine, with respect to any calendar year ending not more than [ * ] prior to such Party’s request, the correctness or completeness of any report or payment made
under this Agreement. The foregoing right of review may be exercised [ * ]. Results of any such examination shall be (a) limited to information relating to the Products, (b) made available to both Parties and (c) subject to
Article 11. The Party requesting the audit shall bear the full cost of the performance of any such audit, unless such audit discloses a variance to the detriment of the auditing Party of more than [ * ] from the amount of the original
report, royalty or payment calculation, in which case the audited Party shall bear the full cost of the performance of such audit. The results of such audit shall be [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 61 

 9.20 Interest. Any payments or portions thereof due hereunder that are not paid on the date such
payments are due under this Agreement shall bear interest at a rate equal to the lesser of: (a) [ * ] Rate as published by Citibank, N.A., New York, New York, or any successor thereto, at 12:01 a.m. on the first day of each quarter in
which such payments are overdue; or (b) the maximum rate permitted by law, in each case calculated on the number of days such payment is delinquent, compounded monthly. 
 9.21 Non-Monetary Consideration. Neither Party shall sell a Product for any consideration other than cash except on terms specified in the
then approved Annual Commercialization Plan. In the event a Party receives any non-monetary consideration in connection with the sale of a Product, such Party’s payment obligations under this Article 9 shall be based on the
fair market value of such other consideration. In such case, the selling Party shall disclose the terms of such arrangement to the other Party and the Parties shall endeavor in good faith to agree on such fair market value. 
 9.22 Cross Border Transactions. 
 (a) In General. The Parties recognize that in certain territories, and in particular in free trade regions, customers or other Third Parties may import Product(s) purchased in one country for commercial sale or use in
another. If Exelixis asks the JEC to determine whether Products purchased outside the U.S. are being imported into the U.S. for such purpose, the JEC shall determine the level that such importation is occurring using data obtained from a source
reasonably acceptable to Exelixis and BMS. If such importation is [ * ] (i.e., [ * ], for [ * ]) then the JEC shall [ * ]. 
 (b) Disputes. If the JEC cannot agree whether such importation has [ * ], then, at the election of either Party, such dispute must be finally resolved through binding arbitration by JAMS in accordance
with its Streamlined Arbitration Rules and Procedures in effect at the time the failure arises, except as modified in this Agreement and applying the substantive law specified in Section 15.2. Either Party may initiate arbitration under
this Section 9.22(b) by written notice to the other Party of its intention to arbitrate, and such notice shall specify in reasonable detail the nature of the dispute. For each arbitration: (i) each Party shall submit to the
arbitrator its proposal for resolving such dispute (i.e., the final form of the equitable mechanism to adjust the compensation of the Parties hereunder to offset the economic effect of cross border transactions described in
Section 9.22(a)), such proposal based on the applicable business factors discussed by the JEC; (ii) the arbitrator shall select the proposal that is the most commercially reasonable; and (iii) such proposal shall become such
equitable mechanism. Notwithstanding anything to the contrary, the arbitrators will not have the ability to change the terms of either Party’s proposal. The award of the arbitrator shall be final and judgment upon such an award may be entered
in any competent court or application may be made to any competent court for judicial acceptance of such an award and order of enforcement. The arbitration proceedings shall be conducted in such location as shall be determined by the arbitrator. The
Parties agree that they shall share equally the cost of the arbitration filing and hearing fees, and the cost of the arbitrator. Each Party shall bear its own attorneys’ fees and associated costs and expenses. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 62 

 9.23 Payments to or Reports by Affiliates. Any payment required under any provision of this
Agreement to be made to either Party or any report required to be made by any Party shall be made to or by an Affiliate of that Party if designated in writing by that Party as the appropriate recipient or reporting entity. 
  

	10.	INTELLECTUAL PROPERTY 

 10.1 Ownership.

 (a) The inventorship of all Sole Inventions and Joint Inventions shall be determined under the U.S. patent laws. 
 (b) Each Party shall own the entire right, title and interest in and to any and all of its Sole Inventions, and Patents claiming only such Sole
Inventions (and no Joint Inventions) (“Sole Invention Patents”). BMS and Exelixis shall be joint owners in and to any and all Joint Inventions and Patents claiming such Joint Inventions (“Joint Invention Patents”).
BMS and Exelixis as joint owners each shall have the right to exploit and to grant licenses under such Joint Inventions, and where exercise of such rights require, under the laws of a country, the consent of the other Party, with the consent of the
other Party (such consent to not be unreasonably withheld, delayed or conditioned) unless otherwise specified in this Agreement. 
 (c) All employees, agents and contractors of each Party shall be under written obligation to assign any inventions and related intellectual property to the Party for whom they are employed or are providing services. 
 (d) The Parties acknowledge and agree that this Agreement shall be deemed to be a “Joint Research Agreement” as defined under 35
U.S.C. 103(c). 
 10.2 Disclosure. Subject to Section 3.6, Each Party shall submit a written report to the JRC no less
frequently than within [ * ] end of each [ * ] describing any Sole Invention or Joint Invention arising during the prior [ * ] in the course of the Collaboration or thereafter in accordance with this Agreement which it believes
may be patentable or at such earlier time as may be necessary to preserve patentability of such invention. Each Party shall provide to the other Party such assistance and execute such documents as are reasonably necessary to permit the filing and
prosecution of such patent application to be filed on such Sole Invention or Joint Invention, or the issuance, maintenance or extension of any resulting Patent. 
 10.3 Patent Prosecution and Maintenance; Abandonment. 
 (a) Prosecution Prior to BMS’ Exercise
of its Co-Development Option. Prior to BMS’ exercise of its Co-Development Option for a given Collaboration Program, Exelixis shall (1) prepare, file, prosecute and maintain (including conducting any interferences,
reexaminations, reissues, oppositions, or requests for patent term extension relating thereto), all Exelixis Licensed Patents (other than Joint Patents) in [ * ] (the “Primary Prosecution Countries”), and (2) make a
corresponding PCT filing (designating all countries) no later than twelve (12) months subsequent to initial filing, and a corresponding EPO application (designating all EPO countries/extension countries). no later than thirty (30) months
subsequent 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 63 

 
to initial filing, [ * ]; provided that such responsibilities shall be [ * ], and provided further that, in each case, [ * ]. If BMS
requests that Exelixis prepare, file, prosecute or maintain an Exelixis Licensed Patent in a country other than a Primary Prosecution Country, BMS shall [ * ] Exelixis in connection with preparing, filing, prosecuting or maintaining such
Exelixis Licensed Patent in such non-Primary Prosecution Country. Exelixis shall: (i) keep [ * ] as to the status of filing, prosecution, maintenance and extension of such Exelixis Licensed Patents, such that there is reasonable time to
review, comment upon and approve (as set forth in this Section 10.3(a)) any documents intended for submission to any patent office; (ii) furnish to [ * ] copies of documents relevant to any such filing, prosecution,
maintenance and extension including copies of any Patent Office, foreign associate, and outside counsel correspondence; and (iii) reasonably [ * ] on documents filed with any patent office with respect to Exelixis Licensed Patent claims
that Cover Collaboration Compounds or Products. For the purpose of this Section 10.3(a), such [ * ] shall only have the right to review any such documents provided by Exelixis if such [ * ] agrees in writing [ * ] or
other structural information disclosed in such documents [ * ]. 
 (b) Prosecution After BMS’ Exercise of its Co-Development
Option. 
 (i) Filing, Prosecution and Maintenance of Invention Patents Controlled by Exelixis. Subject to Sections
10.3(b)(ii) and (v) below, [ * ] shall be responsible for the preparation, filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of all Joint Invention Patents, Sole Invention
Patents Controlled by Exelixis, and Exelixis Licensed Patents that in each case are co-owned, or co-exclusively or exclusively licensed to BMS under Section 8.1 (the “Exelixis Prosecuted Patents”), provided that such
responsibilities shall be carried out by [ * ], and provided further that, in each case, [ * ]. [ * ], or its [ * ], shall provide [ * ] with an update of the filing, prosecution and maintenance status for each of
the Exelixis Prosecuted Patents on a periodic basis, and shall use commercially reasonable efforts to consult with and cooperate with [ * ] with respect to the filing, prosecution and maintenance of the Exelixis Prosecuted Patents, including
[ * ] of proposed filings to allow BMS a reasonable opportunity for review and comment before such filings are due. [ * ] shall provide to [ * ] copies of any papers relating to the filing, prosecution and maintenance of the
Exelixis Prosecuted Patents promptly upon their being filed and received. 
 (ii) Abandonment. In no event shall [ * ]
knowingly permit any of the Exelixis Prosecuted Patents to be abandoned in any country, or elect not to file a new patent application claiming priority to a patent application within the Exelixis Prosecuted Patents either before such patent
application’s issuance or within the time period required for the filing of an international (i.e., Patent Cooperation Treaty), regional (including European Patent Office) or national application, without [ * ] written consent (such
consent to not be unreasonably withheld, delayed or conditioned) or [ * ] otherwise first being given an opportunity to assume full responsibility [ * ] for the continued prosecution and maintenance of such Exelixis Prosecuted Patents
or the filing of such new patent application. Accordingly, [ * ], shall provide [ * ] with notice of the allowance and expected issuance date of any patent within the Exelixis Prosecuted Patents, or any of the aforementioned filing
deadlines, and [ * ] shall provide [ * ] with prompt notice as to whether [ * ] desires [ * ] to file such new patent application. In the event that [ * ] decides either: (A) not to continue the prosecution or
maintenance of a patent application or 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 64 

 
patent within the Exelixis Prosecuted Patents in any country; or (B) not to file such new patent application requested to be filed by [ * ], [
* ] shall provide [ * ] with notice of this decision at least [ * ] prior to any pending lapse or abandonment thereof, and [ * ] shall thereafter have the right to assume responsibility for the filing, prosecution and
maintenance of such patent or patent application. In the event that [ * ] assumes such responsibility for such filing, prosecution and maintenance, [ * ] shall have the right to transfer the responsibility for such filing, prosecution
and maintenance of such patent applications and patents to patent counsel (outside or internal) selected by [ * ], and [ * ] shall cooperate as reasonably requested by [ * ] to facilitate control of such filing, prosecution and
maintenance by [ * ]. In the case where [ * ] takes over the filing, prosecution or maintenance of any patent or patent application as set forth above, [ * ] to [ * ] in any way with respect to its handling of, or the
results obtained from, the filing, prosecution, issuance, extension or maintenance of any such application or any resulting patent or any failure by it to so file, prosecute, extend or maintain. In addition, [ * ] shall, [ * ], provide
such assistance and execute such documents as are reasonably necessary to continue or permit the filing, prosecution or maintenance of such patent or patent application or the issuance, maintenance or extension of any resulting patent or permit
enforcement of such patent application or any such patent, including assignment of same to [ * ] in accordance with Section 10.3(f). 
 (iii) Filing, Prosecution and Maintenance of Sole Invention Patents Controlled by BMS. In accordance with this Section 10.3(a)(iii), BMS shall be responsible for the filing, prosecution (including
any interferences, reissue proceedings and reexaminations) and maintenance of all Sole Invention Patents Controlled by BMS. 
 (iv)
Patent Term Extension. Exelixis and BMS shall each cooperate with each another and shall use commercially reasonable efforts in obtaining patent term extension (including any pediatric exclusivity extensions as may be available) or supplemental
protection certificates or their equivalents in any country with respect to patent rights covering the Products. If elections with respect to obtaining such patent term extensions are to be made, BMS shall have the right to make the election to seek
patent term extension or supplemental protection. 
 (v) Exelixis Right to Separate Claims. To the extent that any Sole Invention
Patent of Exelixis contains claims that cover compounds that are not Collaboration Compounds, Exelixis shall have the right to separate any claims that cover such compounds and to file such claims in a separate application (e.g., a continuation,
continuation-in-part, or divisional application). Exelixis shall notify BMS in writing prior to separating such claims, and such separation shall be at Exelixis’ sole expense. 
 (c) Payment of Prosecution Costs. BMS shall bear the out-of-pocket expenses (including reasonable fees for any outside counsel, but not
Exelixis’ inside counsel fees) associated with the filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of: (X) [ * ]; and (Y) the [ * ], provided that: 
 (i) if Exelixis or a Third Party licensee of Exelixis is practicing (A) a particular [ * ], or (B) a particular [ * ], or
(C) a particular [ * ] (where expressly permitted by 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 65 

 
this Agreement), and such Invention is covered by a Patent for which BMS would otherwise bear the out-of-pocket patent expenses pursuant to
Section 10.3(c) above, then, subject to Section 10.3(c)(ii) below, Exelixis shall provide written notice to BMS and the Parties shall mutually agree on the percentage of such expenses that each Party shall bear (which, in the
absence of any other agreement between the Parties, shall be [ * ]); and 
 (ii) if any [ * ] covered by clause
(b) above is part of a patent application or patent that covers other inventions that are not subject to clause (b) above and that are not [ * ], then the Parties shall mutually agree upon an appropriate allocation of the expenses
so that BMS does not bear any portion of the [ * ] attributable to such other inventions. 
 (d) Exelixis and BMS shall
mutually agree on the percentage of expenses that each Party shall bear with respect to Joint Inventions for which the cost of filing, prosecuting or maintaining such Joint Invention is not the responsibility of a Party under Sections 10.3(c)
hereof (which, in the absence of any other agreement between the Parties, shall be divided [ * ]). 
 (e) Non-payment of
Expenses. 
 (i) If a Party elects not to pay its share of any expenses with respect to a Patent covering a Joint Invention in a
given country under any of Sections 10.3(c) or (d) (each, a “Joint Patent”), such Party shall inform the other Party in writing not less than [ * ] before any relevant deadline (or, in the event of a
shorter period in which to respond to a patent office, as soon as reasonably practicable), and, if the other Party assumes the expenses associated with the Joint Patent, then the assuming Party [ * ] and the other Party shall [ * ].

 (ii) If a Party is the assignee or owner of a Patent (other than a Joint Patent) that is licensed to the other Party under any of
Sections 8.1 or 8.2, and such owning Party elects not to pay its share of expenses pursuant to Sections 10.3(c) or 10.3(d) in a given country, such owning Party shall inform the other Party in writing not less than [ * ]
before any relevant deadline (or, in the event of a shorter period in which to respond to a patent office, as soon as reasonably practicable). If the other Party assumes the expenses associated with the Patent in such country, then the assuming
Party [ * ] and the owning Party shall [ * ]. 
 (iii) If a Party is the licensee of a Patent (other than a Joint
Patent) under any of Sections 8.1 or 8.2, and such Party elects not to pay its share of expenses pursuant to Sections 10.3(c) or 10.3(d) in a given country, such Party shall inform the other Party in writing not less than
[ * ] before any relevant deadline (or, in the event of a shorter period in which to respond to a patent office, as soon as reasonably practicable) (such Patent(s) in such countries, as identified in such notice, being a “[ * ]
Right”), and [ * ] under such Sections 8.1 or 8.2, as applicable, with respect to the relevant Patent in such country, provided that [ * ]. It is also understood that such licensee shall be offered the
opportunity to assume its share of the responsibility for the costs of filing, prosecution and maintenance of any Patent(s) claiming priority directly or indirectly from any such [ * ] Right, and that where such expenses are assumed by such
licensee, it shall be afforded all the rights and licenses as provided under this Agreement for the licensed Patents (other than the [ * ] Right) with respect to such Patent(s) claiming priority directly or indirectly from any such [ *
] Right. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 66 

 (f) Notwithstanding Sections 10.3(c), (d) and (e), , any costs incurred by the Parties
associated with the filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of a U.S. Patent in the Exelixis Prosecuted Patents or the BMS Licensed Patents shall, solely to the extent such Patent
claims the use, manufacture, or sale of a Co-Promoted Product, shall be included as an element of Allowable Expenses. 
 (g) Each
Party shall provide to the other Party, on a [ * ] basis, a patent report that includes the serial number, docket number and status of each Patent for which, pursuant to Section 10.3(b), such Party has the right to direct the
filing, prosecution and maintenance and which covers a Sole Invention (in the case of [ * ]) or Joint Invention. The Parties through their patent counsel shall discuss as appropriate (but not more than [ * ]) ways in which to allocate
such out-of-pocket expenses in an appropriate, cost-effective manner consistent with the purposes of this Agreement and Exelixis’ obligations to Third Parties. 
 10.4 Enforcement of Patent Rights. 
 (a) Enforcement of Exelixis Sole Patents. 
 (i) Enforcement by BMS. In the event that management or in-house counsel for either Party becomes aware of a suspected infringement, by a Third
Party of a Patent claiming a Sole Invention of Exelixis that claims the composition of matter (including formulation), manufacture or use of one or more Products that is being Developed or Commercialized using Diligent Efforts and which is
co-exclusively or exclusively licensed to BMS under Section 8.1 (for purposes of this Section 10.4(a)(i) only, an “Exelixis Sole Patent”), such Party shall notify the other Party promptly, and following such
notification, the Parties shall confer. Each Party shall provide the same level of disclosure to the other Party’s in-house counsel concerning suspected infringement of an Exelixis Sole Patent as such Party would provide with respect to
suspected infringement of its own issued Patent or an exclusively licensed issued Patent claiming a product it is developing or commercializing independent of this Agreement. Where such suspected infringement involves such Third Party’s
development, manufacture, use or sale of a small molecule product directed against a target in a Collaboration Program, [ * ] shall have the right, but shall not be obligated, to bring an infringement action against any such Third Party or to
defend such proceedings at its own expense, in its own name and entirely under its own direction and control. [ * ] shall reasonably assist [ * ] (at [ * ]’ expense) in such actions or proceedings if so requested, and shall
lend its name to such actions or proceedings if requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions at [ *
] request. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope, or adversely affects the
enforceability, of any such [ * ] Sole Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent to not be unreasonably withheld, delayed or conditioned). 
 (ii) Enforcement by [ * ]. If [ * ] elects not to bring any action for infringement or to defend any proceeding described in
Section 10.4(a)(i) and so notifies [ * ], or where [ * ] (or any other party other than [ * ] who is licensed under such [ * ] Sole Patent) otherwise desires to bring an action or to defend any proceeding
directly involving an [ * ] Sole 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 67 

 
Patent, then [ * ] may bring such action or defend such proceeding at its own expense, in its own name and entirely under its own direction and
control; provided that [ * ] must confer with [ * ] with respect to any such action or proceeding and obtain the prior written consent of [ * ] to commence such action or proceeding, such consent not to be unreasonably
withheld, delayed or conditioned; provided further, that with respect to any [ * ] Sole Patent that is a Patent listed or listable in the FDA’s Orange Book (or foreign equivalent(s) of such Patent or the FDA’s Orange Book) by
[ * ] (a “Listable Patent”), if [ * ] fails to consent to any such action or proceeding, the Royalty Term for any Product that is claimed in such [ * ] Sole Patent shall in no event be diminished by any failure
to enforce such [ * ] Sole Patent. [ * ] shall reasonably assist [ * ] (at [ * ]’ expense) in any action or proceeding being prosecuted or defended by [ * ], if so requested by [ * ] or required by law,
and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at
its own expense. No settlement of any such action or defense which restricts the scope, or adversely affects the enforceability, of a Listed Patent with respect to small molecules, may be entered into by [ * ] without the prior consent of
[ * ] (such consent to not be unreasonably withheld, delayed or conditioned). 
 (b) Enforcement of Joint Patents. 

(i) Joint Product Patents. 
 (1) Enforcement by [ * ]. In the event that management or in-house counsel for either Party becomes aware of a suspected infringement of a Patent claiming a Joint Invention that pertains to the composition of matter (including
formulation), manufacture or use of one or more Products that is being developed or commercialized using Diligent Efforts and which is co-exclusively or exclusively licensed to BMS under Section 8.1 (a “Joint Product
Patent”), such Party shall notify the other Party promptly, and following such notification, the Parties shall confer. Each Party shall provide the same level of disclosure to the other Party’s in-house counsel concerning suspected
infringement of a Joint Product Patent as such Party would provide with respect to suspected infringement of its own issued Patent or an exclusively licensed issued Patent claiming a product it is developing or commercializing independent of this
Agreement. [ * ] shall have the right, but shall not be obligated, to bring an infringement action or to defend such proceedings at its own expense, in its own name and entirely under its own direction and control. [ * ] shall
reasonably assist [ * ] (at [ * ]’ expense) in such actions or proceedings if so requested, and shall lend its name to such actions or proceedings if requested by [ * ] or required by law, and [ * ] shall hold [ *
] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of
any such action or defense which restricts the scope or affects the enforceability of a Joint Product Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent to not be unreasonably withheld, delayed or
conditioned). 
 (2) Enforcement by [ * ]. If [ * ] elects not to bring any action for infringement or to defend any
proceeding described in Section 10.4(b)(i)(1) and so notifies [ * ], or for any other enforcement by [ * ] of a Joint Product Patent which is co-exclusively or exclusively licensed to [ * ] under
Section 8.1, then [ * ] may bring such action or defend such 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 68 

 
proceeding at its own expense, in its own name and entirely under its own direction and control; provided that [ * ] must confer with [ *
] with respect to any such action or proceeding and obtain the prior written consent of [ * ] to commence such action or proceeding, such consent not to be unreasonably withheld, delayed or conditioned; provided further, that with
respect to any Joint Product Patent that is a Listable Patent, if [ * ] fails to consent to any such action or proceeding, the Royalty Term for any Product that is claimed in such Joint Product Patent shall in no event be diminished by any
failure to enforce such Joint Product Patent. [ * ] shall reasonably assist [ * ] (at [ * ]’ expense) in any action or proceeding being prosecuted or defended by [ * ], if so requested by [ * ] or required by
law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such suit by its own
counsel at its own expense. No settlement of any such action or defense which restricts the scope or affects the enforceability of a Joint Product Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent to
not be unreasonably withheld, delayed or conditioned). 
 (ii) Other Joint Patents. 
 (1) Enforcement by [ * ]. In the event that management or in-house counsel for either Party becomes aware of a suspected infringement of a Patent
that claims a Joint Invention but is not a Joint Product Patent (an “Other Joint Patent”), such Party shall notify the other Party promptly, and following such notification, the Parties shall confer. Each Party shall provide the
same level of disclosure to the other Party’s in-house counsel concerning suspected infringement of an Other Joint Patent as such Party would provide with respect to suspected infringement of its own issued Patent or an exclusively licensed
issued Patent claiming a product it is developing or commercializing independent of this Agreement. [ * ] shall have the right, but shall not be obligated, to prosecute an infringement action or to defend such proceedings at its own expense,
in its own name and entirely under its own direction and control. [ * ] shall reasonably assist [ * ] (at [ * ]’ expense) in such actions or proceedings if so requested, and shall lend its name to such actions or
proceedings if requested by [ * ] or required by law, and [ * ] shall hold [ * ] harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to
participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or defense which restricts the scope or affects the enforceability of an Other Joint Patent may be entered into by [ * ]
without the prior consent of [ * ] (such consent to not be unreasonably withheld, delayed or conditioned). 
 (2) Enforcement by [
* ]. If [ * ] elects not to bring any action for infringement or to defend any proceeding described in Section 10.4(b)(ii)(1) and so notifies [ * ], then [ * ] may bring such action or defend such proceeding at
its own expense, in its own name and entirely under its own direction and control; provided that [ * ] must confer with [ * ] with respect to any such action or proceeding and obtain the prior written consent of [ * ] to
commence such action or proceeding, such consent not to be unreasonably withheld, delayed or conditioned; provided further, that with respect to any Other Joint Patent that is a Listable Patent, if [ * ] fails to consent to any such
action or proceeding, the Royalty Term for any Product that is claimed in such Other Joint Patent shall in no event be diminished by any failure to enforce such Other Joint Patent. [ * ] shall reasonably assist [ * ] (at [ *
]’ expense) in any action or 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 69 

 
proceeding being prosecuted or defended by [ * ], if so requested by [ * ] or required by law, and [ * ] shall hold [ * ]
harmless from any liability incurred by [ * ] arising out of any such proceedings or actions. [ * ] shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any
such action or defense which restricts the scope or affects the enforceability of an Other Joint Patent may be entered into by [ * ] without the prior consent of [ * ] (such consent to not be unreasonably withheld, delayed or
conditioned). 
 (c) General Provisions Relating to Enforcement of Patents. 
 (i) Withdrawal. If either Party brings such an action or defends such a proceeding under this Section 10.4 and subsequently ceases to
pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section 10.4 (including such prior written consent
as provided for under this Section 10.4) at its own expense. 
 (ii) Recoveries. In the event either Party exercises the
rights conferred in this Section 10.4 and recovers any damages or other sums in such action, suit or proceeding or in settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses
incurred by the Parties in connection therewith, including attorneys fees. If such recovery is insufficient to cover all such costs and expenses of both Parties, it shall be shared in proportion to the total such costs and expenses incurred by each
Party. If after such reimbursement any funds shall remain from such damages or other sums recovered, such funds shall be [ * ]. 
 (iii) Patent Enforcement in the U.S. Notwithstanding any cost allocations set forth in Sections 10.4(a) and (b), and notwithstanding the allocation of recoveries set forth in Section 10.4(c)(ii):
(A) any costs incurred by either Party in connection with actions taken under this Section 10.4 against suspected infringement by a Third Party in the U.S. that involves such Third Party’s development, manufacture, use or sale
of a small molecule product reasonably likely to materially affect sales of a Co-Promoted Product shall constitute Patent Costs and shall be [ * ]; and (B) any recoveries received by either Party in connection with such actions shall,
[ * ]. 
 (d) Data Exclusivity and Orange Book Listings. With respect to data exclusivity periods (such as those periods listed
in the FDA’s Orange Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83, and all international equivalents), BMS shall use commercially reasonable efforts
consistent with its obligations under applicable law (including any applicable consent order) to seek, maintain and enforce all such data exclusivity periods available for the Products. With respect to filings in the FDA Orange Book (and foreign
equivalents) for issued patents for a Product, upon request by BMS (and at BMS’ expense), Exelixis shall provide reasonable cooperation to BMS in filing and maintaining such Orange Book (and foreign equivalent) listings. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 70 

 (e) No Action in Violation of Law. Neither Party shall be required to take any action pursuant to
this Section 10.4 that such Party reasonably determines in its sole judgment and discretion conflicts with or violates any court or government order or decree applicable to such Party. 
 (f) Notification of Patent Certification. [ * ] shall notify and provide [ * ] with copies of any allegations of alleged patent
invalidity, unenforceability or non-infringement of an Patent licensed to [ * ] hereunder pursuant to a Paragraph IV Patent Certification by a third party filing an Abbreviated New Drug Application, an application under §505(b)(2) or
other similar patent certification by a third party, and any foreign equivalent thereof. Such notification and copies shall be provided to [ * ] by [ * ] as soon as practicable and at least within [ * ] after [ * ]
receives such certification, and shall be sent by facsimile and overnight courier to the address set forth below: 
 [ * ] 

10.5 Defense of Third Party Claims. If a claim is brought by a Third Party that any activity related to work performed by a Party under the
Collaboration infringes the intellectual property rights of such Third Party, each Party shall give prompt written notice to the other Party of such claim, and following such notification, the Parties shall confer on how to respond. 
 10.6 Copyright Registrations. Copyrights and copyright registrations on copyrightable subject matter shall be filed, prosecuted, defended, and
maintained, and the Parties shall have the right to pursue infringers of any copyrights owned or Controlled by it, in substantially the same manner as the Parties have allocated such responsibilities, and the expenses therefor, for patent rights
under this Article 10. 
  

	11.	CONFIDENTIALITY 

 11.1 Nondisclosure of
Confidential Information. All Information disclosed by one Party to the other Party pursuant to this Agreement, and, subject to Section 11.6, Information that is generated in furtherance of the Collaboration pursuant to this
Agreement with respect to Collaboration Compounds or Products (for so long as such Collaboration Compound or Product is not removed from the Collaboration), shall be “Confidential Information” for all purposes hereunder. The Parties
agree that during the term of this Agreement and for a period of [ * ] thereafter, a Party receiving Confidential Information of the other Party shall: (a) use Diligent Efforts to maintain in confidence such Confidential Information (but
not less than those efforts as such Party uses to maintain in confidence its own proprietary industrial information of similar kind and value) and not to disclose such Confidential Information to any Third Party without prior written consent of the
other Party (such consent to not be unreasonably withheld, delayed or conditioned), except for disclosures made in confidence to any Third Party under terms consistent with this Agreement and made in furtherance of this Agreement or of rights
granted to a Party hereunder; and (b) not use such other Party’s Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 11.1 shall not create or imply any rights
or licenses not expressly granted under Article 8 hereof). 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 71 

 11.2 Exceptions. The obligations in Section 11.1 shall not apply with respect to any
portion of the Confidential Information that the receiving Party can show by competent written proof: 
 (a) Subject to the last
sentence in Section 11.1, is publicly disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party hereunder; or 
 (b) Was known to the receiving Party or any of its Affiliates, without obligation to keep it confidential, prior to disclosure by the disclosing Party; or 
 (c) Is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without
obligation to keep it confidential; or 
 (d) Is published by a Third Party or otherwise becomes publicly available or enters the
public domain, either before or after it is disclosed to the receiving Party, and is not directly or indirectly supplied by the receiving Party in violation of this Agreement; or 
 (e) Has been independently developed by employees or contractors of the receiving Party or any of its Affiliates without the aid, application or
use of the disclosing Party’s Confidential Information. 
 11.3 Authorized Disclosure. A Party may disclose the Confidential
Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances; provided that notice of any such disclosure shall be provided as soon as practicable to the other Party: 
 (a) Filing or prosecuting Patents relating to Sole Inventions, Joint Inventions or Products, in each case pursuant to activities under this
Agreement; 
 (b) Regulatory filings; 
 (c) Prosecuting or defending litigation; 
 (d) Complying with applicable governmental laws and
regulations; and 
 (e) Disclosure, in connection with the performance of this Agreement, to Affiliates, potential collaborators,
partners, and actual and potential licensees (including potential co-marketing and co-promotion contractors, research contractors and manufacturing contractors), research collaborators, potential investment bankers, investors, lenders, and
investors, employees, consultants, or agents, in each case to the extent permitted by this Agreement, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set
forth in this Article 11. 
 The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties.
Such terms may be disclosed by a Party to individuals or entities covered by Section 11.3(e) above, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to
those set forth in this 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 72 

 
Article 11. In addition, a copy of this Agreement may be filed by either Party with the Securities and Exchange Commission in connection with any
public offering of such Party’s securities or as otherwise necessary under applicable law or regulations. In connection with any such filing, such Party shall endeavor to obtain confidential treatment of economic, competitively sensitive, and
trade secret information. 
 In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information except as
permitted hereunder. 
 11.4 Termination of Prior Agreements. This Agreement supersedes the Confidential Disclosure Agreement between
Exelixis and BMS effective as of September 22, 2005, and amended on November 9, 2005 and November 10, 2006 (such confidential disclosure agreement, as amended, the “Prior CDA”). All Information exchanged between the
Parties under the Prior CDA shall be deemed Confidential Information and shall be subject to the terms of this Article 11. 
 11.5
Publicity. The Parties agree that the public announcement of the execution of this Agreement shall be substantially in the form of the press release attached as Exhibit 11.5. Any other publication, news release or other public
announcement relating to this Agreement or to the performance hereunder, shall first be reviewed and approved by both Parties; provided, however, that any disclosure which is required by law, including disclosures required by the U.S.
Securities and Exchange Commission or made pursuant to the requirements of the national securities exchange or other stock market on which such Party’s securities are traded, as advised by the disclosing Party’s counsel may be made without
the prior consent of the other Party, although the other Party shall be given prompt notice of any such legally required disclosure and to the extent practicable shall provide the other Party an opportunity to comment on the proposed disclosure.

 11.6 Publications. 
 (a) [ * ] shall publish or present the results of studies performed in connection with Provisional Collaboration Programs prior to [ * ]. Subsequent to [ * ], publication decisions regarding the results of
studies performed in connection with Co-Developed Products shall be made by the JDC or JCC, as appropriate, and, in all cases, in accordance with [ * ] with respect to the disclosure of [ * ]. 
 (b) Subject to paragraph (a) above and Section 11.3, each Party agrees to provide the other Party the opportunity to review any
proposed disclosure which contains Confidential Information of the other Party and would or may constitute an oral, written or electronic public disclosure if made (including the full content of proposed abstracts, manuscripts or presentations)
which relate to any Inventions, or which otherwise may contain Confidential Information, at least [ * ] prior to its intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication
until the other Party is given a reasonable period of time to secure patent protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of
publication of information or filing of patent 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 73 

 
applications. The Parties agree to review and consider delay of publication and filing of patent applications under certain circumstances. The JRC, JDC or
JCC (or the Parties), as appropriate, shall review such requests and recommend subsequent action. Subject to paragraph (a) above and Section 11.3, neither Party shall have the right to publish or present Confidential Information of
the other Party which is subject to Section 11.1. Nothing contained in this Section 11.6 shall prohibit the inclusion of Confidential Information of the non-filing Party necessary for a patent application, provided the
non-filing Party is given a reasonable opportunity to review the extent and necessity for its Confidential Information to be included prior to submission of such patent application related to the Collaboration. Any disputes between the Parties
regarding delaying a publication or presentation to permit the filing of a patent application shall be referred to the JRC, JDC or JCC (or the Parties), as appropriate. 
  

	12.	TERM AND TERMINATION 

 12.1 Term. This
Agreement shall become effective on the Effective Date and shall remain in effect until terminated in accordance with Sections 12.2 or 12.3 or by mutual written agreement, or until the expiration of all payment obligations under Article 9
(the “Term”). 
 12.2 BMS’ Right to Terminate With respect to [ * ] pursuant to the terms of this
Agreement, BMS shall have the right to terminate this Agreement [ * ] upon: (a) [ * ], in the event that such termination is [ * ] or (b) [ * ], in the event that such termination is [ * ]. In any
termination under this Section 12.2, BMS shall remain responsible for its share of all Development Costs and Allowable Expenses during the applicable [ * ] or [ * ] period. 
 12.3 Termination for Material Breach. 
 (a) If either Party believes that the other is in material breach of this Agreement (including any material breach of a representation or warranty made in this Agreement), then the non-breaching Party may deliver notice of such
breach to the other Party. In such notice the non-breaching Party shall identify the actions or conduct that such Party would consider to be an acceptable cure of such breach. For all breaches other than a failure to make a payment set forth in
Article 9, the allegedly breaching Party shall have [ * ] to cure such breach. For any breach arising from a failure to make a payment set forth in Article 9, the allegedly breaching Party shall have [ * ] to cure such
breach. 
 (b) Subject to Section 12.3(c), if the Party receiving notice of breach fails to cure such breach within the
[ * ] or [ * ] period (as applicable), or the Party providing the notice reasonably determines that the proposed corrective plan or the actions being taken to carry it out is not commercially practicable, the Party originally
delivering the notice may terminate this Agreement upon [ * ] advance written notice, provided, that if the breach applies only to a given Product or to a given country, the non-breaching Party may only terminate the breaching Party’s
rights with respect to such Product or such country. 
 (c) If a Party gives notice of termination under Section 12.3(a)
and the other Party [ * ], or if a Party determines under Section 12.3(b) that [ * ], then the issues of: (i) [ * ]; or (ii) [ * ], shall in any case [ * ]. If [ * ] it is [ *
], then such termination shall be [ * ] if the 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 74 

 
breaching Party fails thereafter to cure such breach in accordance with the [ * ] within the time period set forth in Section 12.3(a) for
the applicable breach following such [ * ]. If as a result of such [ * ] it is [ * ], then [ * ]. 
 12.4
Survival; Effect of Termination. 
 (a) In the event of termination of this Agreement, the following provisions of this Agreement
shall survive: [ * ]. 
 (b) In any event, termination of this Agreement shall not relieve the Parties of any liability which accrued
hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party’s
right to obtain performance of any obligation. 
 12.5 Licenses and Payments on Termination. 
 (a) Termination by BMS (Section 12.2). Subject to Section 12.5(e), if BMS terminates this Agreement pursuant to
Section 12.2 with respect to a particular Product in any country, then the license granted to BMS under Section 8.1 shall automatically terminate solely with respect to such Product in such country, and BMS shall, and hereby
does, grant to Exelixis a royalty-free license, with the right to grant sublicenses, under the BMS Licensed Patents and BMS Licensed Know-How to clinically develop, make, use, sell, offer for sale and import such Product in such
country. The license described in this Section 12.5(a) shall be non-exclusive, except that it shall be exclusive with respect to the manufacture, use and sale of such Products. 
 (b) Termination by Exelixis (Section 12.3). If this Agreement terminates pursuant to Section 12.3 with respect to a particular Product
in any country, and BMS is the breaching Party, then the license granted to BMS under Section 8.1 shall automatically terminate solely with respect to such Product in such country, and BMS shall, and hereby does, grant to Exelixis a
license, with the right to grant sublicenses, under the BMS Licensed Patents and BMS Licensed Know-How to clinically develop, make, use, sell, offer for sale and import such Product in such country or Major Territory. The license described in this
Section 12.5(b) shall be non-exclusive, except that it shall be exclusive with respect to the manufacture, use and sale of such Product. For Products [ * ] prior to termination, the license described in this
Section 12.5(b) shall be fully-paid and royalty-free. For Products [ * ] prior to termination and that are covered by a Valid Claim of an Exelixis Licensed Patent or BMS Licensed Patent that, in either case, covers the Product or
the manufacture, use or sale of such Product, the license described in this Section 12.5(b) shall bear a royalty of [ * ] of Exelixis’ Net Sales of such Product. For Products [ * ] prior to termination and that are
covered by a Valid Claim of an Exelixis Licensed Patent or BMS Licensed Patent that, in either case, covers the Product or the manufacture, use or sale of such Product, the license described in this Section 12.5(b) shall bear a royalty
of [ * ] of Exelixis’ Net Sales of such Product. BMS’ right to receive royalties under this Section 12.5(b) shall expire on a country-by-country and Product-by-Product basis upon the later of: (i) [ * ]; or
(ii) [ * ], in either case, [ * ]. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 75 

 (c) Termination by BMS (Section 12.3). If this Agreement terminates pursuant to
Section 12.3 with respect to a particular Product in any country, and Exelixis is the breaching Party, then the license granted to Exelixis under Section 8.2 shall automatically terminate solely with respect to such Product
in such country, and Exelixis shall, and hereby does, grant to BMS a license, with the right to grant sublicenses, under the Exelixis Licensed Patents and Exelixis Licensed Know-How to clinically develop, make, use, sell, offer for sale and import
such Product in such country or Major Territory. The license described in this Section 12.5(c) shall be non-exclusive, except that it shall be exclusive with respect to the manufacture, use and sale of such Product. For Products [ *
] prior to termination, the license described in this Section 12.5(c) shall be fully-paid and royalty-free. For Products [ * ] prior to termination and that are covered by a Valid Claim of an Exelixis Licensed Patent or BMS
Licensed Patent that, in either case, covers the Product or the manufacture, use or sale of such Product, the license described in this Section 12.5(c) shall bear a royalty of [ * ] of BMS’ Net Sales of such Product. For
Products [ * ] prior to termination and that are covered by a Valid Claim of an Exelixis Licensed Patent or BMS Licensed Patent that, in either case, covers the Product or the manufacture, use or sale of such Product, the license described in
this Section 12.5(c) shall bear a royalty of [ * ] of BMS’ Net Sales of such Product. Exelixis’ right to receive royalties under this Section 12.5(c) shall expire on a country-by-country and
Product-by-Product basis upon the later of: (i) [ * ]; or (ii) [ * ], in either case, [ * ]. 
 (d)
Transfers Related to Licenses. For each license granted under Sections 12.5(a) – 12.5(c), the licensing Party shall transfer via assignment, license or sublicense to the licensee Party: (i) all Information reasonably necessary
for the development and commercialization of the Product to which such license relates; (ii) [ * ] that specifically relate to such Product and that are in the name of the licensing Party; (iii) [ * ] that specifically relate
to such Product; (iv) [ * ] by the licensing Party that specifically relate to such Product; and (v) supplies of such Product (including any intermediates, retained samples and reference standards), that, in each case ((i) through
(v)) are existing and in the Control of the licensing Party. Any such transfer(s) shall be [ * ] licensee Party. 
 (e) Exception
for Termination for Safety Reasons. The license granted to [ * ] under Section 12.5(a) shall be of no force or effect with respect to any given Product where [ * ] termination of Development and/or Commercialization of
such Product was due to [ * ]. For purposes of this Section 12.5(e), “[ * ]” means it is [ * ]’ or [ * ] there [ * ]: (i) [ * ]; or (ii) the [ * ], such as during
[ * ] a Product. Notwithstanding anything to the contrary, this Section 12.5(e) shall not prevent [ * ] from using its license in Section 12.5(a) to [ * ] that was terminated for [ * ]. [ *
] shall provide [ * ] with all relevant data for such [ * ] but [ * ] to [ * ] any [ * ] relating to such [ * ]. 
 (f) Additional Effects of Termination. 
 (i) In the event of any termination pursuant to
Section 12.2, [ * ]: (i) all Information relating to the Product, and all [ * ] with respect to Product in [ * ] name; (ii) all [ * ] related to the Product, to the extent that they may be [ *
]; (iii) all [ * ]related to the Product; and (iv) all supplies of Product (including any intermediates, retained samples and reference standards) that in each case are in [ * ] Control and that relate to the Product.
[ * ] shall take such other actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights hereunder to Exelixis. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 76 

 (ii) In the event of any termination pursuant to Section 12.3, the breaching Party
shall transfer and assign to the non-breaching Party: (i) all Information relating to the Product, and all [ * ] with respect to Product in the breaching Party’s name; (ii) all [ * ] related to the Product, to the extent
that they may be [ * ]; (iii) all [ * ] related to the Product; and (iv) all supplies of Product (including any intermediates, retained samples and reference standards) that in each case are in the breaching Party’s
Control and that relate to the Product. The breaching Party shall take such other actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights hereunder to the non-breaching Party.

  

	13.	REPRESENTATIONS AND WARRANTIES AND COVENANTS 

 13.1 Mutual Authority. Exelixis and BMS each represents and warrants to the other as of the Execution Date that: (a) it has the authority and right to enter into and perform this Agreement, (b) this Agreement is a legal and
valid obligation binding upon it and is enforceable in accordance with its terms, subject to applicable limitations on such enforcement based on bankruptcy laws and other debtors’ rights, and (c) its execution, delivery and performance of
this Agreement shall not conflict in any material fashion with the terms of any other agreement or instrument to which it is or becomes a party or by which it is or becomes bound, nor violate any law or regulation of any court, governmental body or
administrative or other agency having authority over it. 
 13.2 Rights in Technology. 
 (a) During the term of this Agreement, each Party shall use commercially reasonable efforts to maintain (but without an obligation to renew) and
not to breach any agreements with Third Parties that provide a grant of rights from such Third Party to a Party that are Controlled by such Party and are licensed or become subject to a license from such Party to the other Party under Article
8. Each Party agrees to provide promptly the other Party with notice of any such alleged breach or obligation to renew. As of the Execution Date, each Party is in compliance in all material respects with any aforementioned agreements with Third
Parties. 
 (b) Each Party represents and warrants that it: (i) has the ability to grant the licenses contained in or required by
this Agreement; and (ii) is not currently subject to any agreement with any Third Party or to any outstanding order, judgment or decree of any court or administrative agency that restricts it in any way from granting to the other Party such
licenses or the right to exercise its rights hereunder. 
 (c) Each Party represents and warrants that: (i) it has not granted,
and covenants that it shall not grant after the Execution Date and during the term of this Agreement, any right, license or interest in or to, or an option to acquire any of the foregoing with respect to, the intellectual property rights licensed to
the other Party hereunder (including the Exelixis Licensed Patents and the BMS Licensed Patents, as the case may be) that is in conflict with the 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 77 

 
rights (including the rights set forth in Article 10) or licenses granted or to be granted (including any conditional license rights) to the other
Party under this Agreement; and (ii) it has not granted any lien, security interest or other encumbrance (excluding any licenses) with respect to any of the intellectual property rights licensed to the other Party hereunder that would prevent
it from performing its obligations under this Agreement, or permitted such a lien, security interest or other encumbrance (excluding any permitted licenses) to attach to the intellectual property rights licensed to the other Party hereunder.

 13.3 Performance by Affiliates. The Parties recognize that each may perform some or all of its obligations under this Agreement
through Affiliates; provided, however, that each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such
performance. In particular, if any Affiliate of a Party participates under this Agreement with respect to Collaboration Compounds: (a) the restrictions of this Agreement which apply to the activities of a Party with respect to Collaboration
Compounds shall apply equally to the activities of such Affiliate; and (b) the Party affiliated with such Affiliate shall assure, and hereby guarantees, that any intellectual property developed by such Affiliate shall be governed by the
provisions of this Agreement (and subject to the licenses set forth in Article 8) as if such intellectual property had been developed by the Party. 
 13.4 Third Party Rights. Each Party represents and warrants to the other Party that, to its Knowledge as of the Execution Date, its performance of work under the Collaboration as contemplated by this Agreement
shall not infringe the valid patent, trade secret or other intellectual property rights of any Third Party. Each Party represents and warrants to the other Party that, to its Knowledge as of the Execution Date, it will not violate a contractual or
fiduciary obligation owed to such Third Party (including misappropriation of trade secrets) by performing its work under the Collaboration as contemplated by this Agreement. 
 13.5 Notice of Infringement or Misappropriation. Each Party represents and warrants to the other Party that, as of the Execution Date, it has
received no notice of infringement or misappropriation of any alleged rights asserted by any Third Party in relation to any technology that such Party intends, as of the Execution Date, to use in connection with the Collaboration. 
 13.6 HSR Act Filing; Effective Date. The Parties shall each, prior to or as promptly as practicable after the Execution Date of this Agreement,
file or cause to be filed with the U.S. Federal Trade Commission and the U.S. Department of Justice and any relevant foreign governmental authority any notifications required to be filed under the HSR Act and any applicable foreign equivalent
thereof with respect to the transactions contemplated hereby; provided that the Parties shall each file the notifications required to be filed under the HSR Act no later than [ * ] after the Execution Date of this Agreement. Each Party
shall be responsible for its own costs in connection with such filing, except that BMS shall be [ * ]. The Parties shall use commercially reasonable efforts to respond promptly to any requests for additional information made by either of such
agencies, and to cause the waiting periods under the HSR Act and any applicable foreign equivalent thereof to terminate or expire at the earliest possible date after the date of filing. Each Party shall use its commercially reasonable efforts to
ensure 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 78 

 
that its representations and warranties set forth in this Agreement remain true and correct at and as of the Effective Date as if such representations and
warranties were made at and as of the Effective Date. Notwithstanding anything in this Agreement to the contrary, this Agreement (other than Article 11 and this Section 13.6) [ * ] under the HSR Act in the U.S., the
expiration or earlier termination of any applicable waiting period under the antitrust or competition laws of any other jurisdiction, and the approval or clearance of the transactions contemplated by this Agreement in any jurisdiction requiring
advance approval or clearance (the “Effective Date”). 
  

	14.	INDEMNIFICATION AND LIMITATION OF LIABILITY 

 14.1 Mutual Indemnification. Subject to Section 14.4, each Party hereby agrees to indemnify, defend and hold harmless the other Party, its Affiliates, and their respective directors, employees and agents from and against
any and all Third Party suits, claims, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and reasonable attorneys’ fees (“Losses”) to the extent such Losses result from any:
(a) breach of warranty by the indemnifying Party contained in the Agreement; (b) breach of the Agreement or applicable law by such indemnifying Party; (c) negligence or willful misconduct of the indemnifying Party, its Affiliates or
(sub)licensees, or their respective directors, employees and agents in the performance of the Agreement; and/or (d) breach of a contractual or fiduciary obligation owed by it to a Third Party (including misappropriation of trade secrets).

 14.2 Indemnification by BMS. Subject to Section 14.4, BMS hereby agrees to indemnify, defend and hold harmless Exelixis
and its directors, employees and agents from and against any and all Losses to the extent such Losses result from [ * ] by BMS or its Affiliates, agents or sublicensees, except to the extent such Losses result from any: (a) breach of
warranty by Exelixis contained in the Agreement; (b) breach of the Agreement or applicable law by Exelixis; (c) negligence or willful misconduct by Exelixis, its Affiliates or (sub)licensees, or their respective directors, employees and
agents in the performance of the Agreement; and/or (d) breach of a contractual or fiduciary obligation owed by Exelixis to a Third Party (including misappropriation of trade secrets). 
 14.3 Certain Losses. Any Losses resulting from [ * ] by a Party or its Affiliates, agents or sublicensees with respect to which neither
Party owes an indemnification obligation under Section 14.1 shall be [ * ], if incurred prior to [ * ] to which such Loss relates; or (b) [ * ], if incurred after such [ * ] to which such Loss relates.

 14.4 Conditions to Indemnification. As used herein, “Indemnitee” shall mean a party entitled to indemnification
under the terms of Sections 14.1 or 14.2. A condition precedent to each Indemnitee’s right to seek indemnification under such Sections 14.1 or 14.2 is that such Indemnitee shall: 
 (a) inform the indemnifying Party under such applicable Section of a Loss as soon as reasonably practicable after it receives notice of the Loss;

 (b) if the indemnifying Party acknowledges that such Loss falls within the scope of its indemnification obligations hereunder,
permit the indemnifying Party to assume 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 79 

 
direction and control of the defense, litigation, settlement, appeal or other disposition of the Loss (including the right to settle the claim solely for
monetary consideration); provided, that the indemnifying Party shall seek the prior written consent (such consent to not be unreasonably withheld, delayed or conditioned) of any such Indemnitee as to any settlement which would materially diminish or
materially adversely affect the scope, exclusivity or duration of any Patents licensed under this Agreement, would require any payment by such Indemnitee, would require an admission of legal wrongdoing in any way on the part of an Indemnitee, or
would effect an amendment of this Agreement; and 
 (c) fully cooperate (including providing access to and copies of pertinent records
and making available for testimony relevant individuals subject to its control) as reasonably requested by, and at the expense of, the indemnifying Party in the defense of the Loss. 
 Provided that an Indemnitee has complied with all of the conditions described in subsections (a) – (c), as applicable, the indemnifying Party shall provide attorneys reasonably acceptable to the Indemnitee
to defend against any such Loss. Subject to the foregoing, an Indemnitee may participate in any proceedings involving such Loss using attorneys of the Indemnitee’s choice and at the Indemnitee’s expense. In no event may an Indemnitee
settle or compromise any Loss for which the Indemnitee intends to seek indemnification from the indemnifying Party hereunder without the prior written consent of the indemnifying Party (such consent to not be unreasonably withheld, delayed or
conditioned), or the indemnification provided under such Section 14.1 or 14.2 as to such Loss shall be null and void. 
 14.5
Limitation of Liability. EXCEPT FOR AMOUNTS PAYABLE TO THIRD PARTIES BY A PARTY FOR WHICH IT SEEKS REIMBURSEMENT OR INDEMNIFICATION PROTECTION FROM THE OTHER PARTY PURSUANT TO SECTIONS 14.1 AND 14.2, AND EXCEPT FOR BREACH OF SECTION
11.1 HEREOF, IN NO EVENT SHALL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR
ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THE AGREEMENT, UNLESS SUCH DAMAGES ARE DUE TO THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THE LIABLE PARTY (INCLUDING GROSS NEGLIGENCE OR
WILLFUL BREACH WITH RESPECT TO A PARTY’S REPRESENTATIONS AND WARRANTIES IN ARTICLE 13). 
 14.6 Collaboration Disclaimer.
EXCEPT AS PROVIDED IN ARTICLE 13 ABOVE, BMS EXPRESSLY DISCLAIMS ANY AND ALL OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES WITH RESPECT TO ANY COMPOUNDS OR INFORMATION (AND ANY PATENT RIGHTS OBTAINED THEREON) IDENTIFIED, MADE OR GENERATED BY BMS AS PART OF THE COLLABORATION OR OTHERWISE MADE AVAILABLE TO 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 80 

 
EXELIXIS PURSUANT TO THE TERMS OF THE AGREEMENT. EXCEPT AS PROVIDED IN ARTICLE 13 ABOVE, EXELIXIS EXPRESSLY DISCLAIMS ANY AND ALL OTHER WARRANTIES OF ANY
KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES WITH RESPECT TO ANY COMPOUNDS OR INFORMATION (AND ANY PATENT
RIGHTS OBTAINED THEREON) IDENTIFIED, MADE OR GENERATED BY EXELIXIS AS PART OF THE COLLABORATION OR OTHERWISE MADE AVAILABLE TO BMS PURSUANT TO THE TERMS OF THE AGREEMENT. 
  

	15.	MISCELLANEOUS 

 15.1 Dispute Resolution.
Unless otherwise set forth in this Agreement and excluding in particular any dispute described in Section 15.3 (which will be handled exclusively in accordance with Section 15.3), any dispute over matters within the authority
of the JEC pursuant to Article 2 (which will be handled exclusively in accordance with Section 2.7(c)), and any dispute handled pursuant to Section 3.6(c)(iii), Section 8.5(b)(i), Section 9.12(b) or
Section 9.22(b), in the event of any dispute, controversy or claim arising out of, relating to or in connection with any provision of the Agreement, the Parties shall try to settle their differences amicably between themselves first, by
referring the disputed matter to the Party’s respective Executive Officers. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and, within [ * ] after such notice, such
Executive Officers shall meet for attempted resolution by good faith negotiations. If such Executive Officers are unable to resolve such dispute within [ * ] of their first meeting for such negotiations, either Party may seek to have such
dispute resolved in any U.S. federal or state court of competent jurisdiction and appropriate venue, provided, that if such suit includes a Third Party claimant or defendant, and jurisdiction and venue with respect to such Third Party appropriately
resides outside the U.S., then in any other jurisdiction or venue permitted by applicable law. 
 15.2 Governing Law. Resolution of
all disputes, controversies or claims arising out of, relating to or in connection with the Agreement or the performance, enforcement, breach or termination of the Agreement and any remedies relating thereto, shall be governed by and construed under
the substantive laws of the State of Delaware, without regard to conflicts of law rules. 
 15.3 Patents and Trademarks; Equitable Relief.

 (a) Any dispute, controversy or claim arising out of, relating to or in connection with: (i) the scope, validity,
enforceability or infringement of any Patent rights covering the research, development, manufacture, use or sale of any Product; or (ii) any trademark rights related to any Product, shall in each case be submitted to a court of competent
jurisdiction in the territory in which such Patent or trademark rights were granted or arose. 
 (b) Any dispute, controversy or claim
arising out of, relating to or in connection with the need to seek preliminary or injunctive measures or other equitable relief 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 81 

 
(e.g., in the event of a potential or actual breach of the confidentiality and non-use provisions in Article 11) need not be resolved through the
procedure described in Section 15.1 but may be immediately brought in a court of competent jurisdiction. 
 15.4 Entire
Agreement; Amendments. This Agreement sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and
terminates all prior agreements and understandings between the Parties. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth
herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 
 15.5 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the U.S.
or other countries which may be imposed upon or related to Exelixis or BMS from time to time. Each Party agrees that it shall not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any
products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other
governmental entity. 
 15.6 Bankruptcy. 
 (a) All rights and licenses granted under or pursuant to this Agreement, including amendments hereto, by each Party to the other Party are, for all purposes of Section 365(n) of Title 11 of the U.S. Code
(“Title 11”), licenses of rights to intellectual property as defined in Title 11. Each Party agrees during the term of this Agreement to create and maintain current copies or, if not amenable to copying, detailed descriptions or
other appropriate embodiments, to the extent feasible, of all such intellectual property. If a case is commenced by or against either Party (the “Bankrupt Party”) under Title 11, then, unless and until this Agreement is rejected as
provided in Title 11, the Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 Trustee) shall, at the election of the Bankrupt Party made within sixty (60) days after the
commencement of the case (or, if no such election is made, immediately upon the request of the non-Bankrupt Party) either (i) perform all of the obligations provided in this Agreement to be performed by the Bankrupt Party including, where
applicable, providing to the non-Bankrupt Party portions of such intellectual property (including embodiments thereof) held by the Bankrupt Party and such successors and assigns or otherwise available to them or (ii) provide to the non-Bankrupt
Party all such intellectual property (including all embodiments thereof) held by the Bankrupt Party and such successors and assigns or otherwise available to them. 
 (b) If a Title 11 case is commenced by or against the Bankrupt Party and this Agreement is rejected as provided in Title 11 and the non-Bankrupt Party elects to retain its rights hereunder as provided in Title
11, then the Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 Trustee) shall provide to the non-Bankrupt Party all such intellectual property (including all embodiments thereof)
held 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 82 

 
by the Bankrupt Party and such successors and assigns or otherwise available to them immediately upon the non-Bankrupt Party’s written request therefor.
Whenever the Bankrupt Party or any of its successors or assigns provides to the non-Bankrupt Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 15.6, the non-Bankrupt Party
shall have the right to perform the obligations of the Bankrupt Party hereunder with respect to such intellectual property, but neither such provision nor such performance by the non-Bankrupt Party shall release the Bankrupt Party from any such
obligation or liability for failing to perform it. 
 (c) All rights, powers and remedies of the non-Bankrupt Party provided herein
are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including Title 11) in the event of the commencement of a Title 11 case by or against the Bankrupt Party. The
non-Bankrupt Party, in addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity
(including under Title 11) in such event. The Parties agree that they intend the foregoing non-Bankrupt Party rights to extend to the maximum extent permitted by law and any provisions of applicable contracts with Third Parties, including for
purposes of Title 11, (i) the right of access to any intellectual property (including all embodiments thereof) of the Bankrupt Party or any Third Party with whom the Bankrupt Party contracts to perform an obligation of the Bankrupt Party under
this Agreement, and, in the case of the Third Party, which is necessary for the development, registration and manufacture of licensed products and (ii) the right to contract directly with any Third Party described in (i) in this sentence
to complete the contracted work. Any intellectual property provided pursuant to the provisions of this Section 15.6 shall be subject to the licenses set forth elsewhere in this Agreement and the payment obligations of this Agreement,
which shall be deemed to be royalties for purposes of Title 11. 
 15.7 Force Majeure. Each Party shall be excused from the
performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be
continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, “force majeure” shall include conditions beyond
the control of the Parties, including an act of God, acts of terrorism, voluntary or involuntary compliance with any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public
utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. The payment of invoices due and owing hereunder shall in no event be delayed by the payer because of a force majeure
affecting the payer. 
 15.8 Notices. Any notices given under this Agreement shall be in writing, addressed to the Parties at the
following addresses, and delivered by person, by facsimile (with receipt confirmation), or by FedEx or other reputable courier service. Any such notice shall be deemed to have been given: (a) as of the day of personal delivery; (b) one
(1) day after the date sent by facsimile service; or (c) on the day of successful delivery to the other Party confirmed by the courier service. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as
described below. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 83 

			
	 For Exelixis:
	 	Exelixis, Inc.
		 	170 Harbor Way
		 	P.O. Box 511
		 	South San Francisco, CA 94083
		 	Attention: SVP, Patents and Licensing
		
	 With a copy to:
	 	Cooley Godward Kronish LLP
		 	Five Palo Alto Square
		 	3000 El Camino Real
		 	Palo Alto, CA 94306
		 	Attention: Robert L. Jones, Esq.
		
	 For BMS:
	 	Bristol-Myers Squibb Company
		 	P.O. Box 4000
		 	Route 206 and Province Line Road
		 	Princeton, NJ 08543-4000
		 	Attention: Senior Vice President, Corporate and Business Development
		 	Phone: 609-252-3413
		 	Fax: 609-252-6880
		
	 With a copy to:
	 	Bristol-Myers Squibb Company
		 	P.O. Box 4000
		 	Route 206 and Province Line Road
		 	Princeton, NJ 08543-4000
		 	Attention: Vice President and Senior Counsel, Corporate and Business Development
		 	Phone: 609-252-5328
		 	Fax: 609-252-4232

 Furthermore, a copy of any notices required or given under Article 10 of this Agreement shall also be
addressed to the Vice President and Chief Intellectual Property Counsel of BMS at the address set forth in Section 10.4(f). 
 15.9 Maintenance of Records Required by Law or Regulation. Each Party shall keep and maintain all records required by law or regulation with respect to Products and shall make copies of such records available to the other Party upon
request. 
 15.10 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the
prior written consent of the other (such consent to not be unreasonably withheld, delayed or conditioned), except a Party may make such an assignment without the other Party’s consent to an Affiliate or to a Third Party successor to all or
substantially all of the business of such Party to which this Agreement relates, whether in a 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 84 

 
merger, sale of stock, sale of assets or other transaction; provided that any such permitted successor or assignee of rights and/or obligations hereunder is
obligated, by reason of operation of law or pursuant to a written agreement with the other Party, to assume performance of this Agreement or such rights and/or obligations; and provided, further, that if assigned to an Affiliate, the assigning Party
shall remain jointly and severally responsible for the performance of this Agreement by such Affiliate. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in
violation of the terms of this Section 15.10 shall be null and void and of no legal effect. 
 15.11 Electronic Data
Interchange. If both Parties elect to facilitate business activities hereunder by electronically sending and receiving data in agreed formats (also referred to as Electronic Data Interchange or “EDI”) in substitution for
conventional paper-based documents, the terms and conditions of this Agreement shall apply to such EDI activities. 
 15.12
Non-Solicitation of Employees. After the Effective Date and during the term of this Agreement, each Party agrees that neither it nor any of its divisions, operating groups or Affiliates shall recruit, solicit or induce any employee of the other
Party directly involved in the activities conducted pursuant to this Agreement to terminate his or her employment with such other Party and become employed by or consult for such Party, whether or not such employee is a full-time employee of such
other Party, and whether or not such employment is pursuant to a written agreement or is at-will. For purposes of the foregoing, “recruit”, “solicit” or “induce” shall not be deemed to mean:
(a) circumstances where an employee of a Party initiates contact with the other Party or any of its Affiliates with regard to possible employment; or (b) general solicitations of employment not specifically targeted at employees of a Party
or any of its Affiliates, including responses to general advertisements. 
 15.13 Further Actions. Each Party agrees to execute,
acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 15.14 Severability. If any of the provisions of this Agreement are held to be invalid or unenforceable by any court of competent jurisdiction from
which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable
provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 
 15.15 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its
rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time. 
 15.16 Construction of this Agreement. Except where the context otherwise requires, wherever used, the use of any gender shall be applicable to all genders, and the word “or” are used in the inclusive sense. When used
in this Agreement, “including” means “including without limitation”. References to either Party include the successors and permitted assigns of 

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 85 

 
that Party. The headings of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this
Agreement or the intent of any provision contained in this Agreement. The Parties have each consulted counsel of their choice regarding this Agreement, and, accordingly, no provisions of this Agreement shall be construed against either Party on the
basis that the Party drafted this Agreement or any provision thereof. If the terms of this Agreement conflict with the terms of any Exhibit, then the terms of this Agreement shall govern. The official text of this Agreement and any Exhibits hereto,
any notice given or accounts or statements required by this Agreement, and any dispute proceeding related to or arising hereunder, shall be in English. In the event of any dispute concerning the construction or meaning of this Agreement, reference
shall be made only to this Agreement as written in English and not to any other translation into any other language. 
 15.17
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile, each of
which shall be binding when sent. 
 Signature page follows. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 86 

 IN WITNESS WHEREOF, the Parties have
executed this Agreement in duplicate originals by their proper officers as of the Effective Date. 
  

									
	BRISTOL-MYERS SQUIBB COMPANY	 		 	EXELIXIS, INC.
					
	By:	 	 /s/ Elliott Sigal, MD, PhD.
	 		 	By:	 	 /s/ George Scangos

	Title:	 	Chief Scientific Officer	 		 	Title:	 	President and CEO
	Date:	 	December 15, 2006	 		 	Date:	 	December 15, 2006

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 87 

 Exhibit 3.2 
 LIST OF INITIAL SCREENING TARGETS 
 [ * ] 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 Exhibit 3.3 
 LIST OF INITIAL LEAD OP TARGETS 
 [ * ] 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

  

 Exhibit 3.9 
 FORM OF TARGET STATUS LIST 
 Instructions for use: 
  

	 	•	 	 The name of each target will be added to the Target column. 

  

	 	•	 	 Under the Status column, each target shall be labeled with one of the following: Screening Target (chosen-awaiting-screening); Screening Target
(screen-in-progress); Rejected Screening Target; Lead Op Candidate; Lead Op Target; Rejected Lead Op Target; or Collaboration Target. 

  

	 	•	 	 For the Other Identified Target column, the name of any other target(s) that is part of the set of Identified Targets will be listed and updated as appropriate.

  

	 	•	 	 The applicable Specificity Criteria and Target Potency Threshold will be added and updated in the appropriate columns. 

  

	 	•	 	 The applicable dates for adding and withdrawing any target will be added to the last two columns. 

  

													
	 TARGET
	  	 STATUS
	  	 OTHER
IDENTIFIED
TARGETS
	  	 SPECIFICITY
CRITERIA
	  	 TARGET
POTENCY
THRESHOLD
	  	 DATE
ADDED
	  	 DATE
WITHDRAWN

		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	
		  		  		  		  		  		  	

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

  

 Exhibit 6.4(c) 
 TERMS OF CO-PROMOTION AGREEMENT 
 Without limiting the generality of either Party’s rights and obligations
contained in the Agreement, the Co-Promotion Agreement shall, in addition to such other terms as the Parties may agree and as are customary in an agreement of that type, include the following terms and conditions, unless otherwise agreed upon by the
Parties: 
  

			
	Allocation of Sales and Marketing
Responsibilities	  	 By [ * ] of each year, the JCC shall decide the [ * ]to be performed by both Parties during the Fiscal year commencing on January 1 of that
year for the promotion of the Product in the U.S. based on indication(s) then available and expected to be available during the forthcoming year for Commercialization of the Product in the U.S. The [ * ] shall be reviewed and may be modified or
adjusted during such year if both Parties so agree. (For each year, the [ * ] for that year.)
  
 As a fundamental principle of the Co-Promotion in the U.S., Exelixis shall perform [ * ] [ * ] in each year. Exelixis may phase-in its required number of representatives by recruiting, hiring and training such representatives over a period
of [ * ] so long as Exelixis maintains, from the time estimated by the JDC to be [ * ] prior to anticipated approval as set forth in the then-current U.S. Commercialization Plan, the greater of (x) [ * ] required total representatives (determined by
the JCC) as Exelixis representatives or (y) [ * ] Exelixis representatives. [ * ] to make up the difference between the above minimum requirement and Exelixis’ share of the [ * ] during such [ * ] period, subject to [ * ] to perform such [ * ]
with any costs associated with such performance by [ * ], (with such approval not to be unreasonably withheld). All Exelixis sales representatives who will be performing sales calls shall [ * ] Additionally, all Exelixis sales representatives, prior
to being assigned by Exelixis to a Collaboration Product, [ * ] shall be set forth in the Co-Promotion Agreement), and [ * ] in accordance with applicable U.S. laws and regulations. All sales representatives shall be [ * ] relevant to the
Product.
  
 Pre-approval, BMS shall provide initial sales training on the Product for the
Exelixis sales representatives who will be performing sales calls in the U.S. Following such initial training, any subsequent training of Exelixis sales representatives shall be made available by [ * ] on the Product.
  
 With respect to marketing activities in the Profit-Share markets, the Parties shall work via the JCC
to discuss positioning, branding, core messaging, distribution channel strategy, development strategy, competitive strategy, target selection, opinion leader development and investor and press relations.

		
	Co-Promotion
Agreement	  	 The Co-Promotion Agreement will be negotiated [ * ]. The parties recognize that a [ * ]. The Co-Promotion agreement shall be limited
to commercialization in the Profit Share Market and shall be consistent with the Agreement and rights granted to the JCC, JDC, JFC and JEC in the Agreement.
  
 In the Co-Promotion Agreement, the Parties shall jointly establish detailing thresholds, measures of sales performance consistent with internal company metrics and Net
Sales and through a well established third party sales reporting entity, value of each detail for profit calculation purposes, and shortfall provisions (e.g., [ * ], etc.) in the definitive Co-Promotion Agreement. The Parties shall decide in the
Co-Promotion agreement on the general [ * ] for each Party to [ * ].

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

  

			
	Breach	  	 The Parties shall jointly establish standards and consequences for material breach of the co-promotion obligations (e.g., the threshold of
material breach and remedies therefor, including without limitation the possibility of termination of the breaching Party’s co-promotion right, etc.) set forth in the definitive Co-Promotion Agreement.
  
 Without limiting the foregoing, in the event that a Party does not provide at least [ * ] for
any [ * ] with respect to a Co-Promotion Product, then the other Party shall have the right to assume all Commercialization responsibilities with respect to such Co-Promotion Product, and (i) in the case of any such failure by Exelixis, such
Co-Promotion Product shall become a Royalty-Bearing Product (with royalties payable to Exelixis as set forth in Section 9.6(b)(iv)), or (ii) in the case of any such failure by BMS, Exelixis will pay to BMS royalties on net sales of such Product in
the U.S. at the rates set forth in Section 9.6(b)(iv). The preceding remedy for a Party’s failure to provide [ * ], and such failure [ * ] Agreement.

		
	Use of Contractors	  	Only during the first [ * ] post [ * ], in order to reach Exelixis’ [ * ] threshold of representatives. Also, if such other Party [ * ], then a contract sales
organization may be used and the expenses incurred by such other Party for such activities shall be [ * ].

  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 2 

 Exhibit 10.37 
 Exhibit 11.5 
 Press Release 
  

			
	

	  	

 For Immediate Release 
  

							
	Contact:	 		 		 	
	Charles Butler	 		 	MEDIA:	 	Jeff Macdonald
	Director,	 		 		 	Bristol-Myers Squibb
	Corporate Communications	 		 		 	(212) 546-4824
	Exelixis, Inc.	 		 		 	jeffrey.macdonald@bms.com
	(650) 837-7277	 		 		 	
	cbutler@exelixis.com	 		 	INVESTORS:	 	John Elicker
				
		 		 		 	Bristol-Myers Squibb
				
		 		 		 	(212) 546-3775
				
		 		 		 	john.elicker@bms.com

 EXELIXIS AND BRISTOL-MYERS SQUIBB SIGN NEW COLLABORATION AGREEMENT TO DISCOVER AND DEVELOP NOVEL ONCOLOGY
COMPOUNDS 
 South San Francisco, CA and New York, NY – December 18, 2006 – Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company
(NYSE:BMY) today announced a worldwide collaboration to discover, develop and commercialize novel targeted therapies for the treatment of cancer. 
 Under
the collaboration, which will become effective upon antitrust clearance, Exelixis will deploy its drug discovery platform and be fully responsible for the identification and pre-clinical development of small molecule drug candidates directed against
mutually selected targets. Bristol-Myers Squibb will have the right to select up to three Investigational New Drug (INDs) candidates against three different targets. Following selection by BMS, Bristol-Myers Squibb will lead all global activities,
although the parties will co-develop and co-commercialize the programs in the United States. 
 Under the terms of the agreement, Bristol-Myers Squibb will
pay to Exelixis an upfront payment of $60 million in cash. Exelixis will also receive $20 million for each of up to three different drug candidates selected by Bristol-Myers Squibb at IND. The parties plan to equally share development costs,
commercial profits and co-promotion responsibilities in the United States. Exelixis will also receive royalties on product sales outside of the United States. For each program selected by BMS, Exelixis may opt out of the co-development or
co-promotion in the United States, in which case Exelixis would receive milestones and royalties in lieu of a U.S. profit share. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

  

 “We are very pleased to collaborate with BMS on the discovery and development of novel treatments for cancer.”
said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. “This collaboration will capitalize on the power of Exelixis’ drug discovery engine and on the breadth and depth of BMS’ expertise in oncology. We have
had excellent, productive collaborations with BMS in oncology since 2000, and I am confident that this new collaboration will build on the excellent relationship between the companies and on the knowledge that we have generated during those
years.” 
 “Bristol-Myers Squibb is dedicated to addressing areas of serious medical need, and oncology remains one of the cornerstones of our
research and development efforts,” said Francis Cuss, M.D., senior vice president of Drug Discovery for Bristol-Myers Squibb. “We have a long-standing and productive history of collaboration with Exelixis and are pleased to expand our
partnership to include the discovery and development of novel, targeted oncology therapies.” 
 About Exelixis 
 Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer
and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. For more information, please visit the company’s web site
at www.exelixis.com. 
 ABOUT BRISTOL-MYERS SQUIBB 
 Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Visit Bristol-Myers Squibb on the World Wide Web at www.bms.com. 
 Exelixis Forward-Looking Statement 
 This press release contains
forward-looking statements, including, without limitation, all statements related to the discovery, development and commercialization of therapies targeting the treatment of cancer under the collaboration as well as related costs and payments,
including milestones, profits and royalties. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Exelixis’ current expectations. Forward-looking statements involve risks and uncertainties and past performance is not indicative of future results. Exelixis’ actual results and
the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that products candidates that appeared promising in
early research do not demonstrate safety or efficacy in clinical trials; the ability of the company to advance preclinical compounds into clinical development; the uncertainty of the FDA approval process; and the therapeutic and commercial value of
the company’s compounds. These and other risk factors are discussed under “Risk Factors” and elsewhere in Exelixis’ quarterly report on Form 10-Q for the quarter ended September 30, 2006 and other filings with the Securities
and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard
thereto or any change in events, conditions or circumstances on which any such statements are based. 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 2 

 Bristol-Myers Squibb Forward-Looking Statement 
 This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the development and commercialization of products. Such
forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the research collaboration agreement described in this release will result in the discovery, development and commercialization of
products. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December 31, 2005, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise. 
 ### 
  

	[ * ] = 	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]